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Abstract
Consumption of illegal drugs of abuse remains a major social issue aligned with a 
global law-enforcement priority. Forensic analysts are faced with the challenge of 
continually developing sophisticated methods of analysis to combat the increasing 
variability that occurs in illicit drug samples. Research work for this thesis has 
focused on the development of High Performance Liquid Chromatography (HPLC) 
methods for the analysis of major drug constituents associated with ecstasy and 
cocaine illicit drug samples. Emphasis has been placed on method development with 
strategies of univariate or multivariate experimental approaches used in the selection 
and optimisation of procedures. Considerations with regard to the choice of 
chromatographic factors, solutes under investigation and the provision of quality 
assurance data throughout the research work have been the main criteria in methods 
developed. Two HPLC methods were developed to qualitatively and quantitatively 
assay for the major drug components and analogue derivatives found in ecstasy and 
cocaine. Methods developed have undergone validation studies including intra- and 
inter- reproducibility, accuracy, and linearity of calibration, limit of detection (LOD) 
and limit of quantification (LOQ) and the use of internal standards. Applications of 
methods to ecstasy and cocaine samples seized in Ireland ensured their suitability for 
routine analysis of illicit drug samples.
As part of this study, chemical profiling of 183 ecstasy tablets seized in Ireland during 
2002-2004 were recorded as discrete data sets. Chemical data sets include both the 
quantification and occurrence in individual tablets of the major amphetamine 
components (i.e. MDA, MDMA, MDEA, MBDB methamphetamine and 
amphetamine), adulterant components (i.e. caffeine, phenacetin, acetaminophen and 
acetylsalicylic acid), excipients components (i.e. sucrose, glucose, lactose, fructose, 
mannitol, sorbitol and inositol) and inorganic components (i.e. Al, Zn, Fe, Mg, Ca, Cr, 
Pb, Na and K ). Chemometrics, including unsupervised methods of principal 
component analysis (PCA), hierarchical cluster analysis (HCA) and Pearson’s 
correlation coefficient, as well as supervised methods of linear discriminant analysis 
(LDA) and artificial neural networks (ANN) was applied to the chemical data sets to 
demonstrate the ability of the statistical approach to linking sample seizures. HCA 
and ANN were the numerical methods that most efficiently distinguished between
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linked and unlinked seizures. Eleven groups were identified from the chemical data 
sets with group classification dependant on the main amphetamine, adulterant and 
excipient components present. The benefits from this study can provide strategic 
intelligence and an understanding of the operational level on the Irish ecstasy market 
and help evaluate the changing profile or dynamics associated with this illegal market 
supply.
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1.1. Introduction.
Illegal drugs remain a dominant social issue. Drug related deaths are on the rise, 
crime levels are escalating and seizures of drugs are at record levels. It is a major 
concern globally for all law enforcement agencies. To conquer this ever growing 
drug problem, efforts have been made at government level, both nationally and 
internationally, to curtail the production, trafficking and distribution of illegal drugs. 
Tighter controls at ports and borders, reduction of cultivation fields in Columbia and 
Afghanistan and establishing international drug intelligence agencies are a few 
measures made to control the drug situation.
One key area identified was the importance of background intelligence concerning 
drug seizures. Drug characterisation studies have shown that it is possible to link 
samples, to classify material from different seizures into groups of related samples 
and to identify the origin of such samples (United Nations International Drug Control 
Programme, 2001). In 1996, the Commission on Narcotic Drugs (United Nations) 
acknowledged the need for united international policy in the field of drug 
characterisation and impurity profiling. At European level, the European council 
launched a strategic plan, the EU Drugs Strategy (2005-2012) on how to ‘solve5 the 
drug problem (Council for the European Union, 2004). Within this, they recognised 
that the reduction of the supply of drugs was a key factor. Central to this was the 
proposal to “adopt and implement and EU wide system for the forensic profiling of 
drugs”. In Ireland, policy makers had a more general view on this and it is 
documented in the ‘National Drugs Strategy 2009 -  20165 (Department of 
Community, Rural and Gaeltacht Affairs, 2009). In this, one of the five strategic aims 
is “To create a safer society through the reduction of the supply and availability of 
drugs for illicit use”, in which an objective is “To disrupt the activities of organised 
criminal networks involved in the illicit drugs trade in Ireland and internationally and 
to undermine the structures supporting such networks”. One other strategic aim is 
“To ensure the availability of accurate, timely, relevant and comparable data on the 
extent and nature of problem substance use in Ireland” and within this, an objective is 
“To ensure the availability of data to accurately inform decisions on initiatives to 
tackle problem substance use”. In order to meet these objectives, research on the drug 
situation in this country is essential.
iI
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1.2. Drugs of abuse.
The variety of illegal drugs currently available in the fmarket p lace’ can be 
categorized into four major pharmacological groupings. Narcotics include opiates 
such as opium, morphine and heroin. Depressants are sedatives that provide 
relaxation from anxiety and include barbiturates and benzodiazepines. Stimulants 
such as cocaine and amphetamines increase the actions within the central nervous 
system resulting in intoxication and often aggressive behaviour. Finally, 
hallucinogenic agents provide a sense of euphoria to users and include LSD (lysergic 
acid diethylamide), amphetamines (ecstasy) and cannabis. Regardless, all categories 
are considered illegal when sold on the ‘street market’ and are totally unregulated and 
have limited medical benefit. Forensic analysts are therefore faced with the challenge 
of continually developing sophisticated methods of analysis to struggle with the 
increasing variability that occurs in ‘street samples \
-•-Cocaine -»-Ecstasy Heroin Amphetamine »-Cannabis
Year
Figure 1.1. Number of seizures of cocaine, ecstasy, heroin, amphetamine and 
cannabis in Ireland, years 1995 -  2009. (Source: EMCDDA Annual Report, 2010).
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Cannabis has been long established as the most popular drug of abuse among young 
adults. Until recently amphetamine and its relative designer drugs, such as ecstasy, 
were the most widespread after cannabis in European and Irish illegal market (Figure
1.1). Since 2000, cocaine and heroin have overtaken ecstasy as the second most 
abused illicit drug which is a trend confirmed by the European Monitoring Center for 
Drugs and Drugs Addiction (EMCDDA Annual Report, 2008). National surveys by 
the National Advisory Committee on Drugs (NACD Annual Report, 2007) indicate 
that drug use is on the increase in Ireland. Illegal drug use during this time period 
increased from 18.5% to 24%. The prevalence of cocaine has risen from 3% to 5.3% 
and ecstasy from 3.7% to 5.4%. These figures are higher that the European average, 
with 3.6% for cocaine and 2.8% for ecstasy abuse.
1.2.1, Narcotics.
A narcotic is a term that describes a drug that produces narcosis, unconsciousness or 
sleep. Included in this group of drugs are opiates or any opiate derivative. The opiates 
are a large group of compounds that are produced from opium, which is found in the 
poppy Papaver somniferum. Opium itself contains morphine, thebaine, codeine and 
papaverine, from which heroin and hydrocodone can be synthesised.
First synthesised in 1874, heroin is the 3,6-diacetyl ester o f morphine, and is 
chemically known as ‘Diacetylmorphine’ (Figure 1.2). Most commonly injected, 
heroin is a painkiller and produces euphoria. Street heroin is typically a brown 
powder, less commonly white, and likely to be produced in Afghanistan. In 2006, 
purity levels ranged from 15% to 25% for the brown powder and 45% to 70% for the 
white powder (EMCDDA Annual Report, 2008). Hydrocodone (Figure 1.2) was first 
produced in Germany in 1920 from codeine and thebaine, It is a narcotic analgesic 
and has a high abuse risk. It is usually found in combination with acetaminophen or 
ibuprofen in tablet or syrup form. Commercially it has many trade names, eg. 
‘Vicodin’. Oxycodone is another semi-synthetic opioid with high abuse potential, 
which is derived from codeine.
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Narcotics
Hydrocodone
Depressants
Barbituric Acid
Stimulants
Caffeine Cocaine
Hallucinogens
MDA MDMA
MDEA
Figure 1.2. Chemical structures of narcotics, depressants, stimulants and 
hallucinogens.
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1.2.2. Depressants.
Depressants are drugs that act as a sedative on the central nervous system. They 
reduce an individual’s capabilities by increasing the activity o f gamma-aminobutyric 
acid (GABA). The most common legal depressant is alcohol. Alcohol is one of the 
most common drugs of abuse. Ethanol is the active drug, which is classified as 
“psychoactive”, meaning it acts on the central nervous system, altering brain function. 
The category of alcohol can be divided into beers, wines and spirits. Alcohol content 
ranges from 4% to upwards of 40% and production of alcohol is not limited by 
geography.
Common illegal depressants include barbiturates and benzodiazepines (Figure 1.2). 
Barbiturates are a group of depressants derived from barbituric acid. They are mostly 
used as a hypnotic and an anticonvulsant. Recently they have been largely replaced 
by benzodiazepines owing to the less potential of a lethal overdose. Benzodiazepines 
are a group of drugs that are similar to barbiturates in medical use (hypnotic, 
anticonvulsant, sedative) and they have also been used for withdrawal from alcohol 
and other drugs. They are produced most commonly as tablets and capsules. The 
most popular benzodiazepine is diazepam or ‘Valium’. More recently, sexual assaults 
have been reported to use flunitrazepam or ‘RohypnoF as a sedative before the 
assaults. Fluoxetine hydrochloride, or ‘Prozac’ is the third most commonly prescribed 
antidepressant in the United States, after sertraline or ‘Zoloft’ and escitalopram or 
‘Lexapro’. These are known as ‘selective serotonin reuptake inhibitors’ (SSRIs) and 
are the standard drugs prescribed for depression. Because of their effects, these 
antidepressants are commonly abused.
1.2.3. Stimulants.
Stimulants increase activity in the central nervous system. They boost consciousness, 
produce euphoria, and raise alertness. The more common legal stimulants include 
nicotine and caffeine. Nicotine is a chemical found in tobacco, the average cigarette 
contains 1 mg nicotine. This highly addictive drug is thought to combat anxiety and 
stress, help concentration and reduce appetite. Caffeine is a psychoactive drug and 
chemically is a bitter white crystalline xanthine alkaloid (Figure 1.2). It is naturally
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occurring in many plants, but primarily found in the cocoa bean. It is both legal and 
unregulated.
Cocaine is a semi-synthetic drug derived from the leaves of the cocoa plant and is the 
more popular illegal stimulant. Its chemical name is benzoylmethyl ecgonine (Figure 
1.2) and it is a crystalline tropane alkaloid. It is categorised as a stimulant; more 
specifically it is a dopamine reuptake inhibitor, a noradrenalin reuptake inhibitor and a 
serotonin reuptake inhibitor. Due to its addictive nature, cocaine has always been a 
popular street drug and has overtaken ecstasy as the second most popular drug of 
abuse in Europe (EMCDDA Annual Report, 2008).
1.2.4. Hallucinogens.
Hallucinogens are a group of drugs that change the state of mind of the user to such an 
extent that reality is altered. Common members include cannabis and Lysergic Acid 
Diethylamide (LSD). Cannabis is the most common illegal drug in Europe today. 
Unlike the opiates and cocaine where production is concentrated in the one 
geographical area. Cannabis saliva L. can be grown in many environments. The 
principal active ingredient in cannabis is A*'- tetrahydrocannabinol. It exists in three 
different physical forms; cannabis resin, herbal cannabis and the less common 
cannabis oil. In many countries, cannabis is seen as a ‘soft' drug, and legal 
prosecutions can vary from fines to cautions. Lysergic Acid Diethylamide (LSD) is a 
semi synthetic hallucinogen. Produced as a sheet of absorbent paper, users tear off 
tiny squares for their dose. This drug is not as popular as it was in the 1960’s and 
I970‘s, and the Drug Enforcement Administration (DEA) reported seizures had 
declined 100% from 2000 to 2005.
Amphetamine -  Type -  Stimulants (ATS) is a large group of synthetic compounds of 
which amphetamine is the chief drug. ATS can be categorised as either stimulant or 
hallucinogen due to their wide and varied psychological effects, and their ultimate 
classification is dependent on the scientist. In total, this group comprises 
amphetamine, methamphetamine and all ring-substituted analogues (Figure 1.2), 
however, new members arc frequently being synthesized. These drugs act by 
increasing levels of norepinephrine, serotonin, and dopamine in the brain.
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Amphetamine was first synthesized in 1887 in Germany, Its chemical name is 7V,a- 
methylbenzeneethanamine. It is a white or off-white powder but can appear in tablet 
form. Purity levels range from 2% to 47% in powders and up to 40 mg in tablets 
(EMCDDA). It is legally used in the treatment o f attention-deficit disorder (ADD) and 
attention-deficit hyperactivity disorder (ADHD). Brand names of the drugs that 
contain amphetamine include ‘Adderall’, ‘Vyvanse’, and ‘Dexedrine’, 
Methamphetamine was first produced in Japan in 1919. Its chemical name is N,a- 
dimethylbenzeneethanamine, Like amphetamine, it is found as a white powder or in 
tablet form. Purity levels range from 20% to 55% in powders and up to 40 mg in 
tablets. It has also been used as an adulterant in ecstasy tablets and has some limited 
medical use.
The most common member of the ATS group is 3,4 -methylenedioxy- N - 
methylamphetamine (MDMA), or ‘Ecstasy5, and is categorized as a stimulant and is 
mildly hallucinogenic, Initially produced by Merck in 1912 it did not become popular 
until the 1970’s. Other analogues found in tablets are MDA (3,4- 
methylenedioxyamphetamine), MDEA (3,4-methylenedioxy-N-ethylamphetamine) 
and MBDB (A^-methyl-l-(l,3-benzodioxoI-5-yl)-2-butanamine). Among the newer 
members of this ATS group are DOB (4-bromo-2, 5-dimethoxyamphetamine), 2C-B 
(4-bromo-2,5-dimethoxyphenethylamine) and DOM (4-Methyl-2,5- 
dimethoxyamphetamine), knowledge of whom are limited and research is ongoing.
1.2.5. Ecstasy.
Ecstasy is the generic name given to 3, 4 methylenedioxymethamphetamine (MDMA) 
by the World Health Organisation (WHO, 1997). MDMA is a ring substituted 
phenylethylamine with a methamphetamine backbone (Figure 1.2). The 
stereochemistry of MDMA is very important pharmacologically. The synthetic 
production of these compounds yield racemic mixtures. The (+) enantiomer is more 
stimulating and more neurotoxic than the (-) enantiomer. The difference in potency of 
the two isomers may vary three to ten fold (Nichols & Glennon, 1984). Pure MDMA 
is a white crystalline solid with a bitter taste. As a salt, the compound is chemically 
stable and does not decompose in heat, air or light, MDMA is usually taken orally as 
a tablet or capsule but may be found in powder or liquid form. It is readily absorbed
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from the gastrointestinal tract into the bloodstream, More rarely, the drug is snorted, 
smoked or injected.
i
! Ecstasy seizures in Ireland were at their peak in 2003 and have since declined (Figure
1.1). In Europe, 2002 was the peak, 2003-2005 seizures were stable and since then,
! they have declined. Ecstasy typically sells for €3 -  €15 per tablet (EMCDDA National
i
I Report, 2007).
Ii
The production of synthetic drugs is not limited by geography or climate, as it is with 
cocaine and heroin, The Netherlands is the main country in which illicit amphetamine 
and ecstasy is produced, During the 1960’s, the provinces in Southern Netherlands 
| were known for large scale amphetamine production. Since the 1990’s, this region
| continues to be used, though the focus has switched from amphetamine to ecstasy
production. The major production of MDMA is reported in the Czech Republic,
| Estonia, France, Poland, Spain and the UK (EMCDDA Annual Report, 2003).
j However, production facilities have been discovered in South East Asia, China, North
1 America, South Africa and South America (EMCDDA Annual Report, 2003). Over
| twenty recipes for MDMA production have been described in the literature, but only
three are common, the reductive amination route, the safrole bromination route and 
the Leuckart reaction (Figures 1,3. to 1.6.),
I)
1. The reductive amination route
This involves a reductive amination of a ketone at a higher temperature. Various 
reducing agents may be used, such as Al/HgCh, NaBH4 (using low temperatures), and 
NaBH3CN.
3t 4-(Methylenedioxy)
phenyl-2-propanone MDMA
Figure 1.3. The reductive animation route for the synthesis of MDMA.
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3 , 4 -  (Methylenedioxy) phenyl -  2 -  propanone is a controlled precursor, so chemists 
devised an alternative synthesis process which involved only non-control led 
precursors. Safrole is known to be a common precursor in MDMA synthesis and is 
typically used to synthesise 3 , 4 -  (Methylenedioxy) phenyl -  2 -  propanone.
Safrole Isosafrole H20 2 3 ,4-(Methylenedioxy)
phenyl-2-propanone
Figure 1.4. The synthesis of 3, 4 -  (Methylenedioxy) phenyl -  2 -  propanone using 
safrole as a precursor.
2. The safrole bromination route.
Safrole 3,4-Methylendioxyphenyl MDMA
-2-bromopropane
Figure 1.5. The safrole bromination route for the synthesis of MDMA,
Here, the safrole is reacted with hydrobromic acid to form 2 -  bromosafrole, which in 
turn produces MDMA.
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3. The Leuckart reaction
This is a popular synthesis method for amphetamine, but is less frequently used for 
the production of MDMA. LiAlH4 can also be used as an alternative to H2SO4/HCI.
Y
.NH
N - Methylformamide
N-Methyl-N-formyl-MDA MDMA
3, 4-(Methylenedioxy) 
phenyl-2-propanone
Figure 1.6. The Leuckart reaction route for the synthesis o f MDMA.
MDMA is often produced as the hydrochloric salt and in tablet form. In addition to 
the main amphetamine ingredient tablets will also contain excipients, adulterants, 
adhesives or colourants,
Excipients are used by the producer to give sufficient bulk to the tablet. Excipients 
include binders, lubricants, disintergrants, and colourants and flavouring agents, each 
of which has a different function in the overall process of tablet manufacture and 
subsequent tablet disintegration in the body. Not every additive will necessarily be 
present in any given dosage and the amount may vary. In the conventional 
pharmaceutical industry, common excipients used are sucrose, lactose, sodium 
hydrogen carbonate and calcium phosphate. Clandestine manufacturers often use 
cheaper, more readily available excipients. Common excipients include cellulose, 
starch, glucose, talc and stearate salts.
Adulterants are compounds that are added to the tablet to mimic or enhance the effect 
of the active ingredient. These also add bulk to the tablet and can also be used to trace 
sources. Many tablets that are sold as ecstasy may be mixed with a variety of 
stimulant or hallucinogenic substances such as amphetamine sulphate or LSD. Other
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amphetamine compounds such as MDA, MDEA and MBDB are commonly present. 
Examples of adulterants include caffeine, acetaminophen, phenacetin and 
acetyl sal icy lie acid (Figure 1.7). Adhesives also referred to as binders, are added to 
the powdered ingredients to increase their cohesive strength. These are usually added 
in concentrations between 1% and 10%. Formulations of clandestine manufacturers 
are likely to contain a natural gum or starch, which in paste form can function as an 
adhesive.
Figure 1.7. Chemical structures of the typical adulterants associated with ecstasy 
tablets.
Seized tablets are mainly white in colour, some are mottled or coloured. Examples of 
reported colours include blue, pink, green and yellow. Reasons for the addition of 
colorant are to increase the aesthetic appeal and distinguish product batches from 
others. The final colour of MDMA may change from white for the pure compound to 
pink or cream/yellow in the presence of by-products associated with the starting 
materials. Ecstasy tablets differ at this point from many other drugs o f abuse, As it is 
in tablet form, no further excipients can be added at the different stages of trafficking. 
This is an essential point for profiling and linking seizures. Only those chemicals 
added at manufacture can be present at street level.
Producers want to differentiate their product from others by imprinting the tablets 
with logos or symbols, this promotes brand awareness and customer loyalty (Figure 
1.8). When one ‘brand’ of tablets gains popularity, other laboratories will utilise the 
same logo punch to gain market share. It is reported that some clandestine 
laboratories can tailor drug combinations and customise logos for regular customers.
Caffeine Acetaminophen Phenacetin Acetylsalicyftc Acid
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Figure 1.8. A selection of seized ecstasy tablets with different logo imprints.
1.2.6. Cocaine.
Due to its addictive nature, cocaine has always been a popular street drug, but recently 
it has overtaken ecstasy as the second most popular drug of abuse in Europe 
(EMCDDA Annual Report, 2007). Cocaine is extracted from the leaves of the coca 
plant (Erythroxylon coca). It was originally used in South America in the mid-19th 
century by natives of the region to relieve fatigue. Pure cocaine (cocaine 
hydrochloride) was first used as a local anaesthetic for surgeries in the 1880’s and was 
the main stimulant drug used in tonics for treatment of various illnesses in the early 
1900’s, The chemical name is benzoylmethyl ecgonine and it is a crystalline tropane 
alkaloid. It is catagorised as a stimulant; more specifically it is a dopamine reuptake 
inhibitor, a noradrenalin reuptake inhibitor and a serotonin reuptake inhibitor.
Cocaine is a white crystalline solid, hygroscopic in nature, odourless and has a bitter 
taste (Figure 1.2). It has a melting point of 197 °C. Cocaine most often appears as a 
white crystalline powder or an off-white chunky material Crack cocaine typically is 
available in rock form. ‘Street’ cocaine may be contaminated accidentally during the 
preparation process or may be adulterated intentionally by a number of compounds in 
order to dilute the amount of cocaine used and increase profits. Examples of 
adulterants include caffeine, phenacetin, lidocaine, procaine, piracetam, and prilocaine 
(Barrio et a l 1997, Bemado, 2003, Lopez-Artiguez et al. 1995, Fucci & 
DeGiovanni, 1998)(Figure 1.9). Common excipients detected in cocaine street 
samples include starch, sugars, carbonates and bicarbonates (Bemado, 2003, Lopez- 
Artiguez et a l 1995).
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H,C0  H*
nh^ / CH
Lidocaine Procaine Piracetam Prilocaine
Figure 1.9. Chemical structures of the typical adulterants associated with cocaine.
Crack cocaine is derived from powder cocaine. The powder cocaine is dissolved in a 
solution of sodium bicarbonate and water. The solution is boiled and a solid 
substance separates from the boiling mixture. This solid substance, crack, is removed 
and allowed to dry. The crack cocaine is then broken or cut into "rocks,” each 
typically weighing from one-tenth to one-half o f a gram. One gram of pure powder 
cocaine will convert to approximately 0.89 grams of crack cocaine. It is estimated that 
crack rocks are between 75% and 90% pure cocaine.
The bulk of cocaine is produced in Colombia, Bolivia and Peru, with the traditional 
clandestine manufacturing process illustrated in Figure 1.10. Colombian drug 
organisations are responsible for producing 80% of the world’s cocaine. Trafficking 
organisations targeted countries in Eastern and Southern Europe as stopovers for both 
sea and air consignments filled with large quantities o f cocaine which were ultimately 
destined to Western Europe. The Americas made over 75% of the 2001 cocaine 
seizures, Western Europe around 13% and the rest of the world around 12% making 
Europe the second-largest cocaine market. Demand is estimated at between 120 and 
150 tons per year and is on the increase. The countries of the European Union seized 
around 56 tons of cocaine in 2001. Spain seized 33 tons of cocaine in 2001, which is 
more than Mexico and almost 60% of the total quantity seized in Western Europe 
(EMCDDA Annual Report, 2007).
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Coca leaves + H20  + lime, crush to a pulp 
i
Add kerosene, stir mixture 
i
Recover kerosene, discard coca leaf pulp 
Add dilute acid
V
Recover aqueous phase, discard kerosene
Add lime 
i
Collect precipitate + dry 
i
Crude cocaine
Figure 1.10, Flow diagram of each step involved in the clandestine manufacture of 
cocaine,
In Europe, average price for cocaine is €50 - €80 per gram (EMCDDA Annual 
Report, 2007). Only anecdotal information is available for the street price of drugs in 
Ireland. Cocaine has been sold for €30 - €40 for a half gram and crack for €50 a rock 
(NACD Annual Report, 2007). An overall decrease in purity was seen in cocaine in 
Europe from 2000-2005, with most countries reporting 30 -  60% purity (EMCDDA 
Annual Report, 2007). It is thought that seizures have not affected the price of 
cocaine but has affected the purity. Cocaine seizures have been on the rise since 2001 
in Ireland, which would comply with the trend in Europe (EMCDDA Annual Report, 
2010).
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1.3. Current analytical techniques for forensic drug analysis.
Various spectrometric and chromatographic methods are available for both routine 
and forensic drug analysis. The main objective for the analytical chemist has been to 
introduce new, versatile techniques with high efficiency, selectivity and precision. In 
this section, analysis of drugs o f abuse using techniques such as Infrared spectroscopy 
(IR), Raman spectroscopy, Nuclear Magnetic Resonance (NMR), Thin Layer 
Chromatography (TLC), Capillary Electrophoresis (CE), Gas Chromatography (GC) 
and High Performance Liquid Chromatography (HPLC) are presented and their 
applications in the analysis of illicit drug and biological samples are reviewed.
1.3.1. Spectrometric methods.
IR spectroscopy is a long established method of analysis. The non-destructive nature 
of this method added with its economy of time and lack of organic solvent usage 
appeals to a wide variety of analysts. Sondermann and Kovar (1999) demonstrated 
the potential use of this technique in screening experiments for MDMA, MDEA and 
amphetamine in ecstasy street samples, Schneider and Kovar (2003) found IR 
analysis in transmission mode to be better than diffuse reflectance when analysing 
ecstasy tablets. IR has been used to chemically differentiate between cellulose and 
lactose and then applied to a number of ecstasy samples in order to differentiate 
between producers (Baer et al. 2007). A portable version of IR spectroscopy has been 
developed for onsite identification of ecstasy (Tsujikawa et al. 2008) and the contents 
of a clandestine laboratory for cocaine production were analysed using IR (Gostic & 
Klemenc, 2007). Infrared spectroscopy has been limited to identification of 
adulterants and excipients in cocaine samples (Lopez-Artiguez et a l  1995).
Raman spectroscopy is a simple, non-destructive, semi-quantitative technique that 
allows for rapid screening of samples and as such has become a popular technique in 
the forensic analysis of drugs o f abuse. Bell et a l  (2000a, 2000b and 2003) have 
carried out numerous studies using this technique. In 2000, initial studies 
demonstrated the rapid drug screening potential of Raman spectroscopy and also 
distinguished between geometrical isomers of MDEA and MBDB and different 
hydrated forms of the same drug (Bell et al. 2000a). Later in 2000, the group 
analysed 400 ecstasy tablets for their active ingredients and excipients and concluded
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that the composition of the seized tablets varied significantly and even batches with 
similar physical appearance could not only have different active compounds but also 
vary in the nature of the excipients, the drug to excipient ratio and degree of MDMA 
hydration (Bell et a l  2000b). Further studies by Bell et al. (2003), demonstrated the 
potential of Raman spectroscopy as a rapid technique in the screening of a large 
sample number (1,500 ecstasy tablets) in characterising ecstasy tablets according to 
Raman composition profiling and concluded that it may be possible to recognise 
batch-to-batch variation in the ‘signature’ of tablets prepared by major manufacturers.
Other studies include the use of Raman spectroscopy in the analysis of cocaine and 
heroin (Ryder et a l  1999). The technique has also been applied to the detection of 
drugs of abuse from different materials and includes: MDMA in clothing (Ali et al. 
2008), cocaine in beverages (Eliasson et al. 2008) and codeine, cocaine, 
amphetamine, barbital and nitrazepam in fingerprints (Day et a l  2004). Milhazes et 
al. (2007) applied the technique in the examination of synthetic precursors associated 
with MDMA. One of the newer members of the ‘ecstasy’ group, 4-bromo 2, 5 
dimethoxtamphetamine (DOB) was screened using surface enhanced Raman 
spectroscopy (Bell et al. 2007). Raman has also been used as a detector for an LC 
method for the analysis of cocaine, heroin, amphetamine, papaverine and procaine 
(Sagmuller et a l  2003).
A more modem spectroscopic method is nuclear magnetic resonance (NMR), The JH
13and C chemical shifts of NMR can provide information on the environment of the 
nuclei being analysed. This technique allows for differentiation between geometrical 
and positional isomers and also between salts and free bases of drugs. This method is 
also non-destructive and can be used quantitatively. However, its lack o f sensitivity 
and the initial cost of the instrument limit this method to specific research rather than 
routine toxicological analysis. Molecular conformational studies using NMR were 
used to characterise cocaine and some of its derivatives (Airaksinen et al. 1999). 
Carter et al. (2002) used NMR to demonstrate its potential to study both the 
precursors and synthetic pathways of MDMA in order to link common batches of 
ecstasy tablets. A method for the analysis of excipients and impurities in ecstasy was 
proposed by Lee et a l  (2000) who then further developed the method to allow for the
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quantification of the percentage carbon attributed to MDMA. Billault et al. (2007) 
used NMR to study the different synthetic routes of MDMA, A new ecstasy 
analogue, 2-chloro-4, 5-methylenedioxymethamphetamine, was identified using the 
same NMR technique (Lewis et al. 2000). More recently, Zapata-Torres et a l  
(2008) used !H NMR and X-ray diffraction studies to determine different 
conformations of MDMA.
1.3.2. Chromatographic methods.
Low cost, speed, simplicity and its capability of simultaneous drug detection are the 
main advantages of thin layer chromatography (TLC). Samples are loaded onto a 
stationary phase, most frequently silica gel, and then the specific solvent system 
(mobile phase) is allowed to move through the stationary phase. The interaction of 
the compounds in the sample with the mobile phase allows for the separation of the 
sample and subsequent identification. This would be considered an inexpensive and 
basic technique and is typically used as a preliminary screening procedure, Within 
the last ten years few research articles on drugs of abuse using TLC method have been 
reported, Reports include the identification of adulterants in Brazilian cocaine 
(Bernardo, 2003) and the separation of opiate alkaloids and its derivatives (Pothier & 
Galand 2005). Kochana et al. (2003(a)) studied the markers of the Leukart production 
of p-methoxymethamphetamine (PMMA) by solid phase extraction (SPE) followed 
by TLC. In 2003, they used SPE-TLC for impurity profiling of intermediates in the 
synthesis o f MDMA (Kochana et al. 2003(b)). In 2006, the same technique was 
applied to examine agglutinants, excipients and adulterant impurities o f MDMA 
(Kochana et al. 2006).
The term ‘capillary electrophoresis’ describes a family of related techniques in which 
separations are carried out in narrow bore capillaries under the influence of an electric 
field with separation of analytes based on their electrophoretic mobilities. The 
exceptional power of separation and resolution, rapid analysis time, low mass 
detection limits, economy of reagents, and minimum sample requirements make CE 
an attractive methodology for forensic laboratories. The potential of this technique 
for forensic analysis was first demonstrated in 1991 by Weinberger and Lurie, who 
applied it to the analysis of a wide range of illicit drugs in synthetic mixtures
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(Weinberger & Lurie 1991). Piette and Parmentier (2002) successfully separated 
seven amphetamines associated with ecstasy within eight minutes without interference 
from adulterants using CE and suggested that the method was an attractive alternative 
to GC-MS for the qualitative and quantitative determination o f amphetamine and 
related compounds. Similarly, a chemometric approach was employed by Dahlen and 
Von Eckardstein (2006) for the development of a CE method to separate 
amphetamine and 13 amphetamine analogues. Complete separation was achieved in 
23 minutes; however the authors did offer an alternative CE method which allowed 
for the separation of the more common amphetamines with cocaine and heroin in less 
than seven minutes.
The applicability of capillary electrophoresis (CE) for the purpose of drug 
classification was examined in the analysis of methamphetamine impurities (Iwata et 
a l  2006). Two possible precursor impurities, namely ephedrine and 
pseudoephedrine were detected and quantified allowing for seized drugs to be 
classified into three groups based oh the contents of the two impurities. Chiral 
separations, i.e. the separation of a racemic mixture into enantiomers, using CE were 
accomplished by Huang et a l  (2003). In this study the R-(-)-isomers and S-(+)- 
isomers of MDA and MDMA were identified in seizures of tablets and urine samples. 
Other applications of CE in forensic drug analysis include investigations of 
adulterants in street cocaine (Ishii et al. 2001) and impurity profiling of heroin (Lurie 
et al. 2001). A method for the separation of cocaine, opiates and amphetamines (10 
compounds in total) was developed using a cyano stationary phase with capillary 
electrochromatography (Aturki et al. 2009). CE has also been extensively used in 
toxicological analysis, including hair (Gottardo et a l 2007), plasma (Boatto et a l
2007) and urine (Lin et a l  2006, Tsai et a l  2006).
Gas chromatography (GC) is one of the more extensively used separation techniques 
in the area of drug analysis. High sensitivity and excellent reproducibility has lead to 
the popularity of this technique; however the analyte of interest must be volatile and 
thermally stable. The variety o f detectors associated with GC is an additional benefit 
for this technique. The flame ionization detector (FID) has been used regularly in the 
area o f ecstasy profiling (Dayrit and Dumlao, 2004, Kuwayama et a l  2008,
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Mitrevski et al. 2005, Puthaviriyakorin et a l  2002, Rashed et a l  2000). Dujourdy 
et a l  (2008) used GC-FID to analyse cocaine samples for residual solvents that may 
be present and a cross border study between France and Switzerland used GC-FID to 
compare cocaine samples (Lociciro et al. 2007). GC in combination with mass 
spectrometer (MS) detector is considered one of the more popular tools for analysis. 
GC-MS has been used for the general analysis of drugs of abuse (O’Connell et al. 
2000, Shin et al. 1996, Whiting et al. 2001) and in impurity profiling of ecstasy 
tablets (Cheng et al. 2006, Gimeno et al. 2002, Gimeno et a l  2003, Palhol et a l  
2002, Swist et a l  2005). 156 street samples of cocaine in Rome were analysed for 
their adulterant content (Fucci et a l  1998). The harmonisation of MDMA profiling 
methods is a project undertaken by the European Commission, titled “Collaborative 
Harmonisation of Methods for Profiling of Amphetamine Type Stimulants” 
(Weyermann et a l  2008). Several researcher groups from different countries 
(Switzerland, France, The Netherlands, Finland, Germany, Czech Republic and the 
UK) have analysed the physical characteristics, chemical composition and organic 
profile of MDMA tablets. The preferred chosen method of analysis by this group for 
MDMA organic profiling was GC-MS.
GC lends itself to a wide variety of applications, such as testing the nails of newborns 
for monitoring in utero drug exposure (Mari et a l  2008), analysis of blood from 
drivers under the influence of drugs for cocaine and cocaine metabolites (Jones et a l
2008), and everyday drug profiling (Dujourdy & Besacier, 2008, Groger et a l 2008, 
Dujourdy et a l 2008, Lociciro et a l 2008, Lock et a l 2007). Analysis of the newer 
designer drugs have been well documented (Ewald et a l  2007, Ewald et a l 2008, 
Theobald et a l 2007, Sauer et a l 2008). The chemical profiling of heroin utilised GC 
to classify different heroin samples (Esseiva et a l 2005). A supported liquid-liquid 
extraction (LLE) method for ecstasy tablets was developed by De Korompay et a l  
(2008). In this study, LLE was used to extract MDMA and was subsequently 
analysed by GC-MS and isotope ratio mass spectrometry (IR-MS). Furthermore, the 
application of GC in toxicological analysis for drug metabolites in hair (Kikura- 
Hanajiri et a l 2007, Wu et a l  2008, Lee et a l 2008), urine (Kim et a l 2008, 
Marchei et a l 2008, Brown et al. 2007, Lin et a l  2006), whole blood and serum 
(Gunnar et a l  2007, Kankaanpaa et a l 2007, Ishida et a l  2005), meconium (Marin
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et al. 2007, Salem et a l 2001), brain tissue (Stimpfl & Reichel 2007) and sweat 
(Huestis et a l  2008, De Martinis et al. 2007, Fucci et al. 2008).
Limitations associated with GC and TLC are overcome by the use of High 
Performance Liquid Chromatography (HPLC). HPLC is not limited by volatility or 
thermal stability as analysis is performed at room temperature. In addition, HPLC 
utilises a liquid mobile phase, which contributes to the separation process, making it 
the most widely used separation technique. Also, developments in columns, high- 
pressure constant delivery pumps and more sensitive detectors have contributed to its 
versatility. As such, HPLC is an integral analytical technique in the area of forensic 
drugs analysis.
The use of HPLC for the analysis of street samples has been limited. Makino et a l  
(2003) used HPLC to analyse a number of tablets on the Japanese market, more 
specifically, they used GC-MS to identify the different components and then LC to 
quantify them, Sadeghipor et al. (1997a, b) used LC in combination with UV and 
fluorescence for each of the studies. Using HPLC-UV, baseline separation was 
achieved for six amphetamines and four adulterants in less than eight minutes. The 
method was validated and application was made to eight tablets. Four amphetamines 
were separated using HPLC- fluorescence and the sensitivity of the fluorimetric 
detector was highlighted by applying the method to serum samples. HPLC-DAD was 
used for the study made by Cole et al. (2002). In this study, the chemical components 
of 136 ecstasy tablets were identified. Liquid chromatography with diode array 
detection has been used for the determination of the major alkaloids such as 
noscapine, papaverine, acetylcodeine, codeine, morphine, 6-monoacetylmorphine, 3- 
monoacetylmorphine and diacetylmorphine (Collins et al. 2006). In addition, this 
technique has been used extensively in toxicological analysis; samples include hair 
(Cairns et al. 2004, Kronstrand et a l  2004), urine (Namera et al. 2008) plasma 
(Concheiro et al. 2006), oral fluid (Concheiro et al. 2007, Wood et al. 2005) and 
whole blood (Cheze et al. 2007).
A newer development associated with both GC and LC is tandem mass spectroscopy 
detector. Here the fragments generated by the first MS are broken down further for a
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clearer result of what the initial compound was. LC-MS/MS has been successfully 
applied to the separation of 14 abused drugs, including amphetamine and MDMA, in 
less than 2.5 minutes (Pihlainen et al. 2003), amphetamine, methamphetamine, 
MDMA and MDA in urine (Andersson et al. 2008) and ten amphetamine related 
compounds in meconium (Kelly et al. 2008).
1.4. Fundamentals of High Performance Liquid Chromatography,
The goal and purpose of liquid chromatography is to physically resolve the individual 
components of a sample from each other so that they may be quantified and/or 
identified. A high performance liquid chromatography instrument has a number of 
components, including a solvent reservoir, a pump, a sample injection system, a 
column and a detection system. The mobile phase (solvent) is a liquid used to carry 
the sample through the column (where separation occurs) and on to the detector 
(where data is generated). The choice of the mobile phase is dependent on the type of 
chromatography to be used and because of this, mobile phase can be used as a tool in 
the optimisation process. A high pressure pump is used to push the mobile phase and 
sample through the system and is capable of delivering a particular flow rate at high 
pressures, e.g. a flow rate of 2 mL min-1 at a pressure of 125 bar. When the sample is 
introduced into the system, it is carried by the mobile phase onto the column. It is here 
that separation occurs. Columns are typically steel tubes with a variety of length, 
diameters and packing materials. Again, the choice of stationary phase is based on 
the type of compounds to be separated. Detection systems are located after the 
column. When the separated compounds leave the column, they pass through the 
detector, where individual signals are recorded for each compound.
1.4.1. Chromatographic interactions.
The type of chromatography dealt with in this study is reversed phase 
chromatography. This essentially means a polar mobile phase is used with a non polar 
stationary phase and separation of the sample is based on the hydrophobic interaction 
of the analyte between each of the phases. The analyte is attracted to the hydrophobic 
surface of the particle in the stationary phase. Polar interactions, primarily hydrogen 
bonding, are an important secondary retention mechanism. The level of hydrophobic 
and polar interaction forces between solute and stationary phase will determine the
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overall analyte retention time. Ion exchange interactions sometimes occur between 
ionisable silanols and positively charged basic groups. Some silanols ionise, gaining 
a negative charge. Chromatographic retention is a sum of the different interactions in 
which the analyte molecule participates. Differential retention results in selectivity 
and hence resolution. Compounds, with no hydrophobic or polar groups are affected 
by ionic interactions only, which are much stronger interactions and more difficult to 
elute and therefore undesirable.
1.4.2. Mobile phase.
The type of mobile phase employed greatly influences solute retention. The mobile 
phase can promote or suppress ionisation of the analyte molecules, and can suppress 
accessible residual silanol groups or any other active adsorption centers on the 
adsorbent surface. The main requirement for the mobile phase is to dissolve analytes 
up to the concentration suitable for detection. Table 1.1 lists the most commonly used 
reversed phase solvent mobile phases.
Table 1.1. Chemical characteristics of typical HPLC solvent mobile phases.
Solvent
Chemical Characteristics
M.W. B.P.(°C) R.I. UV(nm)
Viscosity
(cP)
Dipole
Moment
Relative
Strength
Water 18 100 1.333 185 1.00 1.84 0
Acetonitrile 41 82 1.341 195 0.358 3.37 3.1
Methanol 32 65 1.326 205 0.584 1.66 2.6
Tetrahydrofuran 72 66 1.404 215 2.20 1.70 4.4
M.W. = molecular weight, B.P. = boiling point, R.I.= refractive index
The characteristics of an ideal reversed phase solvent should include low viscosity for 
maximum efficiency (which increases the diffusion coefficient of the analyte) with 
minimum backpressure, limited absorption at low wavelengths (i.e. 200 -  230 nm), 
available at a reasonable cost and high purity and be non-toxic and environmentally 
friendly for ease of disposal.
Solvent strength is a measure of solvent hydrophobicity, tetrahydrofuran is more 
hydrophobic than acetonitrile which is more hydrophobic than methanol, however the
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three solvents do not differ significantly in their hydrophobic selectivity. Solvents 
differ in selectivity primarily based on their polar characteristics. Tetrahydrofuran 
can accept protons in hydrogen bonding, but cannot donate. Methanol can both 
accept and donate protons during hydrogen bonding. While with acetonitrile, solute 
molecules arrange themselves around the solvent molecules and is only a very weak 
proton acceptor.
The strength of the solvent can have a major effect on the analyte retention. With a 
relatively strong solvent, the equilibrium between the stationary and mobile phase 
favours the mobile phase resulting in short retention times and poor resolution. With 
a relatively weak solvent the equilibrium favours the stationary phase and results in 
longer retention times and maximal resolution. An intermediate solvent is required 
for reasonable retention. Solute retention is adjusted by mixing solvent strength -  
acetonitrile, methanol, or tetrahydrofuran, with water to obtain a solvent strength 
which results in efficient separation.
1.4.3. The column.
HPLC columns physically consist of three parts. Firstly, the matrix which refers to 
the chemical characteristics of the particle, secondly, the stationary phase (often added 
to particle) and thirdly, the hardware or steel rod housing encasing the material. The 
most common matrix available is silica. Others include polystyrene-divinylbenzene, 
alumina and zircona, which are stable across the pH range. Silica is the most common 
matrix used as it is very physically robust and it tolerates high pressures, It is 
chemically stable in virtually all solvents. Silica is versatile and is easily derivatised to 
form unique stationary phases through attachment of reactive silanes to surface 
silanols. It is available in pore sizes from 60 A to 300 A, choice of which depends on 
analyte molecular weight, and is readily available in various particle sizes.
The silica surface is not homogenous and consists of various types of silanol groups. 
Surface silanols vary significantly in their reactivity; 15 - 20% of surface silanols are 
“highly” reactive. Isolated silanols are the most acidic, geminal silanols are relatively 
benign and vicinal silanols form hydrogen bonds with adjacent silanols. Metals on 
the silica increase silanol acidity. There are approximately 8 ^moles/m2 of silanols in
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the silica surface. The type and percentage of silanols in the silica surface affect the 
bonding coverage and characteristics. The silica surface area affects the total amount 
of phase that can be bonded. The surface determines the amount and reactivity of free 
silanols that can produce secondary chromatographic interactions. The silica matrix is 
a major factor in the reproducibility of column selectivity.
During the mid -  1970’s? the first silica particles specifically manufactured for HPLC 
were spherical in shape which resulted in much higher column efficiency and much 
longer column lifetimes. They naturally contain metal ions, making it acidic, which 
results in tailing for basic compounds. These types of columns were referred to as 
“Type A” columns and examples of this type of column include ‘Hypersif and 
‘Spherisorb’. High purity silica particles have been made since the mid 1990’s. They 
use high purity silanes as starting materials and are essentially metal free and are 
referred to as “Type B” columns. They are considered to be of superior quality to 
previous materials. They have less tailing for basic compounds and are more 
reproducible. The stationary phase is formed on the surface of the silica by reacting 
with a silane containing a reactive group, such as chlorine, the desired phase 
molecule, Cs or Ci8 and small side groups such as methyl. Many of the surface 
silanols remain unreacted because of the steric hindrance -  the large silanes cannot 
physically react with every silanol. Only 3/8 is reacted due to steric hindrance. Some 
of the available stationary phases include; octadecyl (Cig), octyl (Cg), butyl (C4), 
phenyl, polar (cyano, nitrile) and internal hydrophilic groups (as discussed later). All 
columns used in this research were type B columns.
Carbon load is the amount of carbon present in the stationary phase as a percentage of 
the total weight. This is usually measured by thermal gravimetric analysis and the 
typical carbon load is 12 - 15%. Retention is a function of carbon load-higher carbon 
results in longer retention. The more carbon there is the less likely to have polar 
interactions with silanols. The less carbon there is, the more likely to have polar 
interactions with silanols.
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The best measurement of the hydrophobic phase density is phase coverage, measured
9 0as micromoles per meter (pmoles/m ). Maximum coverage for octadecyl'groups on 
the surface of silica is around 3 - 4  |xmoles/m2. Many separations are sensitive to 
phase coverage.
Di and tri-functional si lanes react not only with the silica surface but also by means of 
a water-catalysed reaction with adjacent silanes. This forms a cross-linked silane 
surface with increased pH stability and different selectivity than monomerically 
bonded stationary phases. Polymeric phases are more commonly available on large 
pore silicas because the polymers begin forming in the liquid phases and have 
difficulty entering small pores. Monomeric produces oil/liquid on surface whereas 
polymeric produces wax/solid surface. Polymeric stationary phases are more rigid 
than monomeric bonded phases and exhibit shape selectivity.
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Figure 1.11. Monomeric vs. polymeric C18 bonding. (Source: Grace Vydac 
Application Notes)
Hydrophobic phases behave differently in a purely aqueous mobile phase. Normal 
Cig phases are solvated in the presence of about 5% or more organic modifier, giving 
full access of the analyte molecules to the stationary phase. When the organic solvent 
concentration in the mobile phase drops below 5% the Cj8 phases can no longer 
interact freely with analyte molecules, thus reducing performance. This is also known 
as phase collapse. To prevent stationary phase collapse and enhance analyte 
interactions with the stationary phase in highly aqueous mobile phases, polar groups
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such as hydroxyls, carbamates or amides are incorporated into the hydrophobic chain 
near the silica surface. These are referred to as “polar embedded” columns. This also 
affects analyte selectivity even in mobile phases of higher organic solvent. This is 
typically used for hydrophilic compounds and stationary phase collapse does not 
occur.
While there are slightly more than 8 |imoles/m2 of silanols on the surface of the silica, 
the highest practical phase density of an octadecyl ligand is approximately 4 
jimoles/m2. This means that approximately half of the silanols remain unreacted and 
available for interactions with solute molecules. Since these silanols can cause 
unwanted interactions leading to peak tailing, reversed-phase materials are often 
reacted a second time with a small silane molecule to “end-cap” these free silanols. 
Small silanes such as trimethylchlorosilane are able to access many unreacted silanols 
after the stationary phase has been bonded. This process, known as endcapping, 
renders the silanols inaccessible to solute molecules.
1.4.4. Application of monolithic columns in the area of forensic drug analysis.
Maximum resolution with minimum analysis time is the fundamental goal for any 
chromatographer. Previously, the chromatographer has reduced analysis time by 
using one or several different approaches, including the use of higher flow rates, 
higher column temperatures, shorter columns and reduced diameter of particles in the 
column. The problem of high back pressure is associated with these approaches to 
improve efficiency in conventional particulate columns. The development of 
monolithic columns provides an alternative to particulate columns and allows for 
faster analysis times without compromising separation efficiency.
Monolithic columns consist of a single rod-like structure containing macropores and 
mesopores in its structure (Figure 1.12). The large pores are typically 2 jxm in size 
and this gives rise to a low flow resistance which allows for higher flow rates. The 
smaller pores are typically 12 nm and this ensures for sufficient surface area for 
separation efficiency. Advantages of this novel column are faster analyses without 
reducing resolution (Figure 1.13). These monolithic columns have greater 
permeability and lower plate height, whilst separation efficiency (i.e. resolution of
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analytes) remains unaffected. Silica is not the only material used in monolithic 
columns. Other materials include various polymers such as polymethacrylates (Hebb 
et al. 2003, Lammerhofer et al. 2001, Peters et al. 1998), 
methacryloxypropyltrimethoxysilane (Kato et al. 2002), cationic steary I acrylates 
(Bedair et al. 2003), acrylamides (Hoegger et al. 2001) and polystyrene- 
divinylbenzene (Huber et al. 2001, Gusev et al. 1999). These columns have been 
commercially available since 2002.
Figure 1.12. SEM -  image of the porous structure of a typical monolithic silica 
column
!
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Figure 1.13. A typical Van Dcemter plot for a 5 particle size column, a 3.5 nm 
particle size column and a monolithic column.
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Much of the research has concentrated on the preparation and testing of the 
monolithic columns (Janco et al. 2002, Hayes et al. 2000, Kang et al. 2002, Coufal 
et al. 2002). Monolithic columns have been used most extensively in capillary 
electrochromatography (CEC) (Komysova et al. 2005, Zhao-Sheng et al. 2004, Yan 
et al. 2004, Hilder et al. 2004, Bandilla et al. 2003). Applications of the monolithic 
columns include DNA research (Urthaler et al. 2005, Forcic et al. 2005, Branovic et 
al. 2004, Lubbad et al. 2002), environmental monitoring (Cledera-Castro et al. 2005, 
Sarafraz Yazdi et al. 2005, Asperger et al. 2002) and the analysis of drugs on 
biological samples (Albu et al. 2005, Pistos et al. 2004, Yi Fan et al. 2004, 
Samanidou et al. 2004).
Monolithic columns have only been recently applied to the analysis of drugs of abuse. 
Most studies reported involve transfer of a method from a conventional particulate 
column to a monolithic column and the subsequent comparison of the two whilst 
using a drug of abuse as the analyte. Schneider and Kovar (2003) demonstrated the 
reduction in run times from 11 to 3.5 minutes for the analysis of amphetamines in 
ecstasy tablets. Macchia et al. (2004) used a Chromolith RP18 (100 x 4.6mm) to 
separate a mixture of nine compounds commonly found in a typical heroin sample in 
less than seven minutes. Aboul-Enein and Hefnawy (2005) decreased the run times 
by six fold in the analysis of ketamine and its two metabolites, norketamine and 
dehydronorketamine in human plasma. A Chromolith Performance RP-18 (100 x 
4.6mm) column was used at a flow rate of 3 mL min'1. Limit of quantifications 
(LOQs) were 25 ng mL'1 for ketamine and norketamine and 15 ng mL'1 for 
dehydronorketamine with run time for complete analysis occurring in less than four 
minutes.
Impurity profiling in ecstasy seizures can provide strategic intelligence for the 
determination of the synthetic origin, and tactical intelligence for the determination of 
whether two or more samples come from an identical source, i.e., same batch from the 
same laboratory. The identification of the impurities and the subsequent statistical 
analysis is what can link different unrelated seizures. Utilising a monolithic column 
Byrska and Zuba (2008) studied the different impurities that were present in ecstasy 
tablets. Initial studies examined the extraction process for potential ecstasy tablet 
impurities, tested different buffers and volumes of eluent required and optimised
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HPLC conditions using a simplex method development approach. Using a 
Chromolith Performance RP-18e (100 x 4.6 mm) column, a gradient elution mobile 
phase and a flow rate of 1 mL min'1, separation of the impurities were achieved in 35 
minutes. The method was subsequently applied to ecstasy of known synthetic route 
and successfully classified samples based on the areas of 33 selected peaks. However, 
the use of the monolithic column under these conditions fails to take advantage of the 
monolithic column, i.e. low back pressure with high flow rates. Subsequently, this 
analysis could possibly been carried out at 4 mL m in'1 with a run time of 10 minutes.
A noteworthy feature o f monolithic columns is the high-throughput efficiency 
achieved particularly for toxicological samples. The simultaneous determination of 
48 antidepressants and antipsychotics from human serum was achieved by Kirchherr 
and Kuhn-Velten (2006) using HPLC with tandem mass spectrometry. Sample 
preparation was limited to protein precipitation and dilution. Samples were separated 
using a Chromolith SpeedROD C l8 (50 x 4.6 mm) column with a flow rate of I mL 
m in 1. The method was quantitative and had recoveries of 92 -  111% with an average 
of 101%. Butalbital, acetaminophen and caffeine were separated by Pistos and 
Stewart (2004) from human serum. Solid phase extraction was employed to extract 
the analytes from the serum and separation was achieved by HPLC using a 
Chromolith Performance RP-18e (100 x 4.6 mm) column. Although flow rate was 9 
mL min'1, backpressure was no greater than 177 bar and this allowed for a separation 
of the three analytes from serum in less than 10 minutes.
Wu et al. (2001) demonstrated the rapid analysis times of monolith columns in the 
separation of four benzodiazepines within one minute from human plasma samples. 
In this study tempazepam, tamoxifen, fenfluramine and alprazolam were extracted 
from plasma samples by solid phase extraction (SPE) and chromatographic separation 
was achieved using a Chromolith SpeedROD (4.6 x 50 mm) monolithic column. 
Similarly, Clobazam, an anticonvulsant drug, and its metabolite were separated from 
human plasma using a Chromolith Performance RP-18 (100 x 4.6 mm) monolithic 
column (Rouini et al. 2005). Cocaine and its metabolites (benzoylecgonine, 
norcocaine and cocaethylene) were separated using a Chromolith Performance RP-18 
(4.6 x 100 mm) monolithic column with a flow rate of 5 mL min’1 with a run time of
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five minutes (Caufiled & Stewart, 2002). Eight benzodiazepines (clonazepam, 
desalkylflurazepam, diazepam, flunitrazepam, lorazepam, midazolam, nordiazepam 
and oxazepam) commonly encountered in forensic toxicology were separated in less 
than four minutes using Chromolith Performance RP-18 (100 x 4.6 mm) (Bugey & 
Staub, 2004).
The development of the monolithic column has been a significant milestone in the 
history of separation technology. This new generation of columns has allowed for 
faster separations at lower backpressures without the loss in efficiency. Other 
advantages include the reduction of analysis times for toxicological samples and the 
ability to transfer methods developed for conventional particulate columns to 
monolithic columns. It can be expected that the monolithic column will have future 
applications in forensic drug analysis and be an integral tool for the war against drugs. 
Future applications may concentrate on the ever expanding illegal drug market and 
adapting analytical methods to separate and detect new chemical compounds with 
high abuse potential.
Since the introduction of the monolithic column, column technology has developed in 
several ways. Initially, manufacturers concentrated on reducing the particle size of 
the traditional particulate column. Particle size was reduced from 5 (xm to 3.5 i^m, 
then 2.5 ^m, 1.7 jim and ultimately 1.5 (im. The efficiency of a column increases as 
the size of the particle decreases as the smaller particle size improves the mass 
transfer kinetics. However, the small particle size generates more back pressure 
because it gives more resistance to solvent flow. With the increase in efficiency 
associated with the smaller particle size, a reduction in column length was also made, 
from the traditional 250 mm to 150 mm and 50 mm resulting in the same efficiency as 
that of a 5 |im, 250 mm particulate column. The reduction in column diameter also 
has been used as a tool to improve efficiency. Smaller diameter columns also use less 
mobile phase per analysis because a slower flow rate is required to achieve the same 
linear velocity through the column. These changes to the physical dimensions of the 
particulate column required pumps of higher pressure which in turn, led to the 
creation of Ultra-Performance Liquid Chromatography (UPLC). Combining the 
advantages o f the monolithic columns with the smaller particle size particulate
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column, a new particle was created. Known as “fused core particle technology”, 
"porous shell” or ‘‘core shell” the column consists of small particle, typically 1.7 nm, 
to which a 0.5 |im porous diffusion path is bonded. The reduction in diffusion path 
serves to increase the mass transfer kinetics, resulting in faster separations. Merck 
have since developed the next generation o f monolithic column, named “Chromolith 
High Resolution”. They state that the column performance of this new type o f column 
is 50% greater than that of the usual Chromolith column, and is comparable to that of 
the sub 3 nm particle size columns.
1.5. C h em om etr ics  and statistical profiling.
Statistics were employed throughout this study in various forms. Initially, 
experimental design combined with Artificial Neural Networks (ANN) were used to 
develop a method for the separation of cocaine components routinely detected in 
street samples. In addition a range o f sample pre-treatment and pattern recognition 
methods were applied to results o f the chemical analyses of ecstasy in order to profile 
the drugs and to establish links.
1.5.1. Experim ental design.
There are two approaches that can be made in order to develop an experimental 
protocol, the univariate or multivariate approach. Univariate method development 
involves studying each factor involved in the experiment individually to assess its 
effect on that experiment. This process can be laborious and time consuming 
however all levels of each factor would be investigated. The second approach, the 
multivariate method, involves simultaneously investigating different factors at 
different levels, thus minimising the effort involved in developing the method. One of 
the most universal procedures used for this is a ‘full factorial design’. It is based on 
varying the most influential chromatographic factors o f the analysis at two levels. A 
‘fractional factorial design’ uses only a subset o f the experimental runs that would be 
involved in the full factorial design, but results in similar statistical information. 
Overall, this approach is more efficient and less time consuming. To illustrate the 
effect each chromatographic factors on analyte separation, artificial neural networks 
arc used to generate response surfaces. From these, the optimal separation conditions 
can be selected.
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Artificial Neural Networks is a computer based system derived from the simplified 
concept o f the brain in which a number o f nodes, called neurons, are interconnected in 
a netlike structure. They are capable o f modeling extremely complex functions. 
Figure 1.14 illustrates a simple ANN. There are two input variables, one layer o f six 
units and one output variable. The number o f input variables, inner layers and output 
variables is dependent on the data set. For the method development, the input 
variables are the different levels o f the different chromatographic factors for each 
experimental run and the output variables are the performance indicators. For the 
tablet classification, the input variables are the pre-treated (as defined on page 51) 
peak areas of the chemical components o f the tablets and the output variables are the 
different chemical classes. A trained network should be able to model the function 
that relates the input variables to the output variables, and can be used to make future 
predictions.
Input Layer Hidden Layer Output Layer
►
►
Figure 1.14. A typical neural network consisting of two input variables, one layer of 
six units and one output variable.
Neural networks tend to be a feed-forward structure, i.e. the signal goes through the 
input variables first, then the inner layers and finally the output layers. This may not 
always be the case as sometimes the structure may be ‘recurrent’, this is where the 
signal flows back again through from the output variable to the input variables. ANN
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operates on the principal of training the data. This involves using input variables with 
their known output variables in order to train the network. The weights of each 
neuron are continuously adjusted until the errors are minimised. Once the network has 
been trained, predictions based on new input variables can be made.
Network architecture is an important aspect of neural networks. Two of the most 
common forms include MultiLayer Perceptrons (MLP) and Radial Base Functions 
(RBF). For each form, the «-dimensional pattern space is divided up using 
hyperplanes (MLP) and hyperspheres (RBF). MLPs are the most common type of 
network. RBFs tend to be slower than MLPs to use, but are very quick to train. Both 
hyperplanes and hyperspheres work by dividing two classes. For both models, each is 
trying to find the lowest point (minimum error) in the «-dimensional space.
1.5.2. Drug classification.
Classification is the arrangement of objects with similar properties together. In order 
to achieve this, the properties (i.e. chemical profiles) of the objects (i.e. drug seizures) 
must be determined. Once identified, the chemical profiles can be used as the data for 
the statistical techniques applied for the classification.
Pre-treatment methods.
Data must be pre-treated so that no one variable (in this case chemical component) 
dominates the others. Normalisation, standardisation, 4th square root and logio are the 
most commonly used pre-treatment methods (Andersson et al. 2007, Baer & Margot, 
2006, Dujourdy et al. 2008, Lociciro et a l  2008).
Normalisation - For each chemical compound, their peak area was divided by the sum 
of all peak areas (see Equation 1.1). For metal analysis, the absorbance value for a 
particular metal was divided by the sum of all the absorbance values for all the metals.
Nt = ^ r -  (Equation 1.1)
Where x, = area of peak /. Although this pre-treatment method will allow all data 
points to be on the one scale, it may happen that larger peak areas will still influence
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smaller peak areas. For this reason, normalisation in combination with other pre- 
treatment methods is recommended.
Standardisation - For each chemical compound, their peak area was divided by the 
standard deviation of all peak areas (see Equation 1.2 and 1.3). This method is also 
referred to as ‘weighting’.
S, =  — ( Equat i on 1.2)
SD,
Where SD; = J  ^ ^ (Equation  1.3)
V n ( w - l )
Where x, -  area of peak /, n = number of samples, SD, = standard deviation of peak /.
Logarithm - For each chemical compound, the logiowas calculated (Equation 1.4).
L i = logic x, (Equation  1.4)
Where = area of peak i. A consideration for this method is the presence in the data 
set of zeros, as logio of zero cannot be calculated.
4,h Square root - For each chemical compound, the forth square root was calculated 
(Equation 1.5). Due to the inability of logio to calculate zeros, this may be used as an 
alternative.
R,= ^  (Equation  1.5)
Where x, -  area o f peak i.
Pattern recognition m ethods.
The statistical techniques used for classification or pattern recognition can be either 
supervised or unsupervised. For some groups of data, prior knowledge of the samples 
is not known. In this case, unsupervised methods such as Hierarchal Cluster Analysis 
(HCA) or Principal Component Analysis (PCA) are used. Again, these specific 
methods may be used when general information on the data is required, e.g. natural 
groups or outliers within the data. Supervised methods assign class membership to the 
data prior to the statistics being applied. The aim is to ‘train’ a model so that future
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samples can be classified automatically. Examples of supervised methods include 
Linear Discriminant Analysis (LDA) and Artificial Neural Networks (ANN).
Pearson Correlation Coefficients - This is a method used to describe the relationship 
or correlation between two samples (Equation 1.6). Values are given in the range -1 to 
1. The closer to 1 the value is the stronger the correlation, closer to -1, the stronger the 
negative correlation. Values at 0 indicate no relationship whatsoever. In the context 
of this study, tablets from similar seizures should have a coefficient value close to 1, 
whilst tablets from different seizures should have a value near 0. A popular alteration 
to this statistic is to multiply the result by 100, as this makes for easier comparison 
with other statistical methods. This type of statistical method is very basic in terms of 
classification and relatively simple to perform and therefore is quite common in 
research studies.
- y ) )
r, = —— ------------------- (Equation 1.6)
Z ( * ; - X ) 2
»=1
Where r = correlation, x is the mean of x value and y  is the value of y  value,
Hierarchal Cluster Analysis (HCA) - This is a method for dividing a group of objects 
into classes so that similar objects are in the same class or cluster. It searches for 
objects which are close together in the variable space. This statistical method 
measures the distance between two objects and if the distance is relatively small then 
similar linked objects will be clustered. The similarity distance between samples is 
calculated by both cluster and interval methods. Typical clustering methods include 
Between groups, Within groups, Nearest neighbour, Furthest neighbour, Centroid, 
Median, and Wards. Interval methods include Euclidean, Square Euclidean, Cosine, 
Pearson, Chebychev, Block and Minkowski. The data variable set will determine the 
most appropriate interval and cluster methods. Results of HCA are typically 
represented as a dendogram which display the clusters associated with the data set. 
Figure 1.15 illustrates six cases clustered to three distinct groups at Euclidean distance 
1. Increasing the Euclidean distance to 10 will generate two groups for the same six 
cases. The distance or similarity measure can therefore be subjective in determining 
the number of clusters present in the dendogram.
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Dendrogram using Average Linkage (Between Groups)
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Figure 1.15. Simple HCA dendogram.
Principal Component Analysis (PCA) -  This is a multivariate procedure used to 
reduce the dimensionality of a data set while retaining as much information as is 
possible. The first principal component is the combination of variables that explains 
the greatest amount of variation. The second principal component defines the next 
largest amount of variation and it is independent of the first principal. When there is 
significant correlation within the data, the number of principal components will be 
much lower than the number of variables. A scree plot is a visual display that 
describes how much of the variance is attributed to each of the principal components. 
Ideally, the first and possibly second principal components should account for the 
majority of the variance. After PCA is performed, scores of each principal component 
for each case is produced. A scores plot is a visual display of these values. This plot 
is important for the classification process, as this identifies the natural groupings 
within the data set. Ideally, related cases should be grouped together on the plot, and 
these linked groups should be distant from others. Figure 1.16 illustrates the score 
plot using the same data from the HCA dendogram above. This example shows an 
ideal grouping, where similar data are grouped together and groups are distant from 
each other.
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Figure 1.16. Score plot of first two principal components.
Linear Discriminant Analysis - For each seizure, the n data points are reduced from n 
dimensions to one dimension. Each dimension is given a coefficient which reflects 
the difference between seizures. This statistical approach works by finding the linear 
discriminant function (Y) for each class or seizure. This is a combination of the 
coefficients (a) o f each variable (X),
The coefficients are assigned so that Y is very different for each class. When new data 
is applied, the resulting value of Y will indicate which class or seizure that data set 
belongs to by comparison of the Y values for each class.
Artificial Neural Networks (ANN) - The major attribute of neural networks, is that 
once established within the laboratory as a classification tool, results of further 
chemical analysis can be added to the network and tablets of similar chemical profile 
can be highlighted. Over a period of time, this information accumulates into “drug 
intelligence” which can lead to dealer networks or even production laboratories being 
more easily identified. Artificial neural networks algorithms have the potential to 
provide complete solutions in the identification of patterns in data sets (Bishop, 1996). 
Individual networks and ensembles of networks can be created and tested using the
Y — ajXi + a2X2+ .. .anXn (Equation 1.7)
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Intelligent Problem Solver (IPS) system function in the Trajan software. The software 
randomly assigns individual data sets from each sample into training, selection and 
test sets. Multiple networks for each data set can be tested by Multi-Layer Perceptron 
(MLP) and Radial Base Functions (RBF) methods. Selection o f the most suitable 
network is based on the performance of the selection set and the difference in the error 
associated with the selection set and the test set, The optimal network based on 
performance, selection and minimum error values should be capable of handling new 
data and have the ability to classify new data adequately (Waddell et a l  2004).
1.5.3 Application of chemometrics to illicit drug profiling.
Although there are numerous reports in the literature on statistical profiling of illicit 
drug samples there is no clear standard protocol or approach to apply (Andersson et 
al. 2007, Baer & Margot 2007, Billault et a i  2007, Byrska and Zuba 2008, Cheng et 
al. 2006, Dayrit & Dumlao 2004, Dufey et al. 2006, Dujourdy et al. 2008, Dujourdy
& Besacier, 2008, Esseiva et al. 2005, Gosav et al. 2006, Janhunen & Cole 1999, 
Klemenc 2001, Koper et a l  2007, Krawczyk and Parczewski 2001, Kuwayama et al. 
2006, Lociciro et al. 2008, Palhol et al. 2002, Puthaviriyakron et al. 2002, 
Weyermann et al. 2008). Various pre-treatment methods, unsupervised pattern 
recognition methods and supervised pattern recognition methods have been applied to 
data sets to determine the most appropriate method. In addition many reports refer to 
impurities as the main target to determine patterns in illicit drug samples. Regardless, 
the overall aim of statistical profiling methods is to identify synthetic routes, identify 
geographical origin or simply highlight seizures of similar chemical profile.
Chemometrics involves the application of statistical protocols to multivariate 
chemical data sets. Various statistical protocols have been applied for the analysis of 
illicit drug samples. Baer & Margot (2007) evaluated different pre-treatment methods 
(i.e. normalisation, standardisation, fourth Square Root, logarithm) and different 
comparison methods (i.e. Pearson’s correlation coefficients, Squared cosine, 
Similarity index, Canberra index, Euclidean distance and Manhattan distance) for the 
statistical profiling of ecstasy tablet samples. Fourteen data variable sets comprised of 
sugar and fatty acid content were examined in various combinations of data pre­
treatment and comparison methods. The combination of fourth squared root with
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squared cosine function was the most successful at classifying data sets with 109 
ecstasy samples categorised into 67 groups. Under the European project for 
Collaborative Harmonization of Methods for Profiling Amphetamine Type Stimulants 
(CHAMP), Andersson et al. (2007) evaluated statistical protocols for profiling of 
amphetamines. Combinations of four different pre-treatment methods with six 
different distance methods were examined and normalisation with 4th square root pre­
treatment method with Pearson’s correlation coefficients comparison method was 
selected as the preferred protocol. Lociciro et al. (2008) examined sixty six statistical 
combinations in a cross border study of cocaine samples between France and 
Switzerland. Ten different data pre-treatments with six distance measurements were 
evaluated and the final combination of Normalisation with Standardisation for data 
pre-treatment with either Pearson’s correlation or squared Cosine function was the 
most appropriate protocol for the cocaine profiling.
Impurity determination is commonly used for drug classification purposes. 
Puthaviriyakron et al. (2002) studied impurities of methamphetamine tablets from 
Thailand. GC peak areas of nine impurities were normalised and then analysed by 
HCA. At a similarity index of 0.55, five groups were identified. A similar study of 
methamphetamine from the Philippines, used HCA to classify the drugs based on 
impurities present (Dayrit & Dumlao, 2004). GC peak areas of each compound were 
normalised. Thirty, forty and fifty impurity compounds were tested and results 
indicated that by increasing the number of impurity data sets the better the resulting 
HCA dendogram. Kuwayama et al. (2006) compared different pre-treatment methods 
with different clustering methods using impurity data of methamphetamine samples. 
A combination of raw data, square root and logarithm with Euclidean, cosine and 
correlation coefficient distance methods was used and resulted in logarithm pre­
treatment with cosine distance being the most appropriate for this analysis. Thirty- 
two samples were classified into nine groups based on eight impurity GC peak areas. 
More recently, Weyermann et al. (2008), was able to reduce the number of target 
impurities from thirty two to eight. The data was normalised with square root pre­
treatment and PCA was applied. No pattern was identified, concluding that the 
MDMA tablets seized in Europe for this study were all produced within the same 
geographical area.
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The identification o f synthetic routes can be a key ingredient in the classification 
process and has been used by a number o f researchers. Koper el al. (2007) analysed a 
large number of ecstasy tablets for their metal content (forty-nine metals analysed) 
with the intention o f identifying the synthesis production method. Clustering based on 
Pearson’s correlation together with average linkage (between groups) was found to be 
the best and most robust clustering technique for this type of data. The production 
method could be identified for eighty-nine o f the ninety-seven tablets analysed. Using 
the element profile, thirteen links were identified within the ninety-seven MDMA 
tablet samples. Billault et al. (2007) synthesised samples of ecstasy using the five 
most common methods and samples were analysed by isotope ratio mass 
spectrometry. PCA was applied to the values from the precursors and the samples. 
Full discrimination was achieved for all but two samples. Byrska and Zuba (2008) 
divided MDMA samples into their different synthetic routes by applying HCA. The 
chemometric approach involved applying Wards’ clustering with Pearson’s distance 
metric was to thirty three impurities associated with samples. PCA was subsequently 
applied to verify the HCA findings. Palhol et al. (2002) investigated the most popular 
synthesis route for MDMA tablets in France. Within this study, thirty impurities from 
fifty two samples were identified. Using HCA, the reductive amination route was 
found to be the most popular synthesis route and 3, 4-methylenedioxyphenyl-2- 
propanone was the most common precursor. Similarly, Dujourdy et al. (2008) 
normalised the peak areas o f forty three impurities from methamphetamine samples 
and the application o f HCA and PCA allowed for the identification different synthetic 
routes.
The geographical origin o f cocaine was determined using HCA and partial least 
squares -  discriminant analysis (PLS-DA) for eighteen residues from 2863 cocaine 
samples (Dujourdy & Besacier, 2008). Unsupervised pattern recognition methods of 
HCA using Wards clustering method and Pearson’s correlation coefficients were 
investigated. At a similarity index of 0.5 Colombian, Peruvian and Bolivian samples 
were distinguished. PLS-DA was used to confirm HCA results o f the three groupings. 
A study by Klemenc (2001) used various statistical methods to observe the influence 
of cxcipicnts on heroin street samples. Samples were deliberately cut with the most 
common excipients (sucrose, glucose, mannitol, procaine, caffeine, paracetamol, citric
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acid) in different combinations and concentrations and analysed by GC-MS. The 
peak areas were normalised and then standardised. Pattern recognition methods used 
were HCA, PCA and K-nearest neighbour. Results indicated that HCA and PCA 
were both better at classification than KNN with both having a correct classification 
rate of 100%. The conclusion from this study was that diluting the samples with any 
of the excipients had no effect on the classification. Five major constituents of heroin 
were successfully used to classify samples by Dufey et al. (2006), GC peak areas for 
the five targeted compounds were normalised and Pearson’s correlation coefficients 
calculated to ascertain the capacity o f the method in determining chemical links 
between seizures.
Many studies aim to identify general connections between seizures, without any 
concern regarding their synthetic route or geographical origin. In a study by Cheng et 
al. (2006), ecstasy tablets in Hong Kong were analysed by GC-MS for their impurity 
content. The data was normalised and HCA catagorised the eighty nine samples into 
four groups at 0.5 similarity index. One thousand amphetamine samples were 
classified into thirty seven groups in a study by Krawczyk and Parczewski, (2001). 
Correlation coefficients were calculated to initially classify the tablets, followed by 
both PCA and HCA. Linear discriminant analysis was applied to heroin samples 
(Janhunen & Cole, 1999). Thirty one samples were classified into eight groups with a 
correct classification rate of 91,9%.
The application o f artificial neural networks has been limited. Gosav et al. (2006) 
built a search library for a GC-FTIR based on two neural networks for amphetamine 
classification. The first neural network could distinguish between amphetamines and 
non-amphetamines and the second neural network could distinguish between 
stimulant amphetamines, hallucinogenic amphetamines and non-amphetamines. The 
choice of neural network was based on the highest correct classification rate. A 
correct classification rate of 96% was achieved by Esseiva et al. (2005) for the 
classification of heroin samples. The peak areas of six compounds for 3371 samples 
were normalised and PCA was applied. This roughly divided the samples into 
different classes, from which correlation coefficients were calculated. The correlated > J 
I
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samples were then used to train the networks. Both MLPs and RJBFs were tested. The 
network with the highest correct classification rate was an RBF 6:121:20.
1.6. Legislation and control efforts in Ireland.
Three treaties drawn up by the United Nations are the backbone to which drugs are 
controlled worldwide; The Single Convention on Narcotic Drugs 1961, The 
Convention on Psychotropic Substances 1971 and The Convention against Illicit 
Traffic in Narcotic Drugs and Psychotropic Substances 1988.
Legislation in Ireland is determined by The Misuse of Drugs Act, 1977 and 1984 and 
the regulations (Irish Statute Book). In 1993, the Misuse of Drugs Regulations was 
added to include the control of production, supply, importation, exportation and 
possession of precursors. In 1999, the 1977 Act was amended, Section (15A) deals 
with the possession of drugs of a street value over €12,700. A person in possession of 
drugs of this value or more is deemed to be supplying or selling and court convictions 
can result in a ten year minimum prison sentence.
There are five categories of drugs in the national legislation:
I. Substances with no medical use
II. Strictly controlled substances with medical use
III. Strictly controlled medicinal products
IV. Less controlled medicinal products
V. Products containing small quantities of category I-IV compounds
In Ireland, possession of cannabis or cannabis resin for personal use is punishable by a 
fíne on first or second conviction but from a third offence onwards it incurs a fine 
and/or a term of imprisonment up to one year.
On the 23rd of August 2010, Ireland introduced new laws with regard to the sale of 
psychoactive substances that were not previously controlled under existing legislation. 
Retail outlets, more commonly known as ‘head shops’ were taking advantage of 
; selling drugs that were new to the market and considered legal. Under the ‘Criminal
}
j Justice (Psychoactive Substances) Act 2010’ psychoactive substances including
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synthetic cannabinoids, mephedrone, piperazine derivatives, flephedrone and 
methylenedioxypyrovalerone (MDPV) were made illegal (Irish Statute Book, 2010),
Various groups and organisations have been established in Ireland to address the drug 
problem. Reduction in supply of drugs is ultimately the responsibility of the 
Department of Justice, Equality and Law Reform, within which An Garda Siochana 
(police service), the courts, the Irish Prison Service, the Irish Customs Service and the 
Irish Naval Service (Department of Defence) all cooperate. Both the National 
Advisory Committee on Drugs (NACD) and the Alcohol and Drug Research Unit 
(ADRU) of the Health Research Board (HRB) are the two main bodies which conduct 
research on drugs and drug related issues. Drug Task Forces, both local and regional, 
are community based groups that assist government agencies to respond quicker and 
more efficiently to established and emerging drug problems within their local area. 
These groups are managed by the National Drugs Strategy Team (NDST), who liaises 
between the local and regional groups and the government. They make policy 
recommendations based on the conclusions of the task forces. The NDST along with 
the Inter-Departmental Group on the National Drugs Strategy are involved with 
monitoring the implementation of the National Drugs Strategy.
In Europe, many agencies have been established whose aim is to disseminate all drug 
related data. Each country has one or more such agencies, for example Ireland has the 
Drug Awareness Programme (DAP) and the Irish Needle Exchange Forum (INEF). 
The EMCDDA is one of the main European organisations responsible for monitoring 
drug developments. They work in conjunction with national agencies and Europol to 
provide information on the drug situation in Europe. Europol deals with all criminal 
intelligence in Europe and has a focus on drug trafficking, Interpol is a worldwide 
police organisation that supports all cross boarder activities that could reduce crime. 
A major focus is drugs, with an emphasis on identifying new drug trafficking 
developments and criminal organisations operating at the international level. The 
European Network of Forensic Science Institutes (ENFSI) is another organisation in 
which forensic laboratories across Europe collaborate on various issues. Within this 
large organisation are 16 ‘expert working groups’, one of which focuses on drugs 
alone.
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As the drug situation grows, new organisations are being established, for example the 
European Maritime Analysis and Operations Centre -  Narcotics (MAOC-N). It is an 
international agency set up to coordinate anti-drug trafficking by several European 
countries. Based in Lisbon, its objective is to use intelligence on drug smuggling 
operations, by air or sea, and apply the most suitable military and/or law enforcement 
teams to respond to situations that arise. Ireland is a member and is represented by 
An Garda Siochana, the Irish Customs Service and the Irish Naval Service.
Worldwide the main policy maker is the United Nations (UN), or more specifically 
the United Nations Office of Drugs and Crime (UNODC). Within the UNDOC, there 
are two Commissions that deal directly with drugs, The Commission on Narcotic 
Drugs and the Commission on Crime Prevention and Criminal Justice. The former 
established all procedures and guidelines pertaining to illicit drugs based on 
observations of the world drug situation, whilst the later advises policy makers on all 
matters relating to crime prevention and criminal justice. The International Narcotics 
Control Board (INCB) implements all policies and recommendations issued by the 
UNODC. The World Customs Organization (WCO) provides all information of 
custom controls and smuggling.
1.7. Aims and objectives.
The overall aims of this research thesis are to investigate the application of High 
Performance Liquid Chromatography (HPLC) for the analysis of major drug 
constituents associated with ecstasy and cocaine illicit drug samples. Emphasis is 
placed on method development with univariate or multivariate experimental strategies 
used in the selection and optimisation of HPLC protocols. Methods developed are 
applied to the area of forensic drug analysis and chemical data obtained is analysed by 
chemometric methods to determine if statistical profiling can be beneficial in 
establishing links between unrelated ecstasy seizures. The research strategy was 
divided into following areas:
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1. HPLC method development.
Univariate method development approach was applied to the design of a 
HPLC method for the simultaneous detection and quantification of 
amphetamine, methamphetamine, MDMA, MDA, MDEA, MBDB and 
adulterants commonly found in ecstasy tablets. Considerations with regard to 
the choice of chromatographic factors, solutes under investigation and the 
provision of quality assurance data throughout the research work are important 
in method development, Comparative evaluation of monolithic columns versus 
particulate column stationary phase materials in the separation of ecstasy 
analytes was performed.
Alternatively the multivariate HPLC method development approach for the 
analysis of cocaine samples was also evaluated. Multivariate method 
development simultaneously examines all chromatographic separation factors 
to determine optimum performance based on mathematical model response 
surfaces. This approach has the potential to minimise the number of 
chromatographic experiments required and may considerably reduce the time 
taken for the selection of the optimal separation conditions.
2. Analysis of seized ecstasy and cocaine samples.
Once established, the HPLC methods developed were applied to ecstasy and 
cocaine street samples to qualitatively and quantitatively assay for the major 
active ingredients and adulterants associated with street samples. The 
identification of sugar excipients and metal impurities is important from an 
investigative perspective. Knowledge of such components may provide a 
means of establishing the origin or the synthetic routes employed and provide 
evidence of a link between seized drug samples. As such, sugar composition 
and inorganic metal data analysis was determined to obtain a near complete 
chemical profile of ecstasy samples. Physical and chemical profiles were 
evaluated for 183 ecstasy samples seized in the Republic of Ireland during 
2001-2003.
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3. Chemometrics and statistical profiling of ecstasy tablets.
Recently, the applications of drug profiling methods have demonstrated the 
potential o f these statistical techniques in establishing links between illicit 
drug samples. Unsupervised pattern recognition methods of PC A, HCA and 
Pearson’s correlation coefficients and supervised pattern recognition methods 
of LDA and ANN were evaluated in order to determine the applicability of 
methods in profiling illicit drug ecstasy samples. Ecstasy chemical data sets of 
active ingredients, sugar components and metal composition were investigated 
to identifying possible groupings and thereby provide strategic intelligence 
and an understanding of drug trafficking in the Irish ecstasy market.
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Chapter 2: Materials and methods.
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2.1. General materials and instrumentation.
2.1.1. Chemicals and reagents.
All reagents used in this study were of HPLC analytical grade. Acetonitrile, 
ammonium dihydrogen phosphate, magnesium nitrate, nitric acid and phosphoric acid 
were purchased from Lennox Laboratories (Dublin, Ireland). Potassium dihydrogen 
phosphate and methanol were purchased from BDH Laboratory Supplies (Poole, 
England).
A license to purchase and possess drug standards for research purposes was obtained 
from the Irish Medicines Board, formally the Department of Health and Children 
(Drugs Section), Ireland. AH amphetamine standards (amphetamine, 
methamphetamine, MDA, MDMA, MDEA and MBDB) were purchased from Sigma 
(Poole, England). All cocaine standards (cocaine, lidocaine, procaine, prilocaine and 
benzocaine) were purchased from Sigma (Poole, England). The Garda Forensic 
Science Laboratory Dublin, Ireland supplied all ecstasy and cocaine samples used in 
this study.
Acetaminophen, acetylsalicylic acid, caffeine, clomipramine, metoclopramide, 
phenacetin, propyl paraben and uracil were also purchased from Sigma (Poole, 
England). All sugar standards (fructose, glucose, inositol, lactose, mannitol, sorbitol 
and sucrose) were purchased from Sigma (Poole, England). All the metal standards 
(aluminium, calcium, chromium, iron, lead, magnesium, potassium, sodium and zinc) 
were purchased from Merck (Germany).
2.1.2. Liquid chromatography system.
The chromatography was performed on a Shimazdu HPLC system (Mason 
Technology, Dublin, Ireland). This was equipped with an autoinjector (SIL-lOADvp), 
a solvent delivery module (LC-lOATvp), a degasser (DGU-14A), a column oven 
(CTO-1 OACvp) and a system controller (SCL-lOAvp). A UV/Vis photodiode array 
detector (SPD-MlOAvp) was used for the ecstasy and cocaine method development 
and a refractive index detector (RID-10A) was used for the sugar analysis. The 
Shimazdu ClassVp HPLC software was used for instrument control, data acquisition 
and data analysis.
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2.1.3. Atomic Absorption Spectrometry.
A Perkin Elmer Atomic Absorption Spectrometer Model 3300 equipped with a Perkin 
Elmer HGA600 graphite furnace, a Perkin Elmer AS-60 Autosampler and a deuterium 
lamp background correction was used with hollow cathode lamps (Perkin Elmer) for 
the metal analysis.
2.1.4. Miscellaneous instruments.
The ultrasonic bath used was a Cole-Parmer 8890 (VWR, Dublin, Ireland). An Ohaus 
AS 120 analytical balance was used to weigh samples and standards. The deioniser 
used was a Millipore ‘Direct Q \ ASTM Type 1,18 M il (Mason Technology, Dublin, 
Ireland).
2.1.5. Computer software.
Principal component analysis was performed using Minitab statistical software 
(Minitab Inc., PA, USA). Hierarchal cluster analysis and linear discriminant analysis 
of ecstasy data were performed with the statistical software SPSS Version 13 (SPSS 
Inc., Chicago, IL, USA). A Microsoft Excel macros file was provided from the 
European Network of Forensic Science Institutes (ENFSI) for the determination of the 
Pearson’s correlation coefficient. Neural networks for the classification o f ecstasy 
data was generated by Trajan Neural Network software (Trajan Software Ltd., 
Durham, UK).
Minitab statistical software (Minitab Inc., PA, USA) was used to generate fractional 
factorial design for the multivariate cocaine method development. In addition, neural 
networks and response surface plots were constructed using Trajan Neural Network 
software (Trajan Software Ltd., Durham, UK) for the multivariate method 
development.
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2.2. Univariate HPLC method development for the analysis of ecstasy.
2.2.1. Ecstasy standards and sample preparation.
Stock solutions of uracil and the internal standard metoclopramide HC1 were prepared 
in methanol at a concentration of 1 jig mL'1. Amphetamine standards for sample 
analysis and the ecstasy samples were prepared in the internal standard solution. For 
method development a mixed amphetamine standard solution containing; 
amphetamine, methamphetamine, MDA, MDMA, MDEA and MBDB was used to 
examine method selectivity and resolution. Uracil was used as an unretained 
compound. Detection of analytes was at 200 nm.
Application of the developed method was made to 183 ecstasy tablet samples. Ecstasy 
tablet samples were representative of the seizures throughout the Republic of Ireland 
(Figure 2.1.) in 2001 and 2003. Ecstasy tablets were provided as discrete individual 
batches (61 in total) from the Forensic Science Laboratory, Dublin. Batches 1-12 were 
from seizures in 2001 while the remaining batches 13-61 were seizures from 2003. 
Each batch contained three tablets and each tablet had a specific reference number 
assigned, For HPLC analysis ecstasy tablets were individually pulverised into a fine 
powder using a mortar and pestle. Three 10 mg aliquots of each tablet sample were 
dissolved in 10 ml of the internal standard solution. All solutions were sonicated for 
ten minutes and filtered through 0.45 \xm filters (Millipore, MA., USA.) prior to 
HPLC injection.
Six physical parameters (weight, logo, colour, shape, thickness and diameter) were 
recorded to ascertain the physical characteristics of each ecstasy tablet. All weight 
measurements were carried out using a calibrated analytical balance. Callipers were 
used to measure diameter and thickness. A representative tablet from each batch was 
digitally photographed to record sample physical appearance.
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Figure 2.1. Distribution and percentage of ecstasy batch seizures used in this study.
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2.2.2. Univariate method development for analysis of ecstasy.
The design of the experimental procedure concentrated on a univariate method for the 
development of a HPLC method for the analysis of ecstasy tablets. As such, each 
chromatographic factor was considered individually, and the effect of the varying 
factor evaluated on the performance for method development.
Assessment of column stationary phase materials was evaluated by examining seven 
commercially available columns. Columns of different physical and chemical 
characteristics were deliberately chosen (Table 2.1). Selected column types included 
the Luna C 8  column, 5 fxm, 250 x 2.0 mm, ODS2 (Phenomenex Inc.); Phenosphere, 5 
pm, 250 x 4.4 mm ODS2, C18 (Phenomenex Inc.), Luna, 5 pm, 250 x 2.0 mm, 
ODS2, C l 8  (Phenomenex Inc.); a newer type ‘Hybrid5 column XTerra, 5 jim, 250 x 
2.1 mm RP18 (Waters Corporation) and three monolithic columns, namely, 
Chromolith Flash RP-18, 25 x 4.6 mm, Chromolith SpeedROD, RP-18, 50 x 4.6 mm 
and Chromolith Performance RP-18, 100 x 4.6 mm (Merck KgaA).
Analyte separation is dependent on interactions between the mobile and stationary 
phases. A phosphate buffer (20 mM) was used in the preparation o f the mobile phase 
for HPLC and was prepared by adding 2.7 g of potassium dihydrogen phosphate to 1L 
deionised water. Acetonitrile was used as the organic solvent within the mobile phase 
and its effect on the quality of the separation was determined at different solvent 
strengths. Solvent strengths comprising different acetonitrile concentrations ranging 
0% to 30% with 20 mM phosphate buffer (pH 3.0) were evaluated. When required, 
gradient elution technique was applied to columns with poor chromatographic 
separation to enhance solute resolution. The effect of pH was also investigated by 
adjusting buffer pH using phosphoric acid over a pH range of 2.5, 3.0 and 3.5 (as 
discussed on page 85).
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Table 2.1. Physical characteristics of stationary phase columns examined for univariate HPLC method development analysis of ecstasy.
Column
Column physical param eters
Pore Size
(A)
Surface
Area
(m2/g)
Carbon
Load Surface Coverage (nmoles/m2)
Length
(mm)
Internal
Diameter
(mm)
Size
Distribution
(nm)
Particle size
(nm)
Endcapping
Luna C81 100 417 14.40 4.58 250 2.0 1.89 5 Yes
Phenosphere C] 81 80 220 11.00 2.50 250 4.6 1.89 5 Yes
Luna Cl 81 100 417 18.05 3.39 250 2.0 1.89 5 Yes
XTerra RP182 121 190 15.14 2.27 250 2.1 1.61 5 Yes
Performance RP-183 NA 300 17.00 NA 100 4.6 NA NA Yes
SpeedROD RP-183 NA 300 17.00 NA 50 4.6 NA NA Yes
Flash RP-183 NA 300 17.00 NA 25 4.6 NA NA Yes
1. Luna and Phenosphere columns were supplied by Phenomenex Incorporation; 2. XTerra column was supplied by Waters Corporation; 
3. Monolith columns were supplied by Merck Kga, NA: not applicable
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Temperature effects in HPLC are not as significant as in gas chromatography. 
However, theory states that increasing the temperature will decrease retention factor 
(k5) and thus decrease the retention time. The effect of column temperature was 
examined over a range of temperatures. The six standard solution was injected at 
25°C to 45°C in 5°C increments and the most appropriate temperature was selected 
based on retention times and resolution.
Flow rate is an important criterion in optimising a suitable method. Optimum flow 
rates should give a short retention time with good analyte resolution at low pressure. 
In addition, optimal flow rates should consider solvent consumption and waste 
production, which should be kept to a minimum to reduce costs. Flow rates for the 
particulate columns were dependent on the internal diameter and were varied from 0 .1  
mL min' 1 to 2 mL min'1. The main factor which differentiates monolithic columns 
from the traditional particulate columns is the ability to use higher flow rates without 
a high backpressure. The HPLC pump capacity allowed for pump rates up to 9.999 
mL min'1. Monolithic columns had a maximum pressure of 200 bar. Preliminary 
investigations determined that 200 bar allowed for a flow rate of 9 mL min'1. 
Therefore flow rates of 0.5 mL min*1 to 9 mL min ' 1 were assessed in 0.5 mL min ' 1 
increments. The backpressure at each increment was recorded for each column.
2.2.3. Validation of univariate method developed.
Method validation is the process used to confirm that the analytical procedure 
employed for a specific test is suitable for its intended use. Although there is general 
agreement about what type of studies should be assessed, there is great diversity in 
how they are performed. The validation was carried out under the guidelines of the 
International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH) (ICH, 1996), including 
selectivity, linearity, inter and intra-day precision, accuracy, limit of detection and 
limit of quantification.
The ideal internal standard is a compound of known purity that does not cause 
interference with the analysis. Clomipramine, metoclopramide and propyl paraben 
were all assessed for the most suitable internal standard. The selectivity of the
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method was established for all amphetamine standards and the most common 
adulterants found in ecstasy tablets, namely, acetaminophen, acetylsalicylic acid, 
caffeine and phenacetin. Precision was expressed as relative standard deviation (% 
RSD). For intra-day, ten replicates o f 50, 100 and 250 \ig mL-1 were analysed on the 
same day. These standards were analysed in five replicates over five days to establish 
inter-day precision.
With no reference materials, the accuracy of the method was determined by analysing 
spiked samples at three concentration levels of 50, 100 and 250 \ig mL-1. Results 
were calculated as experimental values compared to theoretical values and were 
expressed as percentage recovery.
Linearity was evaluated by regression analysis and MandePs test, which compares 
linear and quadratic models (Mandel, 1964). Limit of detection and limit of 
quantification were established by injection of 0.01 pg mL ' 1 concentrations of each of 
the six compounds and the signal to noise ratio was determined. The limit of 
detection was calculated by LOD= 33a!S, where o is the standard deviation of the 
response of the blank and S  is the slope of the calibration curve. The limit of 
quantification was calculated by LOQ= 10a/S under the ICH guidelines. The limits 
were validated by analysing standards prepared at the concentrations of the LOQs for 
each standard and their precision and accuracy were assessed.
2.3. Multivariate HPLC method development for the analysis of cocaine.
2.3.1. Cocaine standards and sample preparation.
Stock solutions of uracil and the internal standard metoclopramide HC1 were prepared 
at a concentration of 1 jig mL ' 1 in methanol. Cocaine standards were provided in salt 
form and were prepared in the internal standard solution. A mixed standard solution 
was prepared containing cocaine, lidocaine, prilocaine, procaine, benzocaine, 
acetylsalicylic acid, caffeine and phenacetin. Uracil was used as an unretained 
compound and detection of analytes was performed using a diode array detector at 
200 nm.
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The Forensic Science Laboratory, Dublin provided twenty eight cocaine samples 
seized within the Republic of Ireland during 2004. Cocaine samples were in the form 
of a powder, each sample weighing approximately 100 mg and 50 mg of each sample 
was dissolved in 10 mL of the internal standard solution. Samples were sonicated for 
10 minutes to ensure total dissolution and filtered through 0.45 pm filters (Millipore, 
MA., USA.) prior to HPLC injections.
2.3.2. Multivariate method development for the analysis of cocaine.
The design of this experimental procedure was based on a multivariate method 
optimisation. As such, each chromatographic factor is assessed in combination with 
each other, and their combined effect on the separation is examined. The 
chromatographic factors that were considered important for method development 
were strength of organic solvent, ionic strength of phosphate buffer, temperature, pH, 
and flow rates. The quality of the separation was based on the performance indicators 
of resolution (R), retention factor (k5) and efficiency (N) for each analyte. In 
describing the relationship between the chromatographic factors and the performance 
indicators, regression analysis in the form of Artificial Neural Networks (ANN) was 
applied using Trajan Neural Network software. The most successful neural network 
is then used to plot response surfaces. Response surfaces are 3D graphs that illustrate 
the relationship between any two of the chromatographic factors (e.g. pH and 
temperature) and one of the performance indicators (R, k’ or N). Response surface 
plots indicate the levels for each chromatographic factor and determine optimal 
separation conditions. Although, this approach may appear complex, it produces a 
method without experimentally exploring each chromatographic factor at all possible 
levels. The combined use of neural networks and response surfaces for selection of 
chromatographic factor levels overall leads to a more efficient and less time 
consuming method development.
A 25' 1 fractional factorial design was created by Minitab and used as the basis of the 
experimental procedure (Table 2.2.). Within this, two levels (low and high) for each 
chromatographic factor were assigned. For each experiment, a mixed standard 
solution containing five cocaines (cocaine, lidocaine, prilocaine, procaine, and 
benzocaine), three adulterants (caffeine, phenacetin and acetylsalicylic acid) was
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injected in triplicate. As part of the method development for the cocaine analysis, the 
mobile phase was assessed in detail and for this, potassium dihydrogen phosphate 
dissolved in 1 L deionised water was used as the buffer component of the mobile 
phase. Buffer pH was adjusted by adding appropriate amounts of phosphoric acid. 
The column used was a Waters XBridge C l 8 , 50 x 4.6 mm, particle size 3.5 pm, As 
before with the Xterra column, this is a newer type column, using the ‘Hybrid Particle 
Technology’. These are columns which combine the properties of both silica and 
polymer columns. Essentially, every third silanol is replaced with a methyl group 
during synthesis. This results in greater pH stability across the range and also greater 
peak symmetry for basic compounds.
Table 2.2. A 25' 1 fractional factorial experimental design for multivariate method 
development generated using Minitab software, Chromatographic factors examined 
included, A: % Acetonitrile; B: pH; C: Temperature (°C); D: Ionic strength (mM) 
and E: Flow rate (mL min-1).
Factorial Chromatographic Factor
Experiment # A B C D E
1 1 0 2.5 40 50 1.5
2 1 0 3.5 40 50 0.5
3 2 0 3.5 40 50 1.5
4 1 0 3.5 40 1 0 1.5
5 1 0 3.5 30 50 1.5
6 1 0 3.5 30 10 0.5
7 1 0 2.5 40 10 0.5
8 2 0 2.5 40 10 1.5
9 2 0 3.5 40 10 0.5
1 0 2 0 3.5 30 50 0.5
11 2 0 2.5 30 50 1.5
1 2 2 0 2.5 40 50 0.5
13 2 0 2.5 30 1 0 0.5
14 1 0 2.5 30 50 0.5
15 2 0 3.5 30 1 0 1.5
16 1 0 2.5 30 1 0 1.5
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The sixteen experiments were carried but in random order to avoid systematic error. 
For each experiment, retention factors for each analyte, resolutions between analytes 
and efficiencies were calculated by the HPLC software, ClassVp. The average 
retention factor, resolution and efficiency (k’aVe> Rave and Nave) for each experiment 
were also calculated. The data from the sixteen experiments were used to test 
different neural networks (Figure 2.2). The five chromatographic factors at two levels 
were used as inputs, and the retention factors for each analyte, resolutions between 
analytes, efficiencies for each analyte and their averages were used as outputs, Using 
Trajan Neural Networks, one hundred neural networks were examined.
Every network has three layers, an input layer, a hidden layer and an output layer. 
The input layer is the five chromatographic factors at the two different levels for each 
of the sixteen experiments (Table 2.2). Every network decided whether to take all 
these factors or a combination within them, i.e. Acetonitrile + pH + Temperature + 
Ionic Strength + Flow rate or pH + Temperature + Ionic Strength, etc. The hidden 
layer is made up of both connections and neurons. The maximum number of neurons 
tested was set at twenty; the number of connections in the network is dependent on the 
number of neurons, The number of neurons within the hidden layer is an important 
factor. The greater the number of neurons the more powerful the network. This 
however, makes the network time-consuming to run and more complicated to train. 
The reverse of this is true for a small number of neurons and the balance between 
these two is important. The output layer is the calculated performance indicators. To 
test as many networks as possible within minimum time, one hundred networks were 
tested for each of the six outputs. Both three layer multilayer perceptron and radial 
base function networks were investigated. The training algorithms were a 
combination of back propagation and conjugate descent.
For each of the six outputs, the best neural network from the one hundred tested was 
selected. The selection was based on a combination of network performance and 
error values generated by Trajan, The best network produced high values for 
performance and low values for error. Using each of the six networks, the predicted 
values generated were plotted against the observed values. The network with the best 
correlation indicated that it was that network that best described the separation. This
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network was then used to illustrate the separation in the form of response surfaces. 
Optimal conditions for the separation of the eight analytes were decided based on 
these response surfaces (Figure 2. 2)
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Figure 2.2. Schematic representation of the stages involved in the multivariate HPLC 
method development for cocaine analysis. Key for different software packages were 
as follows: □  - Minitab; - Class VP; - Trajan; - Microsoft
Excel
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2.3.3. Validation of multivariate method developed.
As described previously, method validation was performed under the guidelines of the 
International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH) (www.ich.org), including 
selectivity, linearity, inter and intra-day precision, accuracy, limit of detection and 
limit of quantification.
2.4. Sugar analysis.
Previous method development focused on the determination of active ingredients and 
adulterant compounds of ecstasy and cocaine. Other compounds within illicit drug 
samples include sugar and metal content. Ecstasy and cocaine samples were analysed 
for their sugar content in order to obtain a more complete chemical profile.
Ecstasy and cocaine samples were analysed by HPLC for their sugar content. 
Chromatography was performed on an NH2 column from the Phenomenex Luna 
range, a 250 x 4.6 mm, and particle size of 5 |im. Standards for this study included 
fructose, glucose, inositol, lactose, mannitol, sorbitol and sucrose. Conditions for the 
separation were a mobile phase of acetonitrile/water (70/30), oven temperature of 
30 °C and flow rate was at 0.75 mL min'1. Drug samples for the sugar analysis were 
prepared by dissolving 50 mg of each in 20 mL rhamnose internal standard solutionin 
water.
2.5. Metal analysis.
Ecstasy samples were analysed for their metal content. Nine metals, aluminium (Al), 
calcium (Ca), chromium (Cr), iron (Fe), lead (Pb), magnesium (Mg), potassium (K), 
sodium (Na) and zinc (Zn) were detected and quantified by atomic absorption 
methods. This data was then assessed alone and in combination with the other 
chemical data by means of the chosen statistical procedure in order to verify its 
potential as another chemical parameter to aid profiling.
Glassware was soaked overnight in 2% HNO3, and rinsed three times in deionised 
water before any solutions were prepared. The tablets were crushed with pestle and 
mortar and prepared by direct dissolution. Direct dissolution involved adding 10 ml 
of 5% nitric acid (HNO3) to 25 mg of crushed tablet in a polypropylene tube. Each
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mixture was vortexed for 10 seconds and made up to 40 mL with deionised water. 
Two forms of AA were used for metal analysis. If the concentration of the metals is 
in the range of parts per billion (ppb), graphite furnace is recommended. If the 
concentration of the metals is in parts per million (ppm), the standard flame AA can 
be used. Preliminary tests provided information as to which metal should be analysed 
by which instrument.
For the graphite furnace AA analysis, a specific method for each element was used. 
Each method included wavelength, charring temperature and atomisation temperature 
specific for the element of interest (Table 2.3). In order to reduce the volatility of the 
metals, matrix modifiers were used for the elements analysed by graphite furnace.
0.05 mg Mg (N(>3)2 was used for Al, Cr, Fe and Zn and 0.2 mg NH4H2PO4 was used 
for Pb. This was added to the sample during the autosampler run. For the flame AA, 
specific wavelengths, slit widths and lamp currents were stated in the manual (Table 
2.4). Daily, a calibration curve was prepared and the equation of the line was used for 
quantification of each metal in the ecstasy tablets. Blank samples were tested after 
every ten samples. Each standard and sample were analysed in triplicate and the mean 
absorbance value of each was used. Injection volume was 20 jiL,
Table 2.3. Optimum conditions for graphite furnace Atomic Absorption spectrometer.
Element Wavelength (nm) Charring Temp. (°C) Atomisation Temp. (°C)
Al 309.3 1700 2500
Cr 357.9 1650 2500
Fe 248.3 1400 2400
Pb 283.3 850 1800
Zn 213.8 700 1800
Table 2.4. Optimum conditions for flame Atomic Absorption spectrometer.
Element Wavelength(nm) Slit Width (nm) Lamp Current (mA)
Ca 422.7 0.7 1 0
K 766.5 0.4 8
Mg 285.2 0.7 1 0
Na 589 0 . 2 8
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2.6. Data analysis and chemometric procedures.
Conventional profiling of illicit drugs relies on a combination o f physical, chemical 
and statistical techniques to establish links among seizures. In this study various 
chemometric procedures were applied to the ecstasy chemical data sets to determine if 
seizures could be linked. The chemical data sets used in this study consisted of the 
active ingredients plus sugars (AS), metal data (MD) and all data combined (DC) for 
the 183 individual ecstasy tablet samples (see Appendix Table A1 & A2). Variables 
for AS data included MDMA, MDEA, amphetamine, caffeine lactose and sorbitol and 
represent only compounds detected in samples. MD data variables were Al, Zn, Fe, 
Mg, Ca, Cr, Pb, Na and K that were similarly detected in ecstasy samples,
2.6.1. Ecstasy data and pre-treatments.
Since all data sets were generated by different analytical techniques data pre-treatment 
is required due to the differences in the scales between variables. There are two 
standard pre-treatment methods, namely normalisation and standardisation (Miller & 
Miller, 2005). Both of these statistical data transformation methods can be applied in 
combination with logarithm and 4th square root derivatisation. Data pre-treatment 
methods evaluated included the following:
1. Normalisation (N)
2. Normalisation & logarithm (N + Logio)
3. Normalisation & 4th square root (N + 4sqrt)
4. Standardisation (S)
5. Standardisation & logarithm (S + Logio)
6 . Standardisation & 4th square root (S + 4sqrt)
To reduce the complexity and to easily identify the appropriate pre-treatment method, 
eight seizures were selected based on their discrete AS chemical data profile (Table
2.5, Table Al). Each seizure consisted of three tablets giving a combined sample set 
of twenty-four for pre-treatment analysis. Each pre-treatment method was evaluated 
by PCA and HCA methods to determine the most appropriate pre-treatment 
method(s). The appropriate pre-treatment method was then applied to the entire 
ecstasy data sets.
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Table 2.5. Chemical composition of the eight selected ecstasy seizures used in pre­
treatment studies.
Seizure 
Batch No.
Chemical components
MDMA MDEA Amphet Caffeine Lactose Sorbitol
13
14 S
15 S S
17 S
2 2 S
26 S
30
55 Y
2.6.2. Ecstasy data pattern recognition.
Five different pattern recognition methods were evaluated to determine the suitability 
of methods in classifying the various ecstasy tablet data sets. The pattern recognition 
methods evaluated were:
1. Principal Component Analysis (PCA)
2. Hierarchal Cluster Analysis (HCA)
3. Pearson’s correlation coefficient
4. Linear Discriminant Analysis (LDA)
5. Artificial Neural Networks (ANN)
Principal Component Analysis (PCA) is a relatively straightforward procedure. The 
data is reduced to the smallest number of components which describes the maximum 
information of the data. The scores of the first two principal components were plotted 
to produce a score plot, from which groupings, if any, are evident.
Hierarchal Cluster Analysis (HCA) is a statistical method that measure the distance 
between two objects, if the distance is relatively small then the objects are clustered 
together. The method by which the distance is measured can be calculated by 
different cluster and interval methods. Seven different HCA cluster methods were 
evaluated (Between groups, Within groups, Nearest neighbour, Furthest neighbour, 
Centroid, Median and Wards) using the default Squared Euclidean interval setting of
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the SPSS software package. Interval methods included Euclidean, Square Euclidean, 
Cosine, Pearson, Chebychev, Block and Minkowski. Each of these seven interval 
methods were evaluated using the default ‘between groups’ cluster method setting of 
the SPSS software package. For each test, the data set of the eight seizures used for 
data pre-treatment studies (Table 2.5) was applied. Selection of the most appropriate 
cluster and interval method was determined by the numbers of clusters formed by 
each method. The established combination of cluster and interval methods was then 
applied to all ecstasy data sets.
Pearson’s correlation coefficient measures the strength of the linear relationship 
between two samples. The stronger this relationship is, the more likely the two 
samples are related or linked. Pearson’s correlation coefficient is currently the method 
of choice for the European Network of Forensic Science Institutes (ENFSI) for drug 
profiling. A Microsoft excel macros file to calculate Pearson’s correlation was 
supplied by the ENFSI. In order to use this statistical method to link different seizures 
threshold values were assigned to each seizure. Threshold values are a number 
assigned to an individual seizure, above which any subsequent tablet with a 
coefficient equal to or higher than this value is highly correlated to that seizure and 
therefore is strongly linked to that seizure. Tablets that are highly correlated should 
have a value close to 100; those with no correlation have values close to zero. To 
assign threshold values for each seizure, all three replicates of all three tablets within 
each seizure were used. The lowest value that was returned was then used as the 
threshold value for that seizure. Once each seizure had a threshold value assigned, all 
seizures were correlated against each another. Those seizures with correlation 
coefficients greater than the threshold value were considered linked.
Both Linear Discriminant Analysis (LDA) and Artificial Neural Networks (ANN) 
require ‘trained’ data sets. In order to achieve this, groups within the data set had to 
be identified and seizure membership assigned. Linear Discriminant Analysis (LDA) 
was used to identify which data set and which pattern recognition method was the 
most suitable. The groups generated by PC A, HCA and Pearson for each of the three 
data sets were applied to LDA. The best data set combination and pattern recognition 
method should yield a classification rate close to 1 0 0 %.
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As before when ANN was used for method development, there are three layers to any 
network, an input layer, a hidden layer and an output layer. The input layer consisted 
of the various quantities for all variables in each tablet while the output layer was the 
classification groupings identified by unsupervised pattern recognition methods. As 
before, one hundred networks were tested, using both three layer multilayer 
perceptron and radial base function networks. The training algorithms were again a 
combination of back propagation and conjugate descent. The maximum number of 
neurons tested was set at fifty.
The rate at which each of the pattern recognition methods successfully classified the 
tablets is reported, the advantages and disadvantages of each method are evaluated 
and the final combination of data set, pre-treatment and pattern recognition method 
are discussed. The chosen data pre-treatment and pattern recognition method was 
applied to the ecstasy tablet data sets. Results from this highlighted possible links 
between previously unrelated seizures which in theory could potentially allow for law 
enforcement to identify dealer -  user networks.
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Chapter 3: HPLC method development.
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3.1. Univariate HPLC method development for the analysis of ecstasy.
The design of the experimental procedure concentrated on the univariate method for 
the development of a HPLC method for the analysis of ecstasy tablets. As such, each 
chromatographic factor was considered individually, and the effect of the varying 
factor evaluated on the performance for method development. The separation of a 
large number of analytes by liquid chromatography is dependent on many variables 
including stationary phase, mobile phase (type and quantity of organic solvent, ionic 
strength of buffer, buffer pH), temperature and flow rate. For this study, all factors 
were assessed for the separation and quantification of amphetamine type stimulants 
from ecstasy. The quality of each separation was assessed by comparison of three 
performance indicators: resolution (R), retention factor (k’) and height equivalent 
theoretical plate (HETP).
3.1.1. Chromatographic factors.
Columns
Analyte separations were examined on the column chemistries associated with seven 
different commercially available columns (Table 2.1). The analyte mixture contained 
all six amphetamines; amphetamine, MDA, methamphetamine, MDMA, MDEA and 
MBDB. The main differences between the columns are their physical dimensions and 
the particulate or monolith nature of the stationary phase.
Mobile Phase
Water is a weak solvent and when used alone as the mobile phase, the equilibrium 
between the stationary and mobile phase favors the stationary phase. This results in 
maximum resolution however it also results in longer retention times (i.e. high 
retention factors). To balance resolution with retention times, water tends to be mixed 
with a stronger solvent (e.g. methanol or acetonitrile), which shortens the retention 
times and reduces the resolution. The ratio o f water to organic solvent is very specific 
to the separation required and is an important factor in method development. With 
this method development, acetonitrile was the only organic solvent chosen based on 
its chemical properties (Table 1.1). The UV cut off value off for acetonitrile is 195 
nm, while for methanol it is 205 nm and tetrahydrofuran 215 nm. The selection of a 
suitable organic solvent should preferably have a lower UV absorption cut off than the
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analyte UV absorption value. Since sample analysis was performed at 200 nm, 
acetonitrile was chosen as the preferable organic solvent due to its lower UV 
absorption cut off value.
With each column, 0% acetonitrile produced the greatest retention times. As the 
concentration of the acetonitrile increased, the retention times decreased. In addition, 
a decrease of retention times lead to a decrease in resolution. With each column a 
certain concentration of acetonitrile existed that had minimum retention times but 
beyond which peaks were unresolved. For example, Figure 3.1 highlights the effects 
of increasing acetonitrile concentration on analyte resolution. At 5% acetonitrile, all 
six analytes are resolved in 14.4 minutes and resolution between peak 2 and 3 was 
greater than 1, as calculated using the USP equation (see page 92). With increasing 
acetonitrile concentration the retention time decreased, however peaks 2 and 3 were 
not resolved when acetonitrile concentration was greater than 10%. The broad peaks 
that are present at the start of the separation may be due to the use of methanol as the 
sample solvent.
Retention time (minutes)
Figure 3.1. Chromatogram of the six ecstasy standard mixture resolved with the 
XTerra RP18 column at 5% and 15% acetonitrile solvent concentration, pH 3, 30°C, 
20 \i\ sample injection, detection at 200 nm. Peak 1 = amphetamine, Peak 2 = MDA, 
Peak 3 = methamphetamine, Peak 4= MDMA, Peak 5 = MDEA, Peak 6  = MBDB.
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All other columns investigated followed a similar pattern to that of the XTerra RP18 
column. With six of the seven columns, analytes were resolved within a minimal time 
of approximately 15 minutes. The final organic phase concentration was 3% for the 
three monolith columns, 5% for the XTerra RP18, 10% for the Luna C 8  and, 13% for 
the Luna C l 8 . There were slightly longer retention times with the Phenosphere C l8  
column with the last peak eluting at 19.445 minutes (Figure 3.2.). Due to the 
increased retention times for the Phenosphere C l 8  column, gradient elution method 
was assessed for this column. Gradient elution involves varying the concentration of 
the organic solvent in the mobile phase over the run time. The six ecstasy standard 
mixture was injected using varying concentrations of the organic solvent. The most 
appropriate gradient was 90% A (phosphate buffer): 10% B (acetonitrile) at T0 to 60% 
A (phosphate buffer): 40% B (acetonitrile) at Tio. With this gradient elution, retention 
times were reduced by 5.136 minutes and all six analytes were resolved in 14.309 
minutes (Figure 3.2.).
R etention tim e (m inutes)
Figure 3.2. Chromatogram of the six ecstasy standard solution resolved with the 
Phenosphere C l 8  column under gradient elution and isocratic elution conditions, pH 
3, 30°C, 20 |il sample injection, detection at 200 nm. Peak 1 = amphetamine, Peak 2 
= MDA, Peak 3 = methamphetamine, Peak 4= MDMA, Peak 5 = MDEA, Peak 6  = 
MBDB,
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The pH of a mobile phase is an important factor as it affects the ionisability o f analyte 
and therefore greatly influences the selectivity and retention of ionisable compounds. 
Phosphate buffer is a suitable buffer if analysis is at a low pH (2-3) as opposed to an 
acetate or citrate buffers which are suitable for slightly higher pH levels (4-5). 
Adequate buffer concentrations tend to be in the range 10-100 millimolar. Since 
silica will dissolve, at or above pH 7 and at or below pH 2, a pH range between 2 and
7 is preferred for analysis. However, pH in the middle range of 3.5 to 8.5 tend to be 
avoided, as large changes in retention times can occur with minor adjustments to pH 
resulting in difficulties with reproducibility and validation studies. In addition, 
analyte retention can be affected if the pH of the mobile phase is one pH unit within 
the pKa of the compound being analysed. Since the pKa’s for all the amphetamines 
studied were approximately 10 (amphetamine = 9.8, methamphetamine = 10.1, 
MDMA = 9.9, MDA = 9.8, MDEA -  9.5, MBDB = 9.8), the phosphate buffer pH 
conditions were investigated at pH 2.5, 3 and 3.5. Slight differences in peak shape 
(peak symmetry was calculated using the equation As = b/a where a corresponds to 
the width of the front of the peak and b the width of the tail of the peak (at 1 0 % peak 
height) centred around the peak apex), and a is were observed for the three pH levels 
examined, however pH did not affect the quality o f resolution to any great extent. 
With the particulate columns, peak symmetry was best at pH 3 and pH 2.5 gave best 
peak symmetry with the monolith columns.
Temperature
By increasing the temperature, higher flow rates can be achieved and enhanced 
analyte mass transfer can occur, both o f which ultimately would decrease retention 
times. Therefore the ideal temperature for each column should give the shortest 
retention times without jeopardising resolution. Throughout the method development, 
injections were made at 25°C. The effects of temperature were studied in increments 
o f 5°C between the range of 25°C and 45°C. Slight decreases in retention times were 
observed for each column as temperatures increased. The optimum temperature for 
the Luna C8 , XTerra RPI8  and the three monolithic columns was 30°C, based on 
peaks 2 and 3. The Phenosphere C l 8  and Luna C l 8  columns were optimal at 35°C. 
These final temperature levels were chosen based on the resolution between the 
critical peak pair of peaks 2 and 3. Figure 3.3 demonstrates the minimal effect of
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temperature on the separation o f the six analytes at 25°C, 30°C, 35°C, 40°C and 45°C 
for the Luna C l 8  column. Total analysis time was only reduced by 0.704 minutes 
after the 20°C incremental increase.
Retention time (minutes)
Figure 3.3. Chromatogram of the six ecstasy standard solution resolved on the Luna 
C l 8  at five temperatures: 25°C, 30°C, 35°C, 40°C and 45°C. pH at 3, 20 jil sample 
injection, detection at 200 nm. Peak 1 = amphetamine, Peak 2 = MDA, Peak 3 = 
methamphetamine. Peak 4= MDMA, Peak 5 = MDEA, Peak 6  -  MBDB.
Flow Rates
Flow rate is an important factor in method development. Solvent consumption should 
be kept to a minimum to limit costs. The optimum flow rate should give a short 
retention time, good resolution and low pressure. For Phenosphere, flow rates 
between 0.5 mL min ' 1 and 2 mL min 1 were assessed and 1.75 mL min' 1 was chosen 
(Figure 3.4.). The other particulate columns had internal diameters of 2 mm and 2.1 
mm and the flow rates were reduced to prevent high backpressures. The flow rates 
most suitable were 0.3 mL min ' 1 for the XTerra RP18 and 0.4 mL min ' 1 for the Luna
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C8  and C l 8 . These flow rates were chosen based on optimal resolution with minimal 
solvent consumption and column back pressure.
Retention time (minutes)
Figure 3.4. Chromatogram of the six ecstasy standard solution separated on the 
Phenosphere C l 8  column at five flow rates: 1, 1.25, 1.5, 1.75 and 2 mL m in 1. pH 3, 
30°C, 20 i^l sample injection, detection at 200 nm. Peak 1 = amphetamine, Peak 2 = 
MDA, Peak 3 = methamphetamine. Peak 4 = MDMA, Peak 5 = MDEA, Peak 6  = 
MBDB.
The main factor which differentiates monolithic columns from the traditional 
particulate columns is the ability to use higher flow rates without the usual 
accompanying back pressure. The HPLC pump allowed for pump rates up to 9.999 
mL m in 1. The flow rates for the monolithic columns could be increased significantly 
due to the lower backpressure. The flow rates for these columns are discussed in 
greater detail in Section 3.1.3. The most appropriate flow rates for Chromolith Flash, 
Chromolith SpccdROD and Chromolith Performance were 1.5 mL m in 1, 4.5 mL min 
1 and 8.5 mL m in 1, respectively.
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3.1.2. Selection of optimal HPLC conditions for ecstasy sample analysis.
For each column, the most suitable mobile phase (organic solvent, concentration of 
organic solvent, gradient elution, buffer, buffer strength and pH) temperature and flow 
rates were determined. Figures 3.5 to 3.11 are the chromatograms of the optimised 
methods for each column.
The quality of the separation of each method must be evaluated in order to select the 
most appropriate method. The quality of each separation was assessed by comparison 
of three performance indicators: resolution (R), retention factor (k’) and height 
equivalent to theoretical plate (HETP). Chromatographic performance indicators of 
each column type for the separation o f amphetamine standards are provided in Table
3.1.
Table 3.1. Performance indicators for each column for the separation of ecstasy 
compounds.
Column R k1 HETP (jim)
Luna C8 1.16 3.09 12.34
Phenosphere C l 8 1.37 5.05 20.83
Luna C 18 0.74 3.23 15.00
XTerra RP18 1.14 6.71 6.44
Performance RP-18 1.28 9.40 6.58
SpeedROD RP-18 1 . 1 2 7.61 7.83
Flash RP-18 0.95 6.82 6.03
Performance indicators; R; resolution between MDA and methamphetamine, k ’; retention factor for 
MDMA and HETP; height equivalent to theoretical plate for MDMA.
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Retention time (minutes)
Figure 3.5. Chromatogram of the six ecstasy standard solution resolved on Luna C8 . 
Final chromatographic conditions were 90% 20 mM buffer: 10% acetonitrile, 0.4 mL 
min \  pH 3, 30°C, 20 ¿il sample injection, detection at 200 nm. Peak 1 = 
amphetamine. Peak 2 = MDA, Peak 3 = methamphetamine. Peak 4= MDMA, Peak 5 
= MDEA, Peak 6  = MBDB.
Retention time (minutes)
Figure 3.6. Chromatogram of the six standard solution resolved on the Phenosphere 
C l 8 . Final chromatographic conditions were To 90% 20 mM buffer: 10% acetonitrile 
going to Tjo 60% buffer: 40% acetonitrile B, 1.75 mL m in'1, pH 3, 35nC, 20 ^  sample 
injection, detection at 200 nm. Peak 1 = amphetamine, Peak 2 = MDA, Peak 3 = 
methamphetamine, Peak 4 -  MDMA, Peak 5 *  MDEA, Peak 6  ■ MBDB.
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Retention time (minutes)
Figure 3.7. Chromatogram of the six ecstasy standard solution resolved on Luna 
C l8 . Final chromatographic conditions were 87% 20 mM buffer: 13% acetonitrile, 
0.4 mL m in 1, pH 3, 35°C, 20 1^ sample injection, detection at 200 nm. Peak 1 = 
amphetamine, Peak 2 = MDA, Peak 3 = methamphetamine, Peak 4= MDMA, Peak 5 
= MDEA, Peak 6  = MBDB.
Retention time (minutes)
Figure 3.8. Chromatogram of the six ecstasy standard solution resolved on Xterra 
RP18. Final chromatographic conditions were 95% 20 mM buffer: 5% acetonitrile, 
0.3 mL min'1, pH 3, 30°C,20 \i\ sample injection, detection at 200 nm. Peak 1 = 
amphetamine, Peak 2 = MDA, Peak 3 = methamphetamine, Peak 4= MDMA, Peak 5 
= MDEA, Peak 6  = MBDB.
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Retention time (minutes)
Figure 3.9. Chromatogram of the six ecstasy standard solution resolved on 
Chromolith Performance RP18, 100 x 4.6 mm. Final chromatographic conditions 
were 97% 20 mM buffer: 3% acetonitrile, 8.5 mL min'1, pH 2.5, 30°C, 20 jil sample 
injection, detection at 200 nm. Peak 1 = amphetamine, Peak 2 = MDA, Peak 3 = 
methamphetamine, Peak 4= MDMA, Peak 5 = MDEA, Peak 6  = MBDB.
Retention time (minutest
Figure 3.10. Chromatogram of the six ecstasy standard solution resolved on 
Chromolith SpeedROD, RP18, 50 x 4.6 mm. Final chromatographic conditions were 
97% 20 mM buffer: 3% acetonitrile, 4.5 mL min“1, pH 2.5, 30°C, 20 |il sample 
injection, detection at 200 nm. Peak 1 = amphetamine, Peak 3 = methamphetamine, 
Peak 2 = MDA, Peak 4 = MDMA, Peak 5 -  MDEA, Peak 6  = MBDB.
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Retention time (minutes)
Figure 3.11. Chromatogram of the six ecstasy standard solution resolved on the 
Chromolith Flash RP18, 25 x 4,6 mm. Final chromatographic conditions were 97% 20 
mM buffer: 3% acetonitrile, 1.5 mL min-1, pH 2.5, 30°C, 20 i^l sample injection, 
detection at 200 nm, Peak 1 = amphetamine, Peak 3 = methamphetamine, Peak 2 = 
MDA, Peak 4 = MDMA, Peak 5 = MDEA, Peak 6  = MBDB.
The difference in peak heights in the seven chromatograms is due to standard 
solutions of different concentrations being injected. A peak shift was observed with 
peaks 2 and 3 when moving from the particulate columns to the monoliths. This can 
occur and reasons may be due to silanol activity or endcapping.
For the separation of a large number of analytes, resolution is an important factor in 
the analysis. Chromatograms are only useful if there is a good degree of separation 
between each peak. Good resolution is defined as being greater than 1. Ideally, all 
compounds should have a resolution greater than 1.5. The resolution of each analyte 
was calculated by the ClassVp software, based on USP methods, using the following 
equation:
R = —— (Equation 3.1)
W2 +WX
Where R is the resolution between peak of interest (peak2) and the preceding peak 
(peakl), tj and h  are the retention times of peak 1 and peak 2; respectively and W\ and 
W2 are the widths of the base o f components peak 1 and peak 2  respectively.
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Methamphetamine (peak 3) and MDA (peak 2) were the two analytes that were most 
difficult to resolve. Therefore, in order for a column and method to be successful, it is 
critical that these two analytes have a resolution > 1 . Table 3.1 reports the resolution 
between MDA and methamphetamine. Two columns, the Luna C l 8  and the Flash 
RP-18, were unable to resolve these peaks satisfactorily, with resolutions < 1  for both 
columns. All other columns had resolutions >1, however no column had an ideal 
resolution >1.5. From this, it can be stated that the Luna C l 8  and the Flash RP-18 are 
the least suitable columns (and method) for this analysis.
Retention factor (k’) indicates the interaction between the analyte and the stationary 
phase, relative to the unretained compound. The optimum retention factor lies within 
the range of 2 to 10. The retention factor was calculated using Class Vp software 
package, based on USP methods, as follows:
Where k’ is the retention factor, ¿2 is the retention time of the peak of interest and tQ is 
retention time of an unretamed compound. The average retention factors for all seven 
columns were between 2 and 10. The values reported for the three monoliths and the 
XTerra RP18 were higher than those of the three particulates LunaC 8 , Luna Cl 8  and 
Phenosphere C l 8  (Table 3.1).
Efficiency, defined as the number of theoretical plates in a column, is the measure of 
the sharpness of eluting peaks. The number of theoretical plates is affected by the 
size of the particles, the length of the column and the quality of the procedure used to 
pack the particles into the columns. The theoretical plates were calculated using 
ClassVp software package as follows:
Where N is the theoretical plates, t is the retention time of the component and W is the 
width of the base o f the component peak using the tangent method. The higher the 
value of N, the more efficient the separation. As stated previously, efficiency is 
dependent on column length. In this study, columns of four different lengths were 
studied, 25 cm, 50 cm, 100 cm and 250 cm, and comparison based on their efficiency
(Equation 3.2)
N = ] 6 { w ) (Equation 3.3)
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value is not technically correct. Alternatively, Height Equivalent to Theoretical Plate 
(HETP)(fxm) can be used to directly compare columns of different lengths. HETP is 
calculated as follows:
HETP = — (Equation 3.4)
N
Where L is the length of the column and N is the number of theoretical plates. Low 
values for HETP are desired for efficient separations. HETP values for the three 
monoliths were significantly lower than those of the Luna C 8 , Luna C l8  and 
Phenosphere C18 (Table 3.1). Although XTerra RP18 is the same length as the other 
particulate columns (250 cm), its efficiency was similar to the three monolithic 
columns, which could be explained by the hybrid technology of this column.
When choosing any of the methods developed for the routine analysis in the 
laboratory, the quality of the separation is undoubtedly important. But one has to also 
take into account the speed of the analysis and the costs incurred. As all columns 
were consistent with each other in terms of separation quality, the choice of method 
would lean towards one of the monolithic columns, as analyte separation was 
achieved in shorter run times (Figure 3,9, 3.10 and 3.11). Within the monoliths, the 
50 mm SpeedROD provided good quality separation with minimum solvent 
consumption and run time. For these reasons, the method developed using the 50 mm 
monolithic column was selected for the analysis of ecstasy samples (Figure 3.10).
3.1.3. Comparison of particulate and monolithic columns.
A comparative analysis of the performances of particulate and monolithic columns 
was performed. This involved comparing the performance of the most successful 
particulate column, the Waters XTerra, 5^m, 250 x 2.1 mm RP18 column with the 
three monolithic columns. Measurement o f column backpressure and the creation of 
Van Deemter plots allowed for comparative assessment.
The minimum analysis times for the complete separation of the six analytes using the 
XTerra RP18 column was 14.512 minutes. In contrast the minimum analysis times 
for the complete separation of the six analytes was 6.763 minutes for the Chromolith 
Flash RP18, 25 x 4.6mm (1.5 mL m in'1), 4.160 minutes for the Chromolith
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SpeedROD, RP18, 50 x 4.6 mm (4.5 mL m in 1) and 5.536 minutes for the Chromolith 
Performance RP18, 100 x 4.6 mm (8.5 mL m in1). The effect o f different flow rates 
on resolution was investigated using the Chromolith SpeedROD, RP-18, 50 x 4.6 mm 
column. Resolution was not affected and analysis times were decreased from 18.3 
minutes to 3.8 minutes when using flow rates from I mL min ' 1 to 5 mL min'1, 
respectively (Figure 3.12).
Retention time (minutes)
F igu re 3.12. Chromatogram of the six standard solution resolved on the Chromolith 
SpeedROD, RP-18, 50 x 4.6 mm column at nine flow rates. The chromatographic 
conditions and elution order was as described in Figure 3.10.
Column backpressure was measured for each column flow rate up to recommended 
pressure limit. Figure 3.13 shows column backpressure as a function o f flow rate for 
each column type tested. Maximum flow rate of 3 mL min ' 1 could only be achieved 
with the particulate column, while monolithic columns allowed for an increased flow 
rate of up to 9 mL min ' with reduced back pressure. In addition the slope of the 
monolithic column is much lower than that for the particulate, indicating the ability of 
the monolithic to achieve higher flow rates without the backpressure.
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Figure 3.13. Comparison of column backpressure as a function o f flow rate for the 
XTerra RP18 • particulate column and the three Chromolith RP18 monolithic 
columns. Chromolith columns were o f varying lengths o f 25 mm ♦ , 50 mm ▲ and 
1 0 0  mm ■.
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Figure 3.14. Fitted van Deemter curves o f the plate height (H) vs. Flow rate for the 
XTerra RP18 • particulate column and three Chromolith R P-I8  columns. Chromolith 
columns were of varying lengths of 25 mm ♦ , 50 mm A and 100 mm m.
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Van Deemter curves were created for the monolithic and particulate columns. Figure
3.14 shows the resulting plots for each column type. The flatter curve for each 
monolithic column implies that these columns provide higher efficiency at high flow 
rates compared to the particulate column. For example, the plate height for the 
Chromolith SpeedROD, RP18, 50 x 4.6 mm at 7 mL min ' 1 is approximately the same 
as that for the packed column at 3 mL m in'1. Therefore the monolithic column can be 
run twice as fast as the particulate without sacrificing column efficiency.
3.1.4. Validation of univariate method developed.
Due to good separation of the six amphetamine analytes with reasonable analysis 
times the Chromolith SpeedROD, RP-18, 50 mm x 4.6 mm was selected for 
validation studies. Validation tests were carried out under the guidelines of the 
International Conference on Harmonisation (ICH, 1996).
The highest precision for quantitative chromatography is obtained by the use of 
internal standards because uncertainties produced by sample injection are avoided. 
Here, a compound of known concentration that does not interfere in the analysis is 
added to the sample mixture. Clomipramine, metoclopramide and propyl paraben are 
pharmaceutical compounds that are of similar chemistry to the analytes of interest, but 
have never been reported in any ecstasy sample. Each of the standards were prepared 
at concentrations of 100 jag mL ' 1 and analysed by the HPLC method developed. 
Metoclopramide was chosen as the most suitable internal standard. It had good 
resolution from other analytes and gave a good response at the wavelength chosen, 
200 nm.
Selectivity is the ability of the method to accurately measure the analyte response in 
the presence of all potential sample components. This was a priority due to the many 
possible components that may be present in ecstasy tablets. Acetaminophen, 
acetyl salicylic acid, caffeine and phenacetin were possible adulterants tested. Figure
3.15 shows a chromatogram of the amphetamine type compounds, adulterants and 
internal standard resolved on the Chromolith SpeedROD, RP>18, 50 x 4.6 mm 
column. Peak resolution was calculated to be greater than 1 for all analytes.
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Figure 3.15. Selectivity tests showing the separation of amphetamines, adulterants 
and internal standard on the Chromolith SpeedROD, RP18, 50 mm x 4.6 mm. The 
chromatographic conditions were phosphate buffer/acetonitrile (97/3, v/v) maintained 
in an isocratic mode with pH at 2.5, temperature at 30 °C flow rate at 3 mL min-1. The 
elution order was 7: acetaminophen, 1: amphetamine, 3: methamphetamine, 2: MDA, 
4: MDMA, 5: MDEA, 8 : caffeine, 6 : MBDB, 9: acetylsalicylic acid, 10: phenacetin 
and 11 : metoclopramide
The linearity of an analytical method is its ability to elicit test results that are directly 
proportional to the concentration of analyte in samples within a given range, or 
proportional by means of a well defined mathematical transformation. A correlation 
coefficient of >0.999 is considered acceptable. The y-intercept should be less than a 
few percent of the response obtained for the analyte at the target level. Linearity was 
evaluated using Mandel’s test comparing linear and quadratic models (Mandel, 1964). 
For amphetamine, methamphetamine, MDA, MDMA and MDEA, the quadratic model 
was not significantly better than the linear model at the 5% level. For MBDB, 
deviation from linearity emerged (Fj, n = 4.91, P = 0.04). Linear regression analysis 
was determined on sample concentrations ranging between 10 jig mL* 1 and 250 fig 
mL ' 1 for six calibration points. Linear regression analysis indicated correlation 
coefficients of >0.986 for each analyte tested (Table 3.2).
1 0 2
HPLC method development & chemometric analysis of ecstasy & cocaine
Table 3.2. Linearity studies for the Chromolith SpeedROD, RP18, 50 x 4.6 mm.
Parameter
Amphetamine Standards
Amphetamine Methamphetamine MDA MDMA MDEA MBDB
Correlation 
coefficient (R2)
0.996 0.994 0.986 0.995 0.986 0.994
y-intercept -1.029 2.32 4.766 2.437 5.128 2.328
Slope 0.005 0.0005 0.00016 0.006 0.00016 0.00017
Residual sum 
of squares
4.131 5.195 7.791 2.931 7.725 5.034
The precision of a method is defined as the closeness of a number of replicate 
measurements to each other and is affected mainly by the random error associated 
with the method. Precision was expressed as relative standard deviation (% RSD). 
For repeatability, ten replicates of 50, 100 and 250 jag mL_l were analysed on the 
same day. These standards were again analysed in five replicates over five days to 
establish inter day precision. Repeatabilities were in the range of 0.36-1.09% and 
reproducibilities were in the range of 2.05-5.81% for five replicate determinations 
over five days (Table 3.3).
Accuracy is defined as the closeness of an analysis, or mean of replicate analysis, to 
the true value of the sample. With no reference materials available, the accuracy of 
the method was determined by analysing spiked samples at six concentration levels 
over the range of 25 and 500 jig mL'1. Results were calculated as experimental values 
compared to theoretical values and were expressed as percent recovery. Accuracy of 
the experiment results was always within 90.8-101.2% of the theoretical values (Table 
3.3).
The limit of detection (LOD) is defined as the lowest concentration that produces a 
response three times greater than the background noise and ten times higher for that of 
the limit of quantification (LOQ). LODs for all six amphetamines ranged from 0.2-3 
fig mL ' 1 and LOQs ranged from 0.6-10 jag mL*1. The limits were validated by 
analysing standards prepared at the concentrations of the LOQs for each standard and 
their precision and accuracy were reported (Table 3.3).
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Table 3.3. Validation studies for the Chromolith SpeedROD, RP18, 50 x 4.6 mm. Six amphetamine standards were tested for 
intra-day precision, inter-day precision, accuracy, limit o f detection (LOD) and limit of quantification (LOQ) under ICH 
guidelines.
P a r a m e te r
Amphetamine Standards
Amphetamine Methamphetamine MDA MDMA MDEA MBDB
Intra-day Precision (%  RSD)
50 fig mL'1 0.65 0.51 0.44 0.36 0.85 0.69
100 p g m L 1 0.89 1.09 0.89 0.81 0.94 1.03
250 pgm L '1 0.85 0.63 0.81 0.74 1.01 0.98
Inter-day Precision (%  RSD)
50 ngm L '1 2.33 3.67 2.98 4.74 3.15 3.23
100 fig mL'1 2.07 3.74 3.53 2.49 2.05 2.84
250 ngm L '1 3.92 5.81 5.17 4.33 5.39 4.76
Accuracy (% Recovery)
50 pg mL'1 98.2 98.8 99.1 98.9 98.2 99.4
100 ngm L '1 100.3 97.3 97.8 100.6 99.1 97.8
250 ng mL*1 94.3 90.8 97.6 101.2 98.6 98.2
LOD fig mL’1 1 2 3 3 0.2 2
LOQ ME mL'1 3 6 9 10 0.6 6
Precision (% RSD) 1.02 0.93 0.95 0.81 0.86 0.92
Accuracy (% Recovery) 95.6 97.5 98.8 98.5 93.8 97.5
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3.1.5, Conclusion.
The objective for this study was to develop a HPLC method for the separation of the 
major components of ecstasy tablets. A highly selective HPLC method was 
developed using the univariate approach. The step by step process examined 
chromatographic factors such as column chemistry, type and quantity of organic 
solvent, buffer strength, pH, temperature and flow rate. Chromatography 
'demonstrated good separation of the amphetamines and typical adulterants. The 
mobile phase of a phosphate buffer/acetonitrile satisfactorily separated MDMA and 
its related compounds when used in conjunction with various stationary phases. The 
final chromatographic conditions were 20 mM phosphate buffer/acetonitrile (97/3 v/v) 
maintained in an isocratic mode, pH 2.5, temperature 30°C and flow rate of 3 mL 
min ' 1 using the Chromolith SpeedROD, 50 x 4.6 mm column.
Comparisons of column types indicate that monolithic columns are more efficient 
than particulate columns without loss of resolution. Column back pressure and van 
Deemter plots demonstrated that the monolith columns provide higher efficiency at 
higher flow rates when compared to the particulate column without loss of peak 
resolution or selectivity. Monolithic columns reduced the retention times from 
approximately 18.3 minutes to 3.8 minutes resulting in faster separation without 
sacrificing resolution (Figure 3.12). The method developed for the monolith column, 
the Chromolith SpeedROD 50 x 4.6 mm was validated to ICH standards. This study 
demonstrates the suitability of the method for the routine analysis of ecstasy tablets 
and the practicality of the monolith column.
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3.2. M ultivariate HPLC method development for the analysis of cocaine.
Multivariate method development is the application of statistical and mathematical 
models to the chemical separation of analytes. The separation of a large number of 
analytes by liquid chromatography is dependent on many variables: columns, organic 
solvent, pH, gradient elution and solvent strength, flow rates and temperature. The 
optimisation of a method could in theory be time consuming. Alternatively, 
multivariate method development simultaneously examines all chromatographic 
separation factors to determine optimum performance. Data generated by the 
multivariate approach can be used to calculate a mathematical model with which to 
obtain response surfaces (Baranda et al. 2005, Medenica et al. 2004, Soni et al. 2007, 
Wang et al. 2006, Zhang et al. 2005). A response surface is a 3D plot used to 
illustrate the data from the optimisation analysis and is created by the use of artificial 
neural networks (Boti et al. 2009, Jancic-Stojanovic et al. 2009, Tran et al. 2007, 
Webb et a l  2009). By using multivariate analysis, chromatographic experiments may 
be designed in order to give maximum information from as few experiments as 
possible. With the use of an optimisation strategy, the time taken for method 
development may be reduced considerably.
3.2.1. M ultivariate method development.
The chromatographic factors that were studied were strength of organic solvent, ionic 
strength of buffer, temperature, pH, and flow rates. These were chosen as the most 
influential factors on the analyte separation based on preliminary experiments (data 
not shown). A 25' 1 fractional factorial design was created using the Minitab software 
and used as the basis of the experimental procedure (Table 2.2.). Resolutions between 
each peak and its preceding peak, retention factors and efficiencies and each of their 
averages were calculated for each experimental separation and referred to as 
‘observed’ data (Table 3.4 -  3.6). Each dataset was then used to construct a neural 
network that would best illustrate the relationship between the chromatographic 
factors and the performance indicators. An alternative calculation that could be made 
is the ‘resolution normalised’ where the product of all the resolution values is divided 
by the average resolution value.
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Both Multi Layer Perceptron (MLP) and Radial Base Function (RBF) networks were 
investigated. For each of the six outputs, 100 networks were tested and the best 
performing networks with the highest performance and lowest associated error were 
identified (Table 3.7). From these, the predicted values were plotted against the 
observed values. The correlation for each was then calculated. The combination of 
data set & network that best describes the separation was chosen based on the 
correlation values. That network with the highest correlation values was chosen as 
the best illustration of the separation.
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Table 3.4. Experimental retention factor (k’) values and k’avc values obtained for eight components of cocaine in sixteen discrete experiments
Expt. Cocaine analytes Average
No Procaine Caffeine Lidocaine Prilocaine ASA* Cocaine Phenacetin Benzocaine (k\v,)
1 0.54 1.26 2.05 3.28 5.33 JJ.10 18.44 26.85 8.61 •'
2 1.41 2.28 3.72 5.74 7.13 13.44 20.74 29.95 10.55
~*°*Z 1.29 1.29 1.29 ” " 4.37 11.80 " 3.62 ' i
4 0.56 1.31 2.04 3.12 3-72 6.04 7.09 16.51 5.05
n  v " " 0.40 0.88 2.18 3.40 4.24 13.77 19.34 31.51 9.47
6 0.43 0.94 2.35 3.51 4.34 13.89 19.73 32.88 9.76
0.56 1.30 2.09 5.22 6.36 12.30 18.62 27.47 9.24
8 0.32 0.43 0.99 0.99 2.48 3.82 6.50 9.05 3.07
r . 9 _ 0.44 0.44 1.13 1.13 1.43 4.23 7.93 10.96 3.46 |
10 0.19 0.19 0.34 0.34 0.92 1.96 3.62 7.01 1.82
r r z : ;
0.21 0.21 0.41 0.41 0.72 2.05 4.08 6.54 1.83
12 0.46 0.46 1.15 1.15 3.05 4.46 7.95 12.10 3.85
0.23 ' 0.44 0.77 0.77 2.23 5.03 7.21 8.74 3.18 I
14 0.97 2.17 2.90 4.12 5.15 17.26 19.93 25.35 9.73
' 0.19 0.42 0.53 0.53 1.59 3.84 5.52 6.64 2.41
16 0.34 0.77 1.73 3.36 4.09 12.53 15.55 20.65 7.38
ASA* = Acetyl salicylic acid
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Expt. Cocaineanalytes Average
No Procaine Caffeine Lidocaine Prilocaine ASA* Cocaine Phenacetin Benzocaine (R.v.)
i 1 1.87 2.18 2.11 2.68 3.03 2.58 4.43 3.67 2.82 i
2 4.47 2.34 3.18 3.00 1.47 2.90 3.81 3.54 3.09
[
L - 3 1.13 0.00 1.13 0.00 0.00 2.96 2.15 4.48 "  148 J
4 2.82 2.91 2.45 3.31 1.54 1.28 1.36 7.45 2.89
j 5 1.52 1.42 3.01 1.69 0.63 14.92 5.38 4.59 4.15 !
6 2.26 1.91 4.18 1.95 0.83 3.11 2.22 5.79 2.78
r ' 
i
7 6.01 3.02 4.36 3.94 1.66 4.58 4.36 9.99 4.74 j
8 1.48 0.50 5.28 0.00 8.70 2.25 4.88 2.90 3.25
r ” 
[_ 9 1.75 o;oo 1.59 0,00 0.55 2.76 6.00 2.78 1.93 ;
10 1.28 0.00 0.34 0.00 3.94 0.82 3.20 4.93 1.81
i 11 1.45 0.00 . 1.68 0.00 0.84 2.49 2.85 3.04
: i f i !
ri
¡2 1.08 0.00 1.43 0,00 3.69 J.24 4.63 3.23 1.91
13 1.45 1.27 0.82 0.00 2.66 0.93 2.95 1.06 1.39 j
14 3.18 3.21 1.68 1.76 0.83 6.42 1.28 2.29 2.58
ii_ 15 0.98 0.92 . 0.22 0.00 1.28 3.96 6.91 3.47 2.22 "j
16 1.71 1.94 3.80 2.46 0.98 6.25 2.15 2.94 2.78
ASA* = Acetylsalicylic acid
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in sixteen discrete experiments.
Expt. Cocaine analytes Average
(N.w)No Procaine Caffeine Lidocaine Pri locarne ASA* Cocaine Phenacetin Benzocaine
L .......... 413 637 955 1068 932 1452 1448 1925 1104 !
2 715 1156 1330 1047 957 1308 1502 1754 1221
104 104 289 289 289 768 162 ] 825 479
4 807 988 1618 2249 1850 1301 1773 1578 1521
u t z : 451 328 809 312 157 957 1543 1620 772 '
6 971 496 1696 439 342 298 2117 2118 1060
1326 1326 2069 2921 1709 2288 2225 1961 1978
s 495 727 856 856 1651 1531 2454 1209 1222
n r . r "
412 412 212 212 346 1567 2548 1064 847 j
10 528 528 599 599 688 699 984 1664 786
L 11 355 355 533 533 195 249 285 304 . - 2 5J L J
12 149 149 310 310 903 1062 1825 912 703
l Z ì ì t : 295 315 206 206 455 1248 1705 342' 597 ~]
14 481 1073 1075 496 249 1290 1541 1643 981
l x : : : 1112 257 89 89 454 1573 1856 2248 960
16 757 796 1866 636 639 1678 1970 1909 1281
ASA* = Acetylsalicylic acid
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Table 3.7. The best performing ANN for each of the experimental data sets.
Data A TVT1VT - Performance
Error
Set AJNiN Training Selection Test Training Selection Test
k’ RBF 5:5-2-8:8 0.854 1.309 0.849 1.329 1.416 4.628
k’* ave RBF 5:5-1 -1:1 0.851 0.828 0.632 0.253 0.230 0.290
R RBF 4:4-1-8:8 0.907 0.677 0.998 0.458 0.443 0.398
Rave RBF 4:4-2-l:l 0.961 0.826 0.831 0.855 0.874 0.509
N RBF 5:5-1 -8 :8 0.989 0.990 0.889 0 . 0 0 2 0 . 0 0 1 0.005
Nave RBF 5:5-l-l: 1 0.997 0.963 0.987 0.003 0.004 0.006
k \  Retention factor for each analyte; k \ ve. Average retention factor for all analytes; R. Resolution for 
each analyte; Rave. Average resolution for all analytes; N. Efficiency value for each analyte; Nave. 
Average efficiency value for all analytes
Ideally, the best network should be able to predict the values exactly, thus giving a 
perfect correlation (i.e. R =1) when plotted against the experimental values. Overall, 
resolution as a performance indicator produced the most correlated data. The R data 
set resulted in correlation values ranging from 0.8026 to 0.9744 for each analyte and 
the Rave data set had a correlation vaiue of 0.9382. The k’ data set had correlation 
values ranging from 0.2739 to 0.8263, with the k’ave data set having a correlation 
value of 0.38] 9. Similarly, the efficiency performance indicator produced values 
ranging from 0.6080 to 0.9270 for the each analyte for N, and 0.8109 for the Nave data 
set. Comparison of the correlation values for each of the predicted values versus the 
observed values (the experimental data) indicated that the combination of the Rave data 
set with its network best describes the analyte separation. When plotted the Rave data 
set produced a correlation o f 0.9382 for the network RBF 4:4-2-1:1 (Figure 3.16).
The Rave data set resulted in a neural network constructed as RBF 4:4-2-l:l (Figure
3.17). This means that four of the five inputs (% acetonitrile, pH, Ionic strength, 
temperature) were used as inputs, two neurons were in the hidden layer and there was 
the one output (the Rave value). The algorithm used to train the network was KM, KN, 
PI (K-means, center assignment, K-nearest neighbor, deviation assignment, PI, 
pseudo invert7 linear least squares optimisation).
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Figure 3.16. Linear regression of predicted versus observed values for Ravc data set 
using the ANN of RBF 4:4-2-1:1.
Input Layer Hidden Layer Output Layer
Acetonitrile
pH
Ionic Strength
Temperature
F igu re 3.17. Illustration of the ANN: RBF 4:4-2-1:1.
1 1 2
HPLC method development &  chemometnc analysis o f ecstasy &  cocaine
3.2 .2 . R esp on se Surfaces.
As the neural network for the Ravc data set was the best performing ANN, it was this 
network that was chosen to illustrate the separation in the form o f response surfaces. 
Using these response surfaces the final chromatographic conditions were selected for 
the separation of the eight analytes (Figures 3.18 -  3.20). The red region of each 
response surface signifies the area in which Ra^ e value is at its highest. As it is a high 
Ravc value that is desired, it is in this area in which the optimal separation is achieved. 
From each of the response surfaces, there were no precise levels for each of the 
factors, a range o f levels were produced. For optimal separation, levels o f acetonitrile 
between 12% and 16% and pH values between 2.9 and 3.3 would be suitable (Figure
3.18), along with temperature between 32 and 36 °C (Figure 3.19) and an ionic 
strength between 15 and 45 mM (Figure 3.20).
Figure 3 .18 . Response surface o f Rav* values with acctonitrilc and pH using the ANN 
of RBF 4:4-2-1:1.
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F igure 3.19. Response surface of Rave values with acetonitrile and temperature using 
the ANN of RBF 4:4-2-1:1.
Figure 3.20. Response surface of Ravc values with acetonitrile and ionic strength 
using the ANN of RBF 4:4-2-1:1.
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The final chromatographic conditions chosen were a mobile phase consisting of 
phosphate buffer/acetonitrile (85/15, v/v), the buffer at 20 mM ionic strength, pH 3, 
flow rate at 1 mL min-1 and a column temperature of 35°C. These levels are all 
within the desired range for optimal separation. Figure 3.21 is a chromatogram of the 
separation of the analytes under the optimised chromatographic conditions.
Retention time (minutes)
Figure 3.21. Chromatogram of the eight analytes including the internal standard, 
metoclopramide using the optimised chromatographic conditions. The mobile phase 
was phosphate buffer/acetonitrile (85/15, v/v) and flow rate was 1 mL min-1. 
Temperature was maintained at 35°C, pH at 3, and detection was at 200 nm, The 
column used was a Waters XBridge C l8, 50 x 4.6 mm, particle size 3.5 |im. The 
elution order (retention time in minutes) was: solvent peak (0.33), 1: procaine (0.64) 
2: caffeine (0.83), 3: lidocaine (1.08), 4: prilocaine (2.44), 5: acetylsalicylic acid 
(2.91), 6: metoclopramide (3.27), 7: cocaine (3.61), 8: phenacetin (5.82), and 9: 
benzocaine (7.22).
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3.2.3. Validation of multivariate method developed.
Validation was carried out under the guidelines of ICH. Linearity was evaluated 
using Mandel’s test, comparing linear and quadratic models. For all the cocaine 
analytes tested, the quadratic model was not significantly better than the linear model 
at the 5% level, Linear regression analysis was performed between 50 and 500 i^g 
mL“1 at five calibration points and correlation coefficients of >0.987 for each analyte 
were observed (Table 3.8).
Precision was expressed as relative standard deviation (% RSD). For intra-day, ten 
replicates o f 100, 250 and 500 jug mL-1 were analysed on the same day. These 
standards were analysed in five replicates over five days to establish inter-day 
precision (Table 3.8). Intra-day precision values were in the range of 0.27-1.06% and 
inter-day values were in the range of 0.83-4.58% for five replicate determinations 
over five days (Table 3.3).
The accuracy of the method was determined by analysing spiked samples at three 
concentration levels (300, 250 and 500 \ig mL*1), with three replicates of each. Results 
were calculated as experimental values compared to theoretical values and were 
expressed as percent recovery (Table 3.8). Accuracy of the experiment results was 
always within 95.6-100.3% of the theoretical values (Table 3.3).
The limit of detection was calculated by LOD = 3.3a/S, where a is the standard 
deviation of the response of the blank and S  is the slope of the calibration curve. The 
limit of quantification was calculated by LOQ -  10a/S under the ICH guidelines. 
LODs for all compounds ranged from 0.2-1.9 \ig mL'1 and LOQs ranged from 0.51-
5.5 \ig mL'1.
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Table 3.8. Validation studies for the Waters XBridge Cl 8 50 x 4.6 mm. Cocaine and related compounds were tested for repeatability, 
intermediate precision, accuracy, linearity, limit of detection (LOD) and limit of quantification (LOQ).
Parameter
Cocaine Standards
Cocaine Lidocaine Prilocaine Procaine Benzocaine Phenacetin Caffeine Acetyl. Acid
Intra-day Precision (% RSD)
100 ng mL'1 0.95 1.05 1.04 1.01 0.92 0.67 0.61 1.91
250 ngmL'1 0.94 0.87 1.06 0.79 0.96 0.36 0.44 0.29
500 figmL0 1.04 1.01 0.98 0.94 1.02 0.77 0.27 0.35
Inter-day Precision (% RSD)
100 ngmL'1 2.69 3.47 2.63 3.65 2.96 2.56 0.83 1.57
250 /JgmL'1 2.22 2,87 3.33 3.41 2.90 3.12 2.40 1.96
500 ngmL'1 3.63 4.41 4.23 3.29 4.25 3.39 4,88 4.58
Accuracy (%Recovery)
100 ngmL'1 98.3 96.2 97.8 99.0 96.5 97.8 98.6 97.6
250 fig mL'1 95.6 98.6 96.4 97.4 99.6 100,3 98.7 96.5
500 jigmL’1 96.6 96.3 97.8 99.4 97.8 97.4 97,6 98.2
Linearity ( R2) 0.998 0.997 0.996 0.997 0.998 0.991 0.987 0.992
LOD jig mL’1 1 1.9 0.7 1.8 2 0.25 0.2 0.5
LOQ pg mL'1 3.3 5.5 1.9 5.2 6 0.77 0.51 1.52
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3.2.4. Conclusions.
A HPLC method was developed for the separation of the major components of 
cocaine samples. This was performed using an alternative multivariate method 
development approach. Chromatographic factors such as quantity of organic solvent, 
buffer strength, pH, temperature, flow rate were assessed in combination with each 
other. A two level factorial design was created and used as the basis of the 
experimental procedure (Table 2.2.). The quality of the separation was based on the 
performance indicators of resolution (R), retention factor (k5) and efficiency (N) for 
each analyte. In describing the relationship between the chromatographic factors and 
the performance indicators, regression analysis in the form of Artificial Neural 
Networks (ANN) was applied using Trajan Neural Network software. The most 
successful neural network was then used to plot response surfaces (Figures 3.18- 
3.20). Based on these response surfaces the optimal chromatographic conditions for 
the separation of the cocaine analytes were chosen. These conditions selected were a 
mobile phase consisting of 20 mM phosphate buffer/acetonitrile (85/15, v/v) 
maintained in an isocratic mode, pH at 3, flow rate at 1 mL min-1, column 
temperature at 35°C with Waters XBridge C l8 50 x 4.6 mm, particle size 3.5 [im 
column and sample detection at 200 nm. All eight analytes under investigation were 
separated under ten minutes with good resolution using the optimised 
chromatographic conditions developed (Figure 3.21). Validation studies for the 
method were carried out under the guidelines of the ICH (Table 3.8).
The application of neural networks and response surfaces to this method development 
was an attractive alternative to the laborious step-by-step process that was involved in 
univariate method development previously applied to the ecstasy. Although there is 
the initial expense of purchasing the Trajan software and the steep learning curve 
associated with it, once established within a laboratory, this process of method 
development could be applicable to any complex separation.
1 1 8
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Chapter 4: Physical and chemical analysis of illicit drug samples.
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4.1. Ecstasy analysis.
A definition of drug profiling may be summarised as “the extraction of a drug 
sample’s chemical and/or physical profile, to be used in the application o f policies 
against the illegal use of drugs” (Esseiva et al. 2007). Drug profiling involves 
assembling all information on all aspects of the drug of interest, most notably the 
physical and chemical data. Physical data pertains to the visual and measurable 
characteristics of the seizure. Visual characteristics include colour, format (i.e. 
tablet/powder/plant/capsule) or logo and physical characteristics include weight, 
diameter, thickness and height. Chemical data involves analytical techniques and 
instrumentation, where the main ingredients of the drug is identified and/or quantified. 
Frequently excipients, adulterants, binders and synthetic by-products are also 
determined. Profiling drugs enables linkage of previously unrelated seizures, thus 
allowing law enforcement personnel to apprehend both dealers and/or clandestine labs 
and in turn reduce the supply of drugs (see Chapter 5).
4.1.1. Physical profile of ecstasy.
In this study, 183 ecstasy tablets were analysed for their physical characteristics of 
logo, colour, weight, diameter and thickness. Recorded physical data are provided in 
Table Al (Appendix). A total of 20 different logos were recorded and three tablets 
contained no logo (Figure 4.1). The most frequent logos were ‘Mitsubishi’ logo 
(24.6% of tablets analysed), ‘Bird’ logo (9.8% of tablets analysed) and ‘M&M’s’ logo 
(8.2% of tablets analysed). Other logos included ‘Euro’, ‘Durex’, ‘Smirnoff, 
‘Armani’, ‘Motorola’, ‘Chi’, ‘Rolex’, ‘Dexter’, ‘V2’, ‘Tasmanian Devil’, ‘Red Bull’, 
‘Horse’, ‘Smiley’, ‘Rolls Royce’, ‘Superman’, ‘Coca Cola’ and ‘Heart’.
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Figure 4 .1 . An image of all 21 logo types and corresponding seizure batch numbers 
for ecstasy samples used in this study.
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Weight, diameter and thickness are all measurements that can be reported directly 
without any discrepancy. Whilst the weight o f the tablet is always reported, rarely are 
diameter and thickness reported. In this study tablet weights ranged from 183 mg to
370.6 mg with an average of 260.9 mg (Figure 4.2). The distribution o f weight of the 
tablets may indicate three sub groupings within the sample set. Callipers were used to 
determine diameter and thickness. Diameter o f the tablets ranged from 8 mm to 12 
mm (Figure 4.3) and thickness ranged from 2.5 mm to 6 mm (Figure 4.4).
Tablet weight (m g)
Figure 4.2. Distribution of weights within the 183 ecstasy tablets analysed.
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Figure 4.3. Distribution of tablet diameters within the 183 ecstasy tablets analysed.
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Figure 4.4. Distribution o f tablet thickness within the 183 ecstasy tablets analysed.
When citing physical descriptions of tablets, logos and weights are the two most 
common features reported. Rarely is the colour of the tablet mentioned. The major 
colour reported is ‘white’, however differences in shade colour are possible. In this 
study, the majority of tablets (95%) were white, however only 55.7% of them were 
pure white with the remaining 39.3% being white with either brown or cream 
speckles. Other colours in this study included pink (3.4%) and green (1.6%) (Figure 
4.5). In this study, only one seizure was triangular in shape (1.6% of total number of 
tablets analysed), all others were round.
Figure 4.5. Examples of ecstasy tablet colour types reported in this study.
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4.1.2. Chemical analysis of ecstasy.
The determination of the active ingredients and adulterants within ecstasy tablet 
samples were performed using the validated HPLC method described in section 3.1. 
Sugar analysis was carried out by the method by described in section 2.4. Figure 4.6 
is a chromatogram from a typical ecstasy sample with MDMA, amphetamine and 
caffeine present.
Retention time (minutes)
Figure 4.6. Components of a sample ecstasy tablet resolved on the Chromolith 
SpeedROD, RP18, 50 x 4.6 mm. The chromatographic conditions were phosphate 
buffer/acetonitrile (97/3 v/v) maintained in an isocratic mode, pH 2.5, temperature 
30°C and flow rate of 3 mL min'1. Detection was recorded at 200 nm. The elution 
order was 1: amphetamine, 2: MDMA and 3: caffeine.
1 2 4
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Table 4.1. Major drug components present in 183 samples of ecstasy tablets from the Republic of Ireland seized in 2001 and 2003.
0/ C oncentration of component in ecstasy tablets (mg/tablet)1 aoiet
Pnm nnnpntc
/o
O ccurrence MDMA MDEA Caffeine AmphetamineV^UIIl|JUJlCIIl9
Mean ± SD Range Mean ± SD Range Mean ± SD Range Mean ± SD Range
MDMA only 68.8 76.6 ± 16.7 41 .4 -125 .9 - - • - -
MDMA & Caffeine 14.8 64.3 ± 12.3 37.6 - 89.5 - 1.7± 0.8 0.5 -3.5 - -
MDMA & MDEA & 
Caffeine 6.6 33.7 ±58.3 5.6 - 69.6 5.0 ±4 .5  0 .4-12.7 0.8 ±0.1 0 .4 - 1.1 - *
MDMA & MDEA 6.6 78.8 ± 19.8 47.7 - 125.5 4.1 ±3 .2  0.3 -20.0 - - - -
MDMA & Amphetamine 
& Caffeine 1.6 27.0± 4.1 23 .7-31 .7 - 0.2 ± 0.04 0.1 -0.2 5.4 ±0.7 4 .9 -6 .3
Amphetamine only 1.6 - - - - * 6.7 ± 1.6 4.9 - 8.2
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Using the developed method, six possible drug components were identified and 
quantified in the samples, along with four commonly used adulterants. MDMA, 
MDEA, amphetamine and caffeine were the main components present in the 183 
samples analysed, with MDMA occurring in 98.4% of samples tested (Table 4.1), 
Three tablets did not contain any MDMA, but amphetamine only. A wide variety of 
combinations of each of the four compounds were present in the samples. 
Quantification of the components was by the internal standard method. Depending on 
the batch sample analysed, MDMA concentration ranged from 5.6 - 125,9 mg/tablet. 
Concentrations for other compounds were much less, MDEA ranging from 0.3 - 20 
mg/tablet, amphetamine ranging from 4.9 - 8.2 mg/tablet and caffeine ranging from 
0.1 - 3.5 mg/tablet.
Sugars are often found in ecstasy tablets and other illegal drugs. They tend to be 
inexpensive and are un-controlled and as a consequence are a popular material to add 
bulk to the tablet. The chromatographic method used for sugar determination allowed 
for the detection and quantification of fructose, glucose, inositol, lactose, mannitol, 
sorbitol and sucrose (Section 2.4). Only two sugars, lactose and sorbitol were 
detected in the 183 tablets analysed. The majority of the samples (147) contained 
lactose only (80.3%). Eighteen samples (9.9%) contained sorbitol only. One batch, 
consisting of three tablets, contained both sorbitol and lactose (Figure 4.7) while the 
remaining fifteen tablets contained no sugars. A list of the sugars, quantities and 
combinations are given in Table 4.2.
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Retention tim e (m inutes)
Figure 4.7. Sugar components of an ecstasy tablet resolved on the Phenomenex Luna 
NH2 column, 250 x 4.6 mm. Conditions were acetonitrile/water (70/30), temperature 
of 30 °C and flow rate was at 0.75 mL min*1. The elution order was 1: internal 
standard, 2: Lactose, 3: Sorbitol.
In the lactose only samples, concentrations ranged from 33.9 mg/tablet to 230 
mg/tablet, with an average concentration of 132 ± 53.3 mg/tablet. Expressed as 
percentages, 17.1% was the minimum concentration of lactose in a tablet and 76.3% 
was the maximum concentration in a tablet. In the sorbitol only samples, the 
minimum concentration quantified was 84.9 mg per tablet (28.8% sorbitol per tablet) 
and the maximum was 203.6 mg per tablet (70.4% sorbitol per tablet) with an average 
concentration of 129 ± 41.3 mg/tablet. In the case of the three tablets (one batch) that 
contained both lactose and sorbitol, the lactose and sorbitol were present in an 
approximate ratio of 55% to 45%. Active ingredients, adulterants and sugar 
components are provided in Table A1 (Appendix). The chemical analysis performed 
accounted for as little as 8.5% of the tablet ingredients to as much as 99.4 % of the 
tablet ingredients identified, with an average of 67%. The remaining unidentified 
components of the tablets could be pharmacologically inactive chemical compounds 
such as starch or carbonates.
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Table 4.2. Sugars present in 183 samples of ecstasy seized in Ireland.
Sugars
%
Occurrence
Concentration of components in ecstasy tablets (mg/tablet)
Lactose Sorbitol
Mean ± SD Range Mean ± SD Range
Lactose only 80.3 132.0 ¿53.3 33.9-230.0 - -
Sorbitol only 9.9 - - 129.2 ±41.3 84.9 - 203.6
Lactose & Sorbitol 1.6 95.7 db 10.4 87.3 - 107.4 76.8 ± 8.2 71.9 - 86.3
No Sugars 8.2 - - - -
Inorganic element analysis provided quantitative data on nine different elements 
including aluminum, calcium, chromium, iron, lead, magnesium, potassium, sodium 
and zinc. Table 4.3 provides a summary of the inorganic elements detected in 
samples, the average concentration observed for all samples, the concentration range 
for each element and the percentage occurrence within the samples. Aluminum, iron, 
magnesium and potassium were present in all samples. The use of carbonates 
(CaC0 3 , K2 CO 3 , M gC 0 3 , and N a2C0 3 ) and stearates (Na(CnH 3sCOO), 
Ca(CnH35COO)2 , Mg(Ci7H35COO)2) is very common in the tablet production. The 
high incidence of aluminum could be an insight on how these tablet samples were 
produced, as aluminum is used as a reducing agent in the reductive animation route 
for the synthesis of MDMA. It was detected in all the tablets analysed and at 
concentrations up to 310.9 ppm. The high rates of zinc and iron in these tablets may 
possibly well be from lubricants and dyes used in the production process. A full list 
of all the metals present, at both their concentration levels and their combinations 
within each tablet, are given in Table A2 (Appendix).
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Table 4.3. Concentration (ppm) of inorganic elements and occurrence in ecstasy
Element % Occurrence Average (ppm) Range (ppm)
A1 100 43.9 1.4-310.9
Ca 97.8 256.7 3.5 -2836
Cr 17.4 0.6 0.03-3.5
Fe 100 52.0 2.3 - 402
K 100 0.16 0.1 -0.86
Mg 100 0.93 0.03 - 4.07
Na 93.4 0.3 0.02-3.1
Pb 23 0.2 0.01 -9.5
Zn 97.8 7.9 0.3 -  92
4.1.3. General profiling of ecstasy.
In this study, the relationship between the chemical profile of ecstasy tablets and their 
logo was investigated to ascertain whether users could distinguish tablets based on 
logos only. To test the hypothesis, the four tablet logos of ‘Mitsubishi’, ‘Bird’, 
‘M&M’s’ and ‘Euro’ were chosen.
‘Mitsubishi' Tablets Group
‘Mitsubishi’ tablet group comprised the largest group of seized samples. Fifteen 
different seizures (45 tablets) all bore this particular logo, which is consistent with the 
findings as being one of the most common logos seen on the European market 
(EMCDDA Annual Report, 2008). All tablets within this group, at first glance, seem 
to have the same visual, physical and chemical characteristics. All tablet weights lie 
within the narrow range of 277.8 mg to 324.5 mg, thickness ranges from 3.5 mm to
4.5 mm and diameters from 10.5 mm to 12 mm. All samples were the same colour 
and shape. All tablets contain MDMA with no other active ingredients. However, on 
closer inspection, the purity of the MDMA present in the tablets varies widely from 
41.4 mg/tablet to 125.9 mg/tablet, or 16.6% to 39.6%. The sugar content was 
determined and those with lactose present had lactose concentrations ranging from
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66.8 mg/tablet (23.4%) to 214.8 mg/tablet (69.7%). All metals were present at 
standard concentration levels.
One seizure was obviously different within the ‘Mitsubishi’ group of tablets. This 
particular seizure (seizure 35) had all physical characteristics common to the others, 
shape, colour weight etc, and had similar levels of MDMA present (Figure 4.8). 
However, when determining sugar content, this particular seizure was found to have 
no sugars present. Also, two of the metals, calcium and magnesium, were found in 
significantly higher concentrations than the others. This one seizure highlights the 
importance of a full chemical analysis (i.e. active ingredients and adulterants with 
excipients) o f all samples with the intention of profiling and again emphasises the 
importance of quantification of the compounds.
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Figure 4.8. A digital image and properties of tablets from seizure 37 and seizure 35.
Properties
Seizure No.
37.1 35.1
Weight 300.3 mg 293 mg
Shape Round Round
Colour White White
Thickness 4 mm 4.5 mm
Diameter 11.5 mm 10.5 mm
MDMA 107.5 mg (35.8%) 115.6 mg (39.4%)
Lactose 188.1 mg (62.6%) 0 mg
K 0.04 mg 0.02 mg
Na 0.03 mg 0.01 mg
Ca 0.01 mg 0.17 mg
Mg 0.01 mg 0.34 mg
Fe 0.02 mg 0.01 mg
A1 0.02 mg 0.01 mg
‘Bird’ Tablets Group
This group was comprised of six seizures, 4, 7, 8, 14, 19 and 32. Despite the lower 
number o f seizures, the seizures within the ‘Bird* group are more varied with many 
possible sub groups existing. Seizure 7, 8, 19 and 32 all contained MDMA and 
lactose. Seizure 4 contained MDMA and sorbitol, while seizure 14 contained low 
levels of MDMA, amphetamine and caffeine and no sugar. Seizure 14 also had
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sodium, calcium and magnesium present in appreciably higher levels than other 
seizures. In addition, seizure 14 was pink in colour.
‘M&M V  Tablets Group
A total of five seizures comprised this group, 23, 24, 25, 40 and 41. Again, they all 
have the same colour, shape, thickness and diameter. They all contain MDMA, 
caffeine and lactose. Wide ranges of purity exist with the MDMA and lactose data,
37.6 to 86 mg/tablet for the MDMA and 33.9 to 120.2 mg/tablet for the lactose. 
Caffeine alternatively, was present at low levels, 1.6 to 2.6 mg/tablet. Three of the 
seizures (23, 25 and 40) had significantly higher levels of magnesium present.
‘Euro’ Tablets Group
This group was comprised of three seizures and is one o f the most interesting. All 
tablets had the same physical characteristics, shape, colour, diameter, thickness and 
the tablet weights ranged from 285.5 to 305 mg. All tablets contained MDMA at 
regular levels. None of the samples contained MDEA, amphetamine or caffeine. 
That is where the similarities end. Diluent analysis confirmed that the three seizures 
were produced separately. One had lactose as its main diluent, one had sorbitol and 
one had no sugar present.
Based on the results of this data, three out of four times, the logo does indicate the 
chemical components of the tablet. In other words, the user will be able to tell what is 
in the tablet just by looking at its logo, the majority of the time. All the ‘Mitsubishi’ 
tablets had MDMA only, all ‘M&M’s’ tablets had MDMA, caffeine and lactose, and 
all ‘Euro’ tablets had MDMA. However, it must be noted that the logos do not 
determine the levels o f those chemical component in the tablets. For those tablets 
with the same chemical components, levels ranged significantly.
An alternative approach is to examine the chemical profiles o f tablets as opposed to 
their physical profiles. From the view point of the manufacturer, the logo stamp that 
gives the tablet the logo would be considered relatively cheap in comparison with the 
actual tablet ingredients. Therefore it may be very well possible that the one 
manufacturer has several stampers but only the one set of ingredients. This attempted 
to discover if one manufacturer could have one set of ingredients and recipes but
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several stampers. The active ingredients and adulterants detected and quantified in the 
tablets were MDMA, MDEA, amphetamine and caffeine. There were six 
combinations of these compounds.
‘MDMA only ’ Group
The group ‘MDMA only’ had the largest number o f seizures. 42 seizures, or 68.8% 
of the total number, had MDMA as their only active ingredient. MDMA purity 
ranged from 41.4 to 125.9 mg/tablet (Table 4.1). Within this group however, a wide 
variety was observed in other aspects of the tablet composition. Tablet weights varied 
from 183.4 mg to 370.6 mg, thickness ranged from 4 mm to 6 mm and diameter from 
8 mm to 12 mm. There were 16 different types of logo, the most popular being the 
‘Mitsubishi’. One seizure was pink, the others white, and one seizure was triangular 
in shape. Lactose was present in 33 seizures ranging from 66.6 to 230 mg/tablet. 
Sorbitol was present in only five of the seizures, ranging from 71.9 to 263.1 mg/tablet. 
There was one seizure that had both lactose and sorbitol present. These large ranges 
and sub groupings due to sugars suggests perhaps that more than one manufacturer 
produced these ‘MDMA only’ tablets.
‘MDMA and caffeine ’ Group
The ‘MDMA and caffeine’ group was comprised of nine seizures. The range of tablet 
weights was much narrower, 186.7 mg to 208.7 mg. There were only three logos 
within the group, ‘M&M’s’ being the most popular. All tablets were white and round, 
thickness varied from 3 to 4 mm and diameter from 9 to 10 mm. MDMA 
concentration ranged from 37.6 to 89.5 mg/tablet and caffeine ranged from 0.5 to 3.5 
mg/tablet. Interestingly, lactose was the only sugar present in this group; however a 
large variation existed in its quantities, 33.9 to 130.2 mg/tablet. Again, allowing for 
within batch variability, this still would imply one manufacturer for this group. 
Overall, similar chemical profiles with different physical profiles does not necessarily 
mean the one manufacturer.
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4.1.4. Discussion.
The first published report on ecstasy, profiling was by Renfroe (1986) and research has 
continued to present day. Britain, Japan and the United States have the most 
published reports describing ecstasy tablets seized in their countries. Italy, the 
Netherlands, Israel, China and the Czech Republic have reported one-off studies. The 
number of ecstasy samples analysed have ranged from 13 tablets (Milroy et al. 1996) 
to 20,000 tablets (Schifano 2000), but usually sample size is in the region of 150 
tablets. Results typically include the active ingredients, sometimes adulterants and 
very rarely sugar content. These studies also tend to include a vague description of 
the tablets, limiting the physical characteristics to logos and weight.
Typically amphetamine, methamphetamine, MDMA and MDA are the main 
compounds detected for the tablets. Other compounds that have been detected are 
MDEA (Makino et al. 2003, Cole et al. 2002, Teng et al. 2006, Sherlock et al. 1999), 
ephedrine (Makino et al. 2003, Teng et a l  2006, Sherlock et a i  1999), and ketamine 
(Cheng et al. 2006, Teng et al. 2006, Sherlock et al. 1999). A study based in the US 
(Tanner Smith, 2006), analysed for 30 compounds. The most common compounds 
detected were MDMA, MDEA, MDA, caffeine, ketamine and dextromethorphan 
(DXM). Also detected in small amounts were 2, 5-dimethoxy-4-bromoamphetamine 
(DOB), heroin, ketamine, phenylcyclohexylpiperidine (PCP) and 
paramethoxyamphetamine (PMA).
Traditionally, ecstasy was predominately MDMA, sometimes MDA, but never any 
other drug. Renfroe (1986) analysed 610 ecstasy samples from the years 1972 to 
1985. All tablets contained either MDMA or MDA, or a mixture of both compounds. 
No other drug or adulterants were detected. Since its rise in popularity, other active 
ingredients have been detected in ecstasy tablets. In the Netherlands, a large number 
of tablets were analysed between 1993 and 1996 (Spruit, 1999) of which 48-60% 
contained MDMA alone, 12-20% contained MDEA alone and 2-5% contained MDA 
alone. Each year however, 6-17% contained non-amphetamine type drugs. Detected 
were lysergic acid diethylamide (LSD), DOB, ketamine, 4-bromo-2, 5- 
dimethoxyphenethylamine (2C-B), atropine, caffeine, acetaminophen and other 
unidentified substances. 2, 5-dimethoxy-4-methylamphetamine (DOM), DOB and 
2C-B have also been identified in tablets (Kort & Cramer 1999). A report issued by
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the EMCDDA (EMCDDA Report, 2008) stated that most tablets (70%) contain 
MDMA or MDA or MDEA as the only psychoactive substance. Spain and Portugal 
were exceptions with amphetamine and methamphetamine the most commonly 
detected compound, and often in combination with MDMA or one of its analogues. A 
single tablet in the Netherlands was analysed and found to contain 8 mg strychnine 
(The Netherlands national drug monitor, 2007).
As the chemical components o f ecstasy tablets changed over the years, consequently 
so did the purity of each drug in the tablet. In the UK, average values were 90 to 102 
mg/tablet during the years 1991 and 1995 and then fell to 73 to 88 mg/tablet during 
the years 1996 and 2000 (Cole et al. 2002). Samples analysed in the Czech Republic 
varied from 30 to 100 mg/tablet, also quoting concentrations of 0 mg and 152 mg 
(Palenicek et al. 2002). In Italy, between 1995 and 2000, the concentrations of 
MDMA ranged from 100 mg to 150 mg/tablet (Schifano 2000). In Taiwan, a study 
was carried out on tablets between 2002 and 2005. It was found that the average 
MDMA content fell over those years from 126 mg/tablet in 2002 to 73 mg/tablet in 
2005 (Teng et al. 2006). EMCDDA reported average MDMA content across Europe 
to be between 5 and 72 mg/tablet for 2008. High doses (>130 mg/tablet) have been 
reported in Belgium, Denmark, Germany, France, Netherlands and Norway. Purity 
levels for this study ranged from 41.5 to 117.5 mg MDMA/tablet for MDMA only 
tablets. MDMA levels were at their lowest when in combination with amphetamine 
and caffeine (7 to 9.6 mg MDMA/tablet) or MDEA and caffeine (5.6 to 9.6 mg 
MDMA/tablet).
Within batch variability also exists. That is, in the one seizure or group of similar 
tablets, concentrations of the drugs differ from one another. In this study, four 
seizures 20, 37, 43 and 57, had MDMA concentrations ranging from 57.9-98.7 
mg/tablet, 61.0-117.5 mg/tablet, 50.0-103.8 mg/tablet and 41.4-99.8 mg/tablet, 
respectively. In 2001, Cole et al. (2002) analysed eighty tablets from the one batch. 
Concentrations ranged from 73 mg to 89 mg, with a mean of 79 mg/tablet. Limited 
reports have been published discussing sugar content of ecstasy tablets. In 2000, 
researchers in Northern Ireland identified sorbitol and glucose in a large number of 
tablets (Bell et a l  2000) and then in 2003, the same researchers found lactose to be 
the most common sugar, and sorbitol the second most common (Bell et al. 2003). In
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England, lactose was identified in the tablets at an average quantity of 37% of the 
tablet (Cole et a l  2002). These reports would be consistent with this study, where 
lactose and sorbitol were the only sugars detected with lactose being the predominant 
sugar.
Europol has a catalogue of logos, (Europol Ecstasy Logo System, EELS). In this 
catalogue, tablets are catagorised initially by their logo (e.g. ‘Mitsubishi’, ‘Bird’) and 
then numbered according to their generic logo type. To date, the catalogue contains 
524 logos with 402 logo type variations. The aim of this is to gather information on 
significant seizures and allowing this to match different seizures and further 
investigation by local authorities. In this study of Irish ecstasy samples ‘Mitsubishi’ 
was the most common logo, a feature which also observed by Bell et al. (2003) for 
Northern Ireland seizures for the same time period. Bell et a l (2003) reported that 
after ‘Mitsubishi’, the most common logos were ‘Euro’, ‘Aladdin’, ‘Clover’, ‘Cupid’, 
‘Unicom’, and ‘Teletubby’. Similarly, ‘Mitsubishi’ was the most common logo found 
in a study in North West England (Cole et a l  2002). However, for Sherlock et a l  
(1999), tablets from midlands England had ‘Dove’ as the most common logo. Outside 
of Europe, Levy et a l  (2007) studied tablets between 2001 and 2003 in Israel, and 
reported fifty-eight different logos, the most common being ‘Bulldog’, ‘Feet’, ‘Flag’, 
‘Superman’, and ‘Boss’. Interestingly, studies on the other side of the world, namely 
China and Japan have reported various logos but ‘Mitsubishi’ was a common one 
(Makino et a l  2003, Katagi et a l  2002, Teng et a l  2006). Whilst a range of logos are 
more common than others, ‘Mitsubishi’ remains very popular worldwide. 
Unsurprisingly, almost a quarter of the tablets analysed in this study had this logo.
The weights of the tablets analysed in this study lie within the ranges reported in other 
studies, 105 mg to 348 mg (Makino et a l  2003), 46 mg to 340 mg (Katagi et a l  
2002), 200 mg to 390 mg (Cheng et a l  2006), 300 mg to 400 mg (Lueng 2002) and 
148 mg to 693 mg (Sherlock et al. 1999).
Tablets seized in England have been reported to be white, off-white or beige (Cole et 
a l  2002). Numerous other colours have been reported, particularly in Japan, 
including blue, brown, yellow, grey, orange, green, purple, red, pink and rose (Katagi 
et a l  2002, Makino et a l  2003). The majority of research published have analysed
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tablets that are round in shape. Tablets may be slightly damaged when seized, but the 
original shape of the tablet can usually be evident. Only one study analysed tablets 
that were not all round. Teng et al. 2006, analysed three tablets (1.6% of total number 
of tablets analysed) that were square with rounded edges.
Metals which may be found in ecstasy tablets include Na, Ba, Ca (sulphate, phosphate 
salts) from excipients, Mg, Zn, Al, Li, B from lubricants, Pd, Pt, Ni from catalyst, 
LiAlH4 , NaBH3CN, Al/HgCh from reduction of intermediate ketones, Fe/HCl, SnCb, 
Pb(OAc)2 , PdCh/CuCl from the preparation of intermediate ketones, and I , Fe and 
Cu from dyes (Comment et al. 2001). Inorganic analysis of drugs other than ecstasy 
has become popular, such as amphetamine (Muratsu et al. 2002), methamphetamine 
(Marumo et al. 1994), heroin (Bermejo-Barrera et al. 1996, Bermejo-Barrera et al. 
1997, Bora et al. 2002, Infante et a l 1999, Myors et al. 1998) and cocaine (Bermejo- 
Barrera et al. 1996, Bermejo-Barrera et al. 1997, Bermejo-Barrera et al. 1999).
The metal analysis of drugs may be valuable for linking seizures. Metals in tablets 
may occur from various sources, either the synthetic pathway (by -  products) or the 
tableting process (excipients, colourants, etc). During the chemical process of 
MDMA synthesis, catalysts or reducing agents are used, each being very specific to 
each synthetic process. Knowledge of which were used would lead to information on 
the production of the tablets, which in turn would lead to linkage of seizures. The 
most common method of production of MDMA is the reductive amination route. 
With this method three variations of it exists. First is the high pressure method which 
uses platinum as a catalyst. Second is the low temperature method which uses sodium 
borohydride as a reducing agent. The third is known as the ‘aluminum amalgam 
reduction’ method which uses aluminum and mercury chloride as reducing agents. 
The safrole bromination route uses hydrobromic acid (HBr) and the less common 
Leukart reaction uses LiAlKU. Therefore the metals that would distinguish between 
each synthetic route are platinum (Pt), boron (B), mercury (Hg) and lithium (Li). The 
determination o f these metals was problematic. For mercury analysis, a hydride 
generator is required. This generates mercury fumes which are then analysed, which 
in turn creates obvious safety issues. Other specific equipment was needed for the 
other metals, which were not available.
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4.2. Chemical analysis of cocaine.
Cocaine samples are different to ecstasy tablets and therefore profiling of cocaine 
samples relies on a complete chemical analysis. Ecstasy tablets generally remain 
intact from the production lab, through to the dealer and finally to the user on the 
street. This is in contrast with cocaine samples, which are in powder form and can be 
“cut” or diluted many times between the production lab and the user on the street. 
These alterations to cocaine samples from its original source can complicate profiling 
and makes identifying dealer networks very difficult. In addition, with ecstasy 
seizures, preliminary connections can automatically be based on physical 
characteristics, such as logos or tablet colours, linking cocaine seizures proves more 
difficult as most seizures show the same physical characteristics, i.e. white powders. 
With a view to ascertaining if cocaine samples could be profiled, a chemical analysis 
of the active ingredients, adulterants and sugars was performed. The determination of 
active ingredients and adulterants within the cocaine sample were performed using the 
validated HPLC method described in Section 3.2. and sugar analysis was carried out 
by the method by described in Section 2.4. A number of cocaine samples (28) were 
analysed to determine their active ingredients and adulterants. Figure 4.8 is a 
chromatogram from the analysis of a cocaine sample separated under the conditions 
described in Section 3.2.
Using the developed method, eight possible components, five active ingredients and 
three adulterants, were identified and quantified in the samples. The major active 
drug ingredients present in the samples analysed were cocaine, lidocaine and 
prilocaine (Table 4.4). Samples varied with the level of drug constituent present and 
the combinations in which they occurred in samples. Cocaine occurred in 100% of 
samples (n = 28) and levels of concentration ranged from 0.21 to 22.1 mg/50mg 
sample (0.42 to 44.2% purity) with an average value of 7.6 mg/50mg sample (15.2% 
purity). Lidocaine was present in 53.5% (n = 15) of samples tested and levels of 
concentration ranging from 1.42 to 31.5 mg/50mg sample with an average of 21.7 
mg/50mg sample. Prilocaine occurred in 42.8% of samples (n = 12) and levels ranged 
from 0.15 to 3.3 mg/50mg sample with a mean of 1.69 mg/50mg sample. Procaine 
was detected in 3.5% samples (n = 1) at a concentration of 0.02mg/50 mg sample and 
benzocaine was only present in 3.5% samples (n = 1) and at a concentration of 0.5 
mg/50 mg sample.
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Retention time(minutes)
Figure 4.9. Components of a cocaine sample resolved on the Waters XBridge Cl 8 50 
x 4.6 mm, particle size 3.5 ¡im column. The chromatographic conditions were 
phosphate buffer/acetonitrile (85/15 v/v) maintained in an isocratic mode, pH 3, 
temperature 35 °C and flow rate of 1. mL min'1. Detection was recorded at 200 nm. 
The elution order (retention time in min) was 1: metoclopramide (3.275), 2: cocaine 
(3.616) and 3: phenacetin (5.824).
Adulterants present in samples included phenacetin (53.6% of samples), caffeine 
(46.4% of samples) and acetylsalicylic acid (3.5% of samples). As observed with the 
main drug ingredients, adulterants occurred in different combinations with drug 
components and at different levels. Phenacetin ranged from 0.07 -  2.2 mg/50mg 
sample with an average value of 0.81 mg /sample. Caffeine concentrations ranged 
from 0.06 -  2.1 mg /50mg sample with an average value of 0.80 mg/50mg sample. 
Acetylsalicylic acid was only observed in one cocaine sample and at a low level, 0.63 
mg/50mg sample. All concentrations and combinations of each compound are given 
in Table 4.3.
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Table 4.4. Major drug, sugar and adulterant components (mg/50mg of sample) detected in 
28 cocaine seizures used in this study
M ain drug Sugars Adulterants
Sample #
C
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ne
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1 15.0 - - 6.4 - - - O.t
20 8.5 - - 2.9 - - 1.1 -
11 6.6 - - 4.4 - - 0.5 -
13 7.3 - - 5.7 - - 0.6 -
8 12.0 13.9 - 1.4 - - 1.0 -
17 22.1 23.5 - 3.1 - - ■ 1.5 -
18 0.2 29.2 - 5.2 - - - -
16 15.1 14.4 - 1.5 - - 0.1 0.1
12 0.4 30.6 - 1.9 - - - 1.9
7 0.4 28.7 0.4 4.3 - - - 0.6
9 19.3 1.4 - 5.0 - 17.7 - 0.1
28 5.4 - 1.0 2.6 - 13.2 0.7 -
14fl 5.1 4.5 1.6 - 14.1 - 0.1 0.1
25* 0.2 31.5 1.4 - 7.6 - - -
21 3.1 26.2 2.3 - 12.7 - o oo -
24 10.4 18.0 2.3 - 10.8 - - 1.1
5 6.6 - 2.5 - 16.4 - 0.7 -
26 5.1 - 1.2 - 14.5 - 0.6 -
6 18.3 - 1.2 - 1.2 12.8 2.2 0.1
27 13.9 - 3.3 - 16.1 - - -
3 12.8 - 2.9 - 17.0 - - -
4 13.5 - 0.1 - - 20.3 - -
22 c 0.7 28.5 - - - 11.4 - 1.8
23 0.3 27.1 - - - 8.1 - 0.6
10rf 0.3 - - - - - 0.2 0.4
15* 10.4 - - - - - 1.4 -
2 0.9 22.7 - - - - - 2.1
19 0.5 25.8 - - - - 0.7 1.6
n 28 15 12 12 9 6 15 13
Min 0.2 1.4 0.2 1.4 1.2 8.1 0.8 0.1
Max 22.1 31.5 3.3 6.4 17.0 20.3 2.2 2.1
Mean 7.7 21.8 1.7 3.7 12.3 13.9 0.8 0.8
Stdev 6.7 9.4 1.0 1.7 5.1 4.4 0.6 0.8
= not detected in samples. Other compounds present included: 
a = Procaine (0.02mg/50mg sample 14); b = Acetylsalicylic acid (0.63 mg/50mg sample 25); c = 
Benzocaine (0.57 mg/50 mg sample 22); d -  Sorbitol (1.57 mg/50mg sample 10) and e = Inositol (9.36 
mg/50mg sample 15).
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Sugars have been detected previously in street cocaine samples, namely glucose, sucrose, 
lactose and fructose (Bernardo 2003, King 1997). Mannitol, sucrose, lactose, sorbitol and 
inositol were the sugar components identified in cocaine samples (Table 4.4). Glucose was 
not detected and two cocaine samples did not contain any sugars under test conditions. Sugar 
components occurred as single entities for the most part in cocaine samples with only three 
samples having mixed sugar combinations of mannitol with lactose or sucrose with lactose. 
Mannitol was the main sugar component identified and it occurred as a single sugar in 35.7% 
of samples. Mannitol levels ranged from 1.3 -  6.3 mg/50 mg sample with an average value 
of 3.6 mg/50 mg sample. Sucrose was the second most common sugar occurring as a single 
sugar in 28.5% of samples and ranged from 1.17 -  17 mg/50 mg sample with an average 
value of 12.2 mg/50 mg sample. Lactose when present was at elevated levels compared to 
other sugar components. Lactose occurred as a single sugar in 10.7% of samples and levels 
ranged from 8.1 -  20.2 mg/50 mg sample with an average value of 13.9 mg/50 mg sample. 
Sorbitol and inositol occurred in two separate cocaine samples at levels of 1.5 mg/50 mg 
sample and 9.3 mg/50 mg sample, respectively.
4.2.1. Discussion.
As with the ecstasy tablets, comparisons of the results of the cocaine samples in Ireland were 
made with other published data. Published data includes one-off studies in Australia, UK, 
Spain, Italy and Brazil and comprehensive studies on cocaine purity worldwide (UNDOC), 
Europe (EMCDDA) and America (DEA). Data includes % purity, geographical variations in 
purity, temporal variations in purity, identification and/or quantification of adulterants, 
sugars, impurities and residual solvents. A point to note is a physical profile of these samples 
is limited to “white” and “powder” form. With cocaine, greater emphasis is needed for the 
chemical profile, i.e., the main ingredients and their quantities.
As stated previously, purity levels have been reported without any reference to the original 
seizure weight. However, using these reported values, the samples in this study had a lower 
purity level than the majority of the studies. Most European countries have reported mean 
values between 24% -  80% purity, with an overall average o f 40% - 60% for the year 2004 
(EMCDDA Report, 2006). This figure is similar for America (DEA) and Worldwide 
(UNDOC World Drug report 2006). In Europe, there has been a downward trend in cocaine 
purity from 2003 to 2008, values ranging from 13% to 62% (EMCDDA Report, 2010). This
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may coincide with the increase in demand for this drug, as consumption and seizures rose 
over this time period.
One aspect of reporting purity values which may cause a bias is the sample weight. Seizures 
of a significant weight (e.g. seizures from a dealer) may be more ‘pure’ than seizures of a 
smaller weight (e.g. seizures from a drug user), which are most probably already ‘cut5 a 
number of times, thus lowering the purity value. One study (Barrio et al. 1997) addressed 
this issue by dividing the samples into two weight categories, >5 g and <5 g. Results did 
indicate a difference in the mean values for purity between the two categories. A study by 
Bernardo (2003) analysed samples of weights >5 g. Purity levels in this study ranged from
4.3 and 87.1% (mean ± S.D. = 28.1 ± 28.4). Fucci & De Giovanni (1998) analysed 156 
cocaine samples, 24% of which had weights ranging from 100 to 1000 g. Purity of these 
samples ranged from 23 to 98% and no adulterants were detected. Seizures of smaller 
weights may not always be low purity. Fucci & De Giovanni (1998) analysed two samples of 
small weights (1.7 and 5.2 g) and both had high purity levels, 90% and 99% respectively. 
Therefore, it would seem to be a necessity when stating purity levels, to categorise the 
samples into different weights or to simply state the weight of the analysed sample. Other 
published data did not take this factor into consideration. Darke et al. (2002) reported purity 
levels ranging from 50% to 64% from 1996 to 2000, with a peak in purity during 1997/1998. 
The EMCDDA Report 2010, the World Drug Report from the UNDOC, Interpol documents 
and DEA documents all report purities without stating or categorising the weights of the 
original seizures.
In this study, samples from small seizures, <5 g, were analysed. This may infer that the 
samples were seized from users as opposed to dealers; that the purity level would be low and 
the number and quantity of adulterants/sugars present would be high. Indeed, this was the 
case. Purity levels ranged from 0.4% to 44% with a mean of 15.3%. Seven different 
combinations of active ingredients and adulterants were detected in the samples, individually 
and in different combinations. Five sugars were detected, again individually and in different 
combinations (sucrose & lactose in one sample, mannitol and lactose in one sample and 
mannitol & sucrose in one sample) and quantities (Table 4.4).
Lidocaine is the most common adulterant detected in samples from other studies, closely 
followed by caffeine (Barrio et al, 1997, Bernardo, 2003, Fucci & De Giovanni, 1998, King
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1997). Other adulterants detected include procaine, prilocaine, benzocaine and piracetam. In 
one study (Fucci & De Giovanni, 1998), fourteen different adulterants were detected. 
Phenacetin was also another adulterant identified along with cocaine (Fucci 2004). 
Pharmacologically inactive chemical compounds that may be found in samples include starch 
and carbonates (Lopez - Artiguez et al. 1995).
For classification purposes, the sample size (twenty eight) was too small to make any definite 
links between samples; however there are some general observations. When all the data is 
combined (i.e. drugs/sugars/aduItérants) the twenty eight samples could only be reduced to 
twenty three groups. This would suggest that the samples are street cut samples due to the 
variations and combinations within the samples. The common samples were (11, 13 & 20); 
(8 & 17); (5 & 26) and (3 & 27) the remainder are all unique or have a unique combination of 
all data.
4.3. Conclusions.
The overall aim of this study was the application of HPLC methods developed for the 
chemical profiling of ecstasy and cocaine samples that were seized from the Irish market.
MDMA was the main active ingredient detected in the majority of ecstasy tablets with 62.3 % 
of samples containing only this active ingredient. MDEA was also identified in combination 
with MDMA, and 3.2% of the tablets had a greater quantity of MDEA than MDMA. 
Amphetamine was also found, alone and in combination with MDMA and caffeine. Caffeine 
was the only adulterant detected. Sugars are another major component of ecstasy tablets. 
Only two sugars were detected in the tablets, lactose and sorbitol which were found alone and 
in combination with each other. No sugars were detected in 8.2%. All detectable active 
ingredients, adulterants and sugars were identified and quantified for a large sample of 
ecstasy tablets. Upon combination of all the results, these analytes comprised of 8.5% to 
99.6% of the total weight of the tablets. This study confirmed that the tablets seized in 
Ireland are similar to those seized elsewhere in Europe and Worldwide. This would then lead 
to the conclusion that these tablets are not produced in Ireland, but in other countries, most 
probably in the UK, Netherlands or Belgium.
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The chemical components of street cocaine samples were also detected and quantified. 
Predictably cocaine was present in 100% of the powders analysed. The important detail to 
note though was the purity levels, 0.4 to 44.2%, which is considerably less than results from 
other research (EMCDDA report, 2006). A large number o f both adulterants and sugars were 
detected in the samples. As each seizure was originally from a small weight of sample, one 
could suggest that the seizures were already “cut” a number o f times, before confiscation.
In order to curtail production and sale of cocaine and indeed other drugs, efforts have been 
made at government level to ban the production or sale of the chemical precursors that are 
used in the production process these drugs, e.g. safrole for MDMA production. Whilst this is 
admirable, the large scale production and sale of the most common adulterants and excipients 
should also be prohibited. Clearly, sugars will not be made illegal, but other compounds, 
such as lidocaine— both of which is still legal in Ireland today - should be monitored for sales 
in large quantities. The onus is on the policy makers, both in Ireland and worldwide, to align 
themselves and ban, or restrict such compounds.
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Chapter 5: Chemometrics and statistical profiling of ecstasy tablets.
HPLC method development & chemometric analysis of ecstasy & cocaine
5.1. Introduction.
Chemometrics can be described as the application of statistical methods to multivariate 
chemical data sets allowing for the statistical profiling of illicit drug seizures (Nic Daeid & 
Waddell 2005). Profiling of illicit drug seizures can potentially be used to monitor the extent 
of drug trafficking (Nic Daeid & Waddell 2005), determine the geographical origin of 
samples (Johnston & King 1998) and identify novel trends or developments in illicit drug 
samples (Jonson & Stromberg 1993). The method and types of statistical techniques 
commonly applied to drug profiling include specifically the use of unsupervised pattern 
recognition methods of PCA, HCA and Pearson’s correlation and more recently supervised 
methods of LDA and ANN.
Unsupervised pattern recognition methods require no knowledge as to the origin of samples 
but can provide clusters or groupings from the data sets. PCA ascribes loadings to the 
classification based on the main components present in the data set. HCA gives no indication 
of the variables used for classification but does present all the variation in the data set in the 
form of a dendogram. Pearson’s correlation coefficient measures the relationship between 
variables or samples and is currently recommended by the European Network of Forensic 
Science Institutes (ENFSI) as a method of choice in profiling drug samples. Discriminant 
analysis techniques such as LDA are parametric supervised techniques and are applied in 
cases where data sets are known to be normally distributed (Nic Daeid & Waddell 2005). 
Artificial neural networks (ANN) have the potential to provide the complete solution in 
identifying recognition patterns in data and new seizure data could be applied to the 
established neural networks to monitor developments in drug trafficking or identify new 
trends in illicit drug seizures. The following sections deal with the application of PCA, HCA, 
Pearson’s correlation, LDA and ANN to determine the suitability of classification methods in 
identifying possible groupings within the ecstasy chemical data sets generated in this study.
5.2 Ecstasy data pre-treatm ent methods.
The chemical data sets used in this study consisted of the active ingredients plus sugars (AS), 
metal data (MD) and all data combined (DC) for the 183 individual ecstasy tablet samples 
(see Appendix Table A1 & A2). Variables for AS data included MDMA, MDEA, 
amphetamine, caffeine lactose and sorbitol and represent only compounds detected in 
samples. MD data variables were Al, Zn, Fe, Mg, Ca, Cr, Pb, Na and K that were similarly 
detected in ecstasy samples. The data sets for statistical analysis were comprised of
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chromatogram peak areas (AS data) or absorbance values (MD data) for each compound 
detected by HPLC or atomic absorption methods, respectively. Not all compounds were 
detected in all individual tablet samples and the presence of zeros in data sets can pose 
problems in particular statistical treatment of samples. In order to overcome this possible 
difficulty zero values were replaced with a value corresponding to half the lowest detection 
limit for variables of each data set (Lociciro et al. 2008). In addition, various pre-treatment 
methods were explored to determine the most appropriate method prior to applying the 
statistical protocol to the entire data sets.
Since all data sets were generated by different analytical techniques data pre-treatment is 
required due to the differences in the scales between variables. To reduce the complexity and 
to easily identify the appropriate pre-treatment method, eight seizures were selected based on 
their discrete AS chemical data profile (Table 2.5, Table Al). Each seizure consisted of three 
tablets with six variables giving a combined sample set of 144 data points for pre-treatment 
analysis. Each pre-treatment method was evaluated by PCA and HCA methods to determine 
the most appropriate pre-treatment method(s). Data pre-treatment methods evaluated 
included the following:
1. Normalisation (N)
2. Normalisation & logarithm (N + Logio)
3. Normalisation & 4th square root (N + 4sqrt)
4. Standardisation (S)
5. Standardisation & logarithm (S + Logio)
6. Standardisation & 4th square root (S + 4sqrt)
The calculations for each pre-treatment method are as described in Section 1.5.2. PCA 
allows for the visual inspection by use of score plots and the eight selected seizures should be 
present as discrete individual groups but distant from other seizures. Based on PCA score 
plots (Figure 5.1 & 5.2) the optimal pre-treatment methods of choice were normalisation & 
logarithm and standardisation & logarithm. Within these score plots all three data points for 
each seizure are cluster together while all eight seizures are distant from one another. As 
PCA is subjective, the same data sets using same pre-treatment methods were assessed by 
HCA. Pre-treatment methods should generate eight HCA clusters for the selected data set 
and the three tablets for each seizure should be cluster together at a Euclidean distance of 1.
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Normalisation & logarithm, standardisation & logarithm and standardisation & 4th square 
root were suitable pre-treatment methods for identifying the eight discrete HCA clusters 
(Table 5.1).
Pre-treatment of data by normalisation reduces the order of magnitude for each component 
within a tablet to a fraction of the total concentration of all chemical components within each 
individual tablet. Data pre-treatment by standardisation reduces the order of magnitude for 
each individual chemical component in all tablets to a fraction of the total concentration for 
that chemical component in all tablets. Since chemical data sets were generated by different 
analytical techniques (i.e. HPLC peak areas and AA absorbance units) and are not in the 
same numerical category, data pre-treatment by normalisation is not recommended. 
Conversely, data pre-treatment by standardisation is suitable as it allows for the comparison 
of variables within each chemical data set for all tablets. As such, standardisation & 
logarithm was chosen as the more suitable data pre-treatment method for application to the 
entire 180 ecstasy tablet samples for profiling analysis. All data sets for the three ecstasy 
tablets from seizure 10 were excluded.
Exclusion of seizure 10 was based on the HPLC data for the active ingredients which had a 
reduced peak area for the internal standard suggesting a less than 2 0  j j .1 sample inject volume 
for these samples compared to other samples. Calculation of the concentration of 
components in these samples is not affected as concentrations are determined by reference to 
the internal peak area standard. Since standardisation & logarithm data pre-treatment method 
reduces the order o f magnitude for each individual chemical component in all tablets the 
inclusion of this data set could potentially be misclassified. Seizure 10 was therefore 
excluded from all subsequent statistical analysis.
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Figure 5.1. PCA score plots for normalised data pre-treatment methods. (A) normalised 
data, (B) normalized & logarithm data and (C) normalised & 4,h square root data.
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Figure 5.2. PCA score plots for standardised data pre-treatment methods. (A) standardised 
data, (B) standardised & logarithm data and (C) standardised & 4,h square root data.
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Table 5.1. HCA outcomes of data pre-treatment methods for eight selected ecstasy seizures.
Pre-treatm ent method No. of clusters at a Euclidean distance of 1
Normalisation (N) 6
Normalisation & logarithm (N + Logi0) 8
Normalisation & 4th square root (N + 4sqrt) 7
Standardisation (S) 7 + 1 outlier
Standardisation & logarithm (S + Logio) 8
Standardisation & 4th square root (S + 4sqrt) 8
5.3. Ecstasy data pattern recognition methods.
Three different unsupervised pattern recognition methods o f PCA, HCA and Pearson’s 
correlation coefficients were evaluated for all three pre-treated data sets of AS, MD and DC. 
Unsupervised pattern recognition methods require no prior knowledge as to the origin of 
samples but can provide clusters or groupings from the data sets. Groupings or clusters 
generated can be tested by supervised LDA to determine the percentage correct classification 
rate for each unsupervised pattern recognition method using each of the respective data sets.
5.3.1. Principal component analysis
PCA score plots for standardisation & logarithm pre-treated AS, MD and DC data sets are 
presented in Figures 5.3, 5.4 & 5.5, respectively. The score plot for the first two principal 
components for AS data (Figure 5.3) account for 57.1% of the total data variance and 
illustrated that the active ingredients & sugar variables were classified into 6 discrete 
groupings. Table 5.6 lists the seizure groupings for AS data identified by PCA. Individual 
ecstasy tablets were all clustered to discrete seizures and no outliers were detected, 
confirming that ecstasy tablets were linked to their original seizure number. The first two 
principal components for MD and DC data sets accounted for 38.7% and 29.2% of the total 
data variance, respectively. No distinct groups of samples were observed for the MD data 
(Figure 5.4). Five groups were observed for the DC data set and individual ecstasy tablets 
were all clustered to their original seizure numbers (Figure 5.5). In this instant, principal 
component analysis suggest that AS data is more important for classification purpose.
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5.3.2. Hierarchal cluster analysis
This statistical method measures the distance between two objects and if the distance 
is relatively small then similar linked objects will be clustered. The similarity 
distance between samples is calculated by both cluster and interval methods. In order 
to determine the most appropriate HCA cluster and interval method the AS data set 
for the eight seizures used in pre-treatment studies (Section 5.2) was evaluated prior 
to applying the method to the entire data sets.
Seven different HCA cluster methods were evaluated (Between groups, Within 
groups, Nearest neighbour, Furthest neighbour, Centroid, Median and Wards) using 
the default Squared Euclidean interval setting of the SPSS software package. 
Selection of the most appropriate cluster method was determined by the numbers of 
clusters formed by each method (Table 5.2). All clustering methods at a Euclidean 
distance of 1 generated 8 discrete clusters for the eight selected seizures and all three 
tablets were clustered to their respective seizure (Figure 5.6). At Euclidean distance 5 
the number of clusters observed reduced from 8 to 7 or 6 regardless of clustering 
method employed (Table 5.2). Between groups was selected as the cluster method of 
choice as this is the default cluster method associated with the SPSS software for 
HCA. In addition, since 8 correct discrete clusters were observed at the Euclidean 
distance 1 this was selected as the most appropriate distance to determine group 
classifications for all subsequent analysis.
Table 5.2. Number o f clusters for eight discrete seizures determined by different 
HCA clustering methods.
Cluster M ethod No. of clusters at distance 1
No. of clusters 
at distance 5
Between groups 8 7
Within groups 8 7
Nearest neighbour 8 7
Furthest neighbour 8 6
Centroid 8 7
Median 8 7
Wards 8 7
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Table 5.3. Number of clusters for eight discrete seizures determined by different 
HCA interval methods.
Cluster Method No. of clusters at distance 1
No. of clusters 
at distance 5
Euclidean 4 8
Squared Euclidean 8 7
Cosine 8 7
Pearson 8 7
Chebychev 4 8
Block 4 8
Minkowski 4 8
E u c lid ean  d is ta n c e
Figure 5.6. HCA dcndogram using Between Groups with Squared Euclidean for 
eight selected seizures. The number o f clusters formed was dependent on the 
Euclidean distance measure employed.
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Using Between groups cluster method, seven interval methods were assessed (Table 
5.3). Squared Euclidean, Cosine and Pearson interval methods correctly cluster all 
eight seizures at distance measure of 1. All other interval methods failed to correctly 
cluster the eight seizures. The number of clusters formed at distance 5 was reduced 
from 8 to 7 clusters for Squared Euclidean, Cosine and Pearson interval methods with 
two seizures (i.e. seizures 13 & 15) clustering as one group (Figure 5.6). As such, 
Between group and Squared Euclidean at distance measure of 1 were chosen as the 
HCA cluster and interval methods for application to the entire data sets of AS, MD 
and DC.
Standardisation & logarithm pre-treated AS, MD and DC data sets were analysed by 
HCA. The number of clusters formed, varied dependent on the data sets and 
Euclidean distance measured employed. Dendograms for AS, MD and DC data sets 
generated 11, 23 and 32 HCA cluster groups at Euclidean distance 1, respectively. 
MD and DC data sets did not form discrete clusters with numerous individual tablet 
samples distance from other corresponding members of the same seizure suggesting 
that these samples were incorrectly classified and represent HCA outliers. Analysis of 
MD and DC HCA dendograms at Euclidean distance 5 reduced the number of clusters 
to 7 and 19, respectively; however outliers were still present suggesting that MD and 
DC data sets were unreliable for HCA classification purposes.
Conversely, AS data generated 11 discrete HCA groups with all individual tablet 
samples linked to corresponding members from the same seizures with only two 
exceptions. Due to the large number of samples considered, the ‘dendogram became 
complex when each sample was labelled. A simplified dendogram is illustrated in 
Figure 5.7 which demonstrates group linkages for AS data set, with members of each 
cluster identified, listed in Table 5.6. Individual ecstasy tablet samples 49.3 and 53.3 
were not linked to members of the same seizure at euclidean distance 1, but could be 
linked with group IX and IV if measured at euclidean distance 2 and 6, respectively 
(Figure 5.7).
156
HPLC method development & chemometric analysis of ecstasy & cocaine
HCA identified four clustering groups of A, B, C and D with clusters further 
differentiated into eleven HCA groups (Figure 5.7). Clusters were differentiated 
based on active ingredients and sugar components present and group subdivision was 
based on the combination and concentration of components (Table 5.4). Cluster A 
was defined by two main components of MDMA and lactose. HCA groups I, VII, 
and XI were separated based on the presence of caffeine or sorbitol. Cluster B was 
comprised of groups IV, VIII, IX and X and were differentiated based on the presence 
of MDMA, lactose and MDEA. These groups were primarily separated based on the 
combination and concentration of MDMA and MDEA present (Table 5.4). Cluster C 
was distinguished by the absence of lactose in all samples with groups n, III, and IV 
separated based on the presence of caffeine, sorbitol or amphetamine. Cluster group 
D was comprised of the single seizure 30 and was distinguished by the lack of 
MDMA in either of the three tablet samples.
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Figure 5.7. Dendogram for AS data set illustrating four clusters A, B, C, and D with 
eleven discrete HCA groups. Expanded section highlights the region for HCA groups 
IV and IX and illustrates the linkage of the two ecstasy sample outliers 49.3 and 53.3 
at Euclidean distance 1, 2 or 6.
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Table 5.4. Summary of the active ingredients and sugar components (mg/g) for HCA classification of ecstasy seizures used in this study. HCA 
cluster groups and seizure batch numbers are described in Figure 5.7 and Table 5.6, respectively.
MDMA Lactose MDEA Caffeine Sorbitol Amphetamine
ciusier i»roup
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean SD Mean ± SD
A I (96) 282.1 ± 78.3 566.1 103.2 - * * -
VII (27) 331.0 66.7 374.4 ± 183.3 - 9.1 ± 3.9 - -
XI (3) 252.2 ± 46.2 345.6 ± 34.4 - - 277.1 ± 24.8 -
B VIII (9) 288.4 ± 75.1 566.2 ± 38.7 14.1 ± 1.7 - - -
X (3) 369.5 ± 16.5 681.8 ± 7.4 1.7 ± 0.5 - - -
IX (6) 311.9 44.2 422.7 ± 31.1 4.6 ■± 0.3 5.1 ± 0.6 - -
IV (6) 27.5 ± 5.7 481.5 ± 86.6 46.6 ± 9.0 2.8 ± 0.5 - -
C 11 (12) 279.8 ± 42,8 - - - 550.4 209.4 -
V (3) 81.5 ± 14.2 * 0.6 ± 0.1 - 16.0 ± 2.4
III (12) 282.9 ± 60.8 - - - - -
D VI (3) - 688.6 ± 59.7 - . 29.5 ± 8.6
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5.3.3. Pearson’s correlation coefficients.
Pearson’s correlation coefficients determine the linear relationship between two 
samples. The more correlated the relationship the more likely two samples are linked. 
A Microsoft Excel macros file provided by European Network of Forensic Science 
Institutes (ENFSI) was used to examine Pearson’s correlation matrices for the 
standardisation & logarithm pre-treated AS, MD and DC data sets. Application of 
this method for classification purposes is determined by the minimum acceptable 
threshold value assigned.
Threshold values between two samples are arbitrary and coefficient values equal to or 
greater than the minimum set value will imply a high degree of correlation between 
linked samples. In this study threshold values were initially determined by examining 
all three replicates for each of the three samples from the same seizure. Since samples 
are similar the minimum value obtained is considered the threshold value to link 
replicates of the same sample (Table 5.5). In this example, the minimum threshold 
values for seizure 13 and 14 were 97.97 and 98.31, respectively and both seizures are 
unlinked. The minimum threshold values obtained using this approach for all AS data 
samples ranged from 92.7 (seizure 3) to 99.9 (seizures 2 & 12) with an average value 
of 98.6 for all seizures. This average value of 98.6 was selected as the acceptable 
minimum threshold value to give a high degree o f confidence between correlated AS 
data samples. Using the same approach the minimum average acceptable threshold 
values identified for MD and DC data set samples were 79.2 and 88.2, respectively. 
Correlation matrices values that fall below these minimum average threshold values 
for each of the respective data sets would imply samples were not linked while values 
equal to or above the value would be considered correlated.
Due to the relatively lower threshold values assigned for DC and MD data sets the 
number of groups identified were high (Table 5.7). The DC data set generated 35 
Pearson’s groups which were comprised of 10 groups and 25 unlinked seizures using 
the minimum acceptable threshold value of 79.2. The increased threshold value of
88.2 identified 29 groups for the MD data set, comprising 7 groups and 22 unlinked 
seizures. As previously observed with PCA and HCA methods the inclusion of metal 
data proved unreliable at differentiating unique groups from the data sets.
1 6 0
HPLC method development & chemometric analysis of ecstasy & cocainc
Table 5.5. Pearson correlation coefficients sample matrix for the three replicates of each sample seizure 13 and 14. Minimum threshold values 
(highlighted in red) for seizure 13 and 14 are 97.97 and 98.31, respectively. Shaded section indicates poor correlation between sample replicates 
of seizure 13 and 14 due to low threshold values. Pre-treated AS data set was used in this example.
1311 1312 1313 1321 1322 1323 1331 1332 1333 1411 1412 1413 1421 1422 1423 1431 1432 1433
1311 100
1312 99.98 100
1313 99.99 99.98 100
1321 99.13 99.17 99.16 100
1322 99.14 99.18 99.16 99.99 100
1323 99.09 99.11 99.11 99.99 99.97 100
1331 99.28 99.24 99.25 98.13 98.09 98.09 100
1332 99.26 99.22 99.23 98.21 98.17 98.18 99.99 100
1333 99.17 99.13 99.14 98.02 97.99 97.97 99.98 99.98 100
1411 56.30 56.56 56.53 53.61 53.64 53.36 58.18 58.13 58.26 100
1412 56.42 56.68 56.65 53.68 53.71 53.43 58.34 58.30 58,43 99.99 100
1413 56.76 57.03 57.00 54.23 54.26 53.98 58.52 58.48 58.59 99.98 99.96 100
1421 56.78 57.08 57.04 54.30 54.35 54.04 58.46 58.42 58.54 99.91 99.90 99.94 100
1422 56.90 57.20 57.15 54.47 54.52 54.22 58.53 58.50 58,62 99.88 99.87 99.92 99.99 100
1423 56.74 57.04 57.00 54.31 54.35 54.06 58.39 58.36 58.48 99.89 99.88 99.92 99.99 99.99 100
1431 55.28 55.61 55.46 53.43 53.43 53.20 57.45 57.55 57.67 98.39 98.35 98.45 98.32 98.37 98.31 100
1432 55.56 55.89 55.74 53.81 53.82 53.59 57.62 57.72 57.83 98.41 98.38 98.49 98.38 98.44 98.38 99.98 100
1433 55.53 55.86 55.71 53.78 53.79 53.55 57.57 57.68 57.79 98.36 98.32 98.44 98.35 98.40 98.34 99.98 99.99 100
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Pearson’s correlation for the AS data set generated 13 discrete highly correlated 
groups (threshold value > 98.6) with all individual tablet samples linked to 
corresponding members from the same seizures. Linked seizure numbers for each 
group are provided in Table 5.6. Pearson’s groups for the AS data set were similar to 
HCA groups. The two additional groups (i.e. Group XII & XIII) are considered 
subsets of the HCA groups VII & I while all other groups were identical. Pearson’s 
group XIII is unexplained as this subset did not appear significantly different from 
other members o f Group I. Group XII can be explained based on the concentration 
levels o f lactose in samples. Pearson's group VII had mean lactose levels of 
523.19±94.3 mg/g of sample while group XII contained 188.46±12.3mg/g of sample.
Overall unsupervised pattern recognition methods of PCA, HCA and Pearson’s 
correlation were successful at identifying groups within the 180 individual ecstasy 
tablet samples. From a scientific perspective, linking seizures is useful as an 
operational or strategic tool for law enforcement investigators. In this study, seizures 
could be linked based on groups formed, however the number of groups identified 
varied with the method applied and the sample data set utilised. The ability of PCA, 
Pearson’s correlation and to some extent HCA to classify tablets according to seizure 
was clearly limited by significant variation in the metals present within each tablet 
and seizure (Appendix Table A2). Such variation may always be present in tablets 
that are produced in clandestine laboratories and will consequently limit attempts to 
link tablets and seizures to common batches o f illicit substances.
The most successful data set for classification purposes was the active ingredients and 
sugar components (AS data). All three pattern recognition methods identified various 
groups dependent on whether PCA, HCA or Pearson’s correlation was applied to the 
data set (Table 5.6). PCA classified the 180 ecstasy tablet samples into 6 groups 
based on the chemical constituents present. HCA and Pearson’s correlation identified
11 and 13 groups, respectively, and were further able to classify these groups based 
on the concentration and combination of constituents present in samples (Table 5.4). 
Pearson’s correlation distinguished groups based on similarity between samples while 
HCA provide clustcr linkages of samples. Regardless, the application of these 
statistical methods linked seizures suggesting that the different groups may represent 
discrete suppliers or manufacturing processes.
1 6 2
HPLC method development & chemometric analysis of ecstasy & cocaine
There are many advantages and disadvantages with each of the three pattern 
recognition methods. PCA and HCA require the use of special software package such 
as SPSS, while Pearson’s correlation is performed using a simple Microsoft excel 
macros file. PCA is simple and produces visual score plots of potential groups formed 
but are subject to the analyst’s interpretation. HCA and Pearson’s correlation are 
more informative and provide similarity linkage between samples but require a more 
in-depth knowledge of the statistical protocol to apply.
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Table 5.6. Seizure num bers for groups identified using unsupervised pattern  recognition m ethods o f  PCA, HCA or P earson’s correlation 
for active drug and sugar (A S) data sets.
Pattern recognition method
Group # — — —
PCA HCA Pearson’s
Group 1 1 2 3 5 6 7 8 9 1 2 3 5 6 7 8 9 1 5 6 7 8 9 11 12
11 12 13 15 17 19 20 21 11 12 15 19 20 21 27 28 15 19 20 21 27 28 29 31
23 24 25 27 28 29 31 32 29 31 32 33 34 37 38 44 32 33 34 37 38 44 46 47
33 34 36 37 38 39 40 41 46 47 50 51 54 56 57 59 50 51 54 56 57 59
42 43 44 45 46 47 48 49
50 51 52 54 56 57 59
Group 11 4 26 60 61 4 26 60 61 4 26 60 61
Group 111 16 18 35 55 58 16 18 35 58 16 18 35 58
Group IV 22 53 22 53 22 53
Group V 14 14 14
Group VI 30 30 30
Group Vll 17
39
23
40
24
41
25
45 52
17 25 39 45
Group VIII 36 42 43 36 42 43
Group IX 48 49 48 49
Group X 13 13
Group XI 55 55
Group XII 23 24 40 41
Group XIII 2 3
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Table 5.7. Linear discriminant analysis percentage correct classification rates for the number of groups identified by Principal component, 
Hierarchal cluster and Pearson’s correlation pattern recognition methods.
Number of 
Variables
Pattern recognition method
Data Sets Principal Component Analysis Hierarchal Cluster Analysis Pearson’s Correlation Coefficient
No. of groups % Correct No. of groups % Correct No. of groups % Correct
DC 15 5 98.4% 19 96.7% 35a 80.6%
MD 9 I ND 7 93.9% 29b 76.8%
AS 6 6 93.4% 11 99.5% 13c 99.5%
DC = all data combined; MD = metal data only; AS = active ingredients & sugar data. Minimum threshold values differed for each data set; a = 88.2, 
b = 79.2 and c = 98.6. ND = not determined
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5.4 Supervised pattern recognition methods.
Both LDA and ANN were applied to the chemical data sets of the 180 individual 
ecstasy tablet samples to determine both the correct classification rate and possible 
linked networks in samples. LDA was applied to all groups identified by 
unsupervised pattern recognition methods to confirm percentage correct classification 
rates (Table 5.7). LDA percentage correct classifications ranged from 76.8% to 
99.5% depending on the pattern recognition method and data group set tested 
suggesting that the data groupings were reasonably assigned, As observed previously 
LDA classification rates were poorest for MD data set regardless of pattern 
recognition method employed. When MD and AS were combined classification rates 
improved suggesting that AS data variables were more important in determining 
group classifications. Both HCA and Pearson’s correlation groups for the AS data set 
provided the best classification rates of 99.5%. The 0.5% error was associated with 
the single ecstasy sample 49.3 which was classified with samples from Group IV. 
Since HCA and Pearson’s correlation AS data groups had similar LDA classification 
profiles both groupings were further tested by ANN. Neural networks were applied to 
samples in order to determine the correct classification rate of pattern recognition 
method and also to establish a neural network that could be beneficial in classifying 
new drug seizures.
Artificial neural networks algorithms have the potential to provide complete solutions 
in the identification of patterns in data sets (Bishop, 1996). In this study, individual 
networks and ensembles of networks were created and tested using the Intelligent 
Problem Solver (IPS) system function in the Trajan software. AS data was inputted 
into the software as individual sets o f data coded according to group seizure numbers 
identified by HCA or Pearson’s correlation methods. The software randomly 
assigned individual data sets from each sample into training, selection and test sets. 
One hundred networks for each of the six chemical variables were tested for the three 
layers (input, hidden and output layers) by Multi-Layer Perceptron (MLP) and Radial 
Base Functions (RBF) methods. The training algorithms were a combination of back 
propagation and conjugate descent. Selection of the most suitable network was based 
on the performance of the selection set and the difference in the error associated with 
the selection set and the test set. The errors associated with the selection and test sets 
should be relatively small to ensure the network is capable of generalising new data.
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The performance of the training and selection tests should be similar and close to 1 to 
indicate that the model does not suffer over-learning. The performance of the test 
should also be close to 1 to indicate that the network can classify new data adequately 
(Waddell et al. 2004). The final neural networks selected for the HCA and Pearson’s 
group classification of AS data set are provided in Table 5.8.
Table 5.8. Optimal artificial neural networks selected for HCA and Pearson’s group 
classification of AS data set._________________________________________________
ANN Criteria HCA Pearson’s
Network Profile MLP 6:6-10-11:1 RBF 6:6-46-13:1
Training Performance 1 0.9139
Selection Performance 1 0.8880
Test Performance 1 0.9555
Training Error 0.0002 0.0067
Selection Error 0.0003 0.0681
Test Error 0.0188 0.0665
Correct Classification Rate 100% 85.7%
Training BP 100, CG20, CG41b KM, KN, PI
The optimal network selected was based on the best performing network of the 100 
networks tested for both groups. In the case of the Pearson’s AS data groupings the 
optimal network was an RBF 6:6-46-13:1. This is a radial base function network 
architecture with six input chemical variables, forty six neurons in the hidden layer 
and thirteen output groups. Classification rate for this network was 85.7% with a 
selection performance of 0.888 suggesting mis-classification within the Pearson’s 
group structure. The optimal neural network for the HCA AS data groupings was an 
MLP 6:6-10-11:1 and yielded a perfect 100% correct classification. This is a 
multilayer perceptron network architecture with six input chemical variables, ten 
neurons in the hidden layer and eleven output groups. Error values were low and 
training, selection and test performance values were the ideal value of 1. This neural 
network structured according to the HCA AS data groupings is more than capable of 
handling, generalising and classifying new data. Future chemical data based on the 
combination and concentrations of MDMA, MDEA, amphetamine, caffeine lactose or 
sorbitol applied to this trained neural network could potentially serve as a model to 
monitor trends and developments for ecstasy drug trafficking in Ireland.
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The particular advantage of chemometrics is that it allows for the statistical analysis 
of multivariate chemical data into discrete reliable groups for profiling illicit drug 
samples from clandestine manufacturing processes. In this study, ecstasy seizures 
were linked based on HCA clustering groups and confirmed by the MLP 6:6-10-11:1 
artificial neural network. Group classification was based on the combination and 
concentration of active ingredients and sugar components present in samples. 
Physical data and seizure location data can be combined with these linked groups to 
investigate whether any patterns exist in ecstasy drug trafficking in Ireland during the 
period 2001-2003.
Group I contained the greatest number of seizures, 32 of the 60 seizures analysed. 
This group was distinguished based on the MDMA and lactose content. It is more 
than likely that ecstasy tablets within all 32 seizures from different regions were 
prepared by the same manufacture. This group contained numerous different logo 
types and included; ‘Mitsubishi’ (14 seizures), ‘Bird’ (4 seizures), ‘Horse’ (2 
seizures), ‘Smirnoff (2 seizures) and the remaining ten seizures all had unique logos 
of ‘Armani’, ‘Chi’, ‘Dextran’, ‘Euro’, ‘Heart’, ‘Motorola’, ‘Rolls Royce’, ‘Smiley’, 
‘V2’ and no logo (Figure 4.1) suggesting that the manufacturer was applying logo’s 
randomly. The wide diversity o f logo types imply that this group could not be 
classified based on logos but required chemical profiling. The majority of Group I 
was seized in the Dublin metropolitan area (21 seizures) however the same samples 
were seized in other regions (Cork, Kildare, Kilkenny, Sligo, Waterford and Wexford) 
strongly suggesting that Dublin is the main port of entry with distribution regionally 
via the main North Western, South Western and Southern transport routes (Figure 
5.8).
Group II was similar to Group I in chemical composition but contained sorbitol 
instead of lactose as the main adulterant. This group was seized in Dublin (3 seizures) 
and Donegal (1 seizure) and could not be distinguished based on physical 
characteristics or brand logos. Logos recorded for this group include ‘Heart’ (2 
seizures), ‘Bird’ (1 seizure) and ‘Euro’ (1 seizure). This group represents a possible 
network between Dublin and Donegal. Bell et al (2003) reported MDMA/sorbitol 
ecstasy tablets seized within Northern Ireland during the same period suggesting 
cross-border activity between the two jurisdictions.
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Group III was comprised of 4 seizures, three seized in the Dublin area and the fourth 
seized in Galway. All four seizures had four different logos of ‘Mitsubishi’, ‘Euro’, 
‘Smiley’ and ‘Tasmanian Devil’. This group was unique since it only contained 
MDMA with no adulterants present. Group IV contained
MDMA/MDEA/caffeine/lactose and all contained a ‘Crown’ logo. In addition all 
samples were white in colour and had the same physical dimensions supporting the 
argument that these seizures were produced from the same manufacturing process. 
This group was seized in Louth and Wicklow and may possible be a distribution 
network along the East coast corridor from Northern Ireland as these samples were 
not present in other seizures from the Republic of Ireland,
Group V was a single seizure from Dublin, containing MDMA/caffeine/amphetamine 
with a ‘Bird’ logo and was pink in colour. This group may represent a transient 
seizure since it was not present in other regions of Ireland (Figure 5.8). Group VI was 
a single seizure from Cavan and was distinctly unique based on the Superman brand 
logo, green colour and contained amphetamine and lactose. The uniqueness of this 
seizure may suggest the introduction of a new manufacturing process as amphetamine 
is rarely seen as the only active ingredient in ecstasy tablets.
Group VII was the second largest group of linked seizures and samples were seized in 
Cork (3 seizures), Kildare (2 seizures), Offaly (2 seizures) and one seizure each from 
Dublin and Mayo (Figure 5.8). This group was similar to Group I but contained 
caffeine in addition to MDMA/lactose and had various logo types. Brand logo’s 
included ‘M&M’s’ (5 seizures), ‘Red Bull’ (3 seizures) and ‘Coca-Cola’ (1 seizure). 
Group VIII was comprised of three seizures and all seizures contained a Durex brand 
logo with the main chemical components of MDMA/MDEA/lactose. Samples were 
seized from Cork (2 seizures) and Kilkenny (1 seizure). Group IX was similar to 
Group VIII but contained caffeine in addition to MDMA/MDEA/lactose and the two 
seizures were seized in Cork and Waterford. Both seizures contained the ‘Coca-Cola’ 
brand logo. Since the majority o f Groups VII, VIII and IX were seized in Cork the 
possibility exists that Cork is the importation port with distribution regionally via the 
northern, north eastern and eastern transportation routes,
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Group X and XI were single seizures seized in Waterford and Clare. Group X 
contained MDMA/MDEA/lactose with a ‘Smirnoff logo while Group XI contained 
MDMA/lactose/sorbitol with a ‘Heart’ logo and was pink in colour. It is possible that 
both these seizure are not part of a major network but represent samples for personal 
consumption obtained abroad.
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Figure 5.8 Relative distribution of ecstasy seizures examined in this study by HCA and MLP 6:6-10-11:1 neural network group classification
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5.5. C onclusions.
Recently, the application o f drug profiling methods have demonstrated the potential 
of these techniques in establishing links between illicit drug samples and thereby are 
advantageous in drug intelligence (Locicero et al. 2008, Weyermann et al. 2008, 
Andersson et al. 2007, NicDaeid & Waddell 2005). Physical and chemical data can 
provide useful information however no clear structure can be identified regarding the 
manufacturing process involved. Chemometrics allows for the statistical comparison 
of samples to determine if patterns exist within the population sample. Difficulties 
can arises in directly comparing ecstasy seizures produced by different synthetic 
routes (Section 1.2.5) from unregulated clandestine laboratories. To overcome these 
barriers data sets generated must be pre-treated to allow for statistical comparisons 
(Miller & Miller, 2005) and an appropriate pattern recognition method must be 
selected (Nic Daeid & Waddell 2005).
In this study, the recommended chemometric protocol involved the generation of 
validated HPLC ecstasy data for the main active ingredients and sugar components 
(Sections 2.2 & 2. 4) followed by standardisation & logarithm pre-treatment of HPLC 
peak areas. Data sets for the six chemical variables for all 180 individual ecstasy 
samples were grouped by HCA unsupcrvised pattern recognition method using SPSS 
software. Artificial neural networks using Trajan software were applied to determine 
classification rates and establish a neural network pattern linking unrelated ecstasy 
seizures. The neural network MLP 6:6-10-11:1 was more than capable o f handling 
new data and has the potential to monitor future trends in the Irish ecstasy market. 
Metal data set, alone or in combination with AS data, was on unreliable at classifying 
tablets according to seizure and was clearly limited by significant variation in the 
metals present within each tablet and seizure (Appendix Table A2).
Although the number o f seizures examined was limited to those supplied by the Garda 
Forensic Laboratory, the application of chemometrics demonstrated the potential of 
this approach in establishing links between unrelated illicit ecstasy drug seizures in 
Ireland. The neural network MLP 6:6-10-11:1 identified eleven discrete groups for 
the 60 seizures analysed suggesting eleven different manufacturing processes. 
Alternatively, HCA provided four cluster linkages o f samples (Figure 5.7) with
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groups identified within clusters (Table 5.4) being possible random batch variations in 
a standard manufacturing method. With more extensive data it may be possible to 
recognize the signature of tablets prepared by major manufacturers.
Seizure locations illustrated a random geographical network distribution primarily 
based on the major Irish traffic routes and linked seizures were not specifically 
confined to a particular region. Since ecstasy clandestine laboratories have not been 
reported in Ireland the drug trafficking source is presumably Europe with U.K., 
Belgium or Holland the more than likely sources. Since Dublin and Cork contained 
the greatest number of seizures it is assumed that these sites are the main ports of 
entry to the island of Ireland. A possible alternative entry route, suggested by linked 
seizures in this study, is via the neighbouring Northern Ireland jurisdiction and as 
such future profiling studies should examine the whole of Ireland. The advantage of 
the established neural network MLP 6:6-10-11:1 would allow for the addition on new 
data to build on the database to monitor developments and trends in the Irish ecstasy 
market.
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Chapter 6: Conclusions and future work.
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Forensic analysts are faced with the challenge of continually developing sophisticated 
methods of analysis to combat the increasing variability that occurs in illicit drug 
samples. The main objective for the analytical chemist has been to introduce new, 
versatile techniques with high efficiency, selectivity and precision. Research work for 
this thesis has focused on the development of the analytical method HPLC (High 
Performance Liquid Chromatography) for the analysis of major drug constituents 
associated with ecstasy and cocaine illicit drug samples.
6.1. Method development.
Emphasis in this thesis has been placed on method development with univariate or 
multivariate experimental strategies used in the selection and optimisation of 
procedures. Considerations with regard to the choice of chromatographic factors, 
solutes under investigation and the provision of quality assurance data throughout the 
research work have been the main criteria in methods developed. Methods developed 
have undergone validation studies including, intra- and inter- reproducibility, 
accuracy, linearity of calibration, limit of detection (LOD) and limit of quantification 
(LOQ) and the use o f internal standards. Two HPLC methods have been developed 
and these methods have been successfully applied to the analysis of ecstasy and 
cocaine samples seized from Ireland during the period 2001 to 2004.
The univariate experimental approach was applied to the development and validation 
of a HPLC method that could be used to qualitatively and quantitatively assay for 
MDMA and its analogues in ecstasy tablets. Chromatography performance was based 
on resolution, retention factor and efficiency. A highly selective HPLC protocol with 
DAD using the Chromolith SpeedROD, RP-18, 50 x 4.6 mm was developed to 
quantify MDMA and its analogue derivatives found in ecstasy tablets. 
Chromatography, using monolithic columns, demonstrated good separation of the 
amphetamines and the typical adulterants (Figure 3.15). Comparisons of column 
types indicate that monolithic columns are more efficient than particulate columns 
without loss of resolution. Monolithic columns reduced the retention time from 
approximately 18.3 to 3.8 minutes resulting in faster separation without sacrificing 
column efficiency (Figure 3.12). A single system that could successfully separate 
MDMA and its related compounds, MDA, MDEA and MBDB, is highly desirable as
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these related compounds are increasingly found in combination with the illicit drug. 
The application of the method to a large number of ecstasy tablets demonstrated the 
suitability of the method for the routine analysis of ecstasy tablets and the practicality 
of monolithic columns (McFadden et al. 2006).
Cocaine analysis was performed using the alternative multivariate method 
development approach. The group of analytes under investigation comprised cocaine 
and it’s more commonly occurring components present in street samples. This group 
included cocaine, lidocaine, prilocaine, procaine, benzocaine caffeine, phenacetin and 
acetylsalicylic acid. A two level fractional factorial design was created and used as 
the basis of the experimental procedure. Performance indicators such as resolutions, 
retention factors and efficiencies were calculated for each experimental run. Artificial 
neural networks were applied to create response surfaces illustrating the relationship 
between the chromatographic factors and the performance indicators.
The optimal chromatographic conditions selected for cocaine analysis using this 
experimental approach were a mobile phase consisting of 20 mM phosphate 
buffer/acetonitrile (85/15, v/v) maintained in an isocratic mode, pH at 3, flow rate at 
1.0 mL min“1, column temperature at 35°C with Waters XBridge C l8 50 x 4.6 mm, 
particle size 3.5 ^m column and sample detection at 200 nm. All eight analytes under 
investigation were separated under ten minutes with good resolution using the 
optimised chromatographic conditions developed (Figure 3.21). The method 
developed was applied to seized cocaine samples and major drug constituents and 
adulterants were identified (McFadden et. al. In preparation).
6.2. Analysis of illicit drug samples.
Ecstasy differs from many other drugs of abuse in that it is in tablet form and no 
further excipients can be added at the different stages of trafficking. This is an 
essential point for profiling and linking seizures as only those chemicals added at 
manufacture can be present at street level. Linking seizures of ecstasy tablets is 
primarily based on the similarity between seizures of visual, chemical and physical 
data. Physical data includes colour, logo, shape, weight, diameter and thickness of the 
tablet. Chemical profiling investigates the major amphetamine components, possible
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adulterants and excipients used in the manufacture of tablets. The levels of chemical 
components present in samples will vary in composition and quantities present.
As part of this study, physical and chemical data sets for 183 ecstasy tablets seized 
from Ireland during the period 2002 to 2003 have been recorded as discrete data sets. 
Physical characteristics recorded include tablet shape, colour, presence or absence of 
brand logos, tablet weight, diameter and thickness. Chemical data sets include both 
the quantification and occurrence in individual tablets of the major amphetamine 
components (i.e. MDMA, MDA, MDMA, MDEA, MBDB and amphetamine), 
adulterant components (i.e. caffeine, paracetamol, phenacetin and aspirin), diluent 
components (i.e. sucrose, glucose, lactose, fructose, mannitol, sorbitol and inositol) 
and inorganic components (i.e. Al, Ca, Cr, Fe, K, Mg, Na, Pb and Zn).
With a view to investigative purposes, a detailed chemical analysis of cocaine was 
conducted. Whereas with ecstasy seizures, preliminary connections can automatically 
be based on physical characteristics, such as logos or tablet colours, linking cocaine 
seizures proves more difficult. All samples were analysed for active ingredients, 
adulterants and sugars. The occurrence of drug ingredients, adulterants and sugar 
components present in street samples were as follows; cocaine (100%), prilocaine 
(42.8%), lidocaine (53.5%), benzocaine (3.5%), procaine (3.5%) , caffeine (57.1%), 
phenacetin (64.2%), acetylsalicylic acid (3.5%), mannitol (42.9%), sucrose (35.7%), 
lactose (17.9%o), sorbitol (3.6%) and inositol (3.6%). Samples varied with the level of 
constituents present and in the combinations in which they occurred in each sample. 
Due to the complexity of the chemical profiles associated with cocaine samples and 
the small sample size, statistical analysis was not performed.
6.3. Chemometrics and statistical profiling of ecstasy samples.
Chemometrics, including unsupervised methods o f PCA, HCA and Pearson’s 
correlation, as well as supervised methods of LDA and artificial neural networks was 
applied to the chemical data sets from ecstasy samples to demonstrate the ability of 
the statistical approach to linking seizures with samples (Chapter 5). HCA and ANN 
were the statistical methods that most efficiently distinguished between linked and 
unlinked seizures. Eleven groups were identified from the chemical data sets with
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group classification dependant on the main amphetamine, adulterant and diluent 
present. Further analysis with increased sample size is required to assure the 
statistical reliability of this approach. Nevertheless profiling results by chemometrics 
has the potential to classify drug seizures and to provide links between seized samples 
or between materials found at the crime scene. The benefits from this study will 
provide strategic intelligence and an understanding of the operational level in the Irish 
ecstasy market and help evaluate the changing profile or dynamics associated with 
this illegal market supply.
6.4. Establishing a profiling protocol in a forensic laboratory.
This study used ecstasy as the sample for chemically and statistically profiling 
seizures. However, the protocols developed could lend themselves easily to other 
types of drug seizures. The equipment required for profiling studies is minimal, as 
most forensic laboratories would have a basic LC system. A HPLC with a diode array 
detector proved to be an adequate instrument for the chemical analysis of ecstasy and 
cocaine (qualitative and quantitative data). The data generated was sufficient for 
classification purposes. More sophisticated instruments are available, such as an LC- 
MS/MS. This would provide the same data and have the added advantage of being 
able to detect impurities at very low concentration levels that might be present in the 
sample. Impurity analysis is popular with researchers whose aim is to classify the 
drugs. However, as proven in this study, determination o f impurities is not essential 
for classification purposes. Therefore, a simple LC system with a UV detector is 
sufficient for forensic laboratories establishing a drug profiling protocol. The actual 
sample preparation and chromatographic analysis could be adopted into the routine 
drug analysis already established in the laboratory which would minimise any 
additional time required. Creating the statistical protocol may involve training; 
however, as discussed previously in Chapter 5, once established in the laboratory, the 
neural network software will be of major advantage for classification purposes.
Future methods of analysis should focus on developing a single LC system for the 
simultaneous determination of all the major drug components commonly detected in 
street samples. By using the multivariate approach for the method development, this 
would ensure minimal experiments with maximum results. Also, the use of a
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monolithic column would allow for a large number of analytes to be separated in 
minimal time.
Metals are popular components of drug samples used for classification purposes 
(Waddell et al. 2004, Koper et ol, 2007). In this study, metal data was unsuitable for 
classification. The key to metal analysis is the choice of metals, those which identify 
the synthetic pathways in which the ecstasy tablets were produced. These important 
metals are platinum, boron, mercury and lithium. Any future profiling studies should 
include these metals.
6.5. Future studies on the current major drugs in Ireland.
A temporal analysis of the major drugs from year to year would provide valuable 
information on purity levels, types and levels o f adulterants and also provide 
information on physical characteristics of the tablets such as trends in logos. An in- 
depth geographical comparative analysis, either by county or by province, of each of 
the major drugs could offer additional evidence to support investigations by providing 
insights into dealer networks.
Considering Ireland is an island, one of the most important law enforcement agencies 
is the Irish Customs service. Most of the synthetic and semi-synthetic drugs seized in 
Ireland are produced outside of Ireland, so therefore the points of entry to this country 
are essential to control. An interesting study would be to monitor the drug seizures at 
each customs point for both physical and chemical profiling of all drug types. 
Comparisons between each port and airport would be beneficial. Such a study should 
also include points of entry in Northern Ireland. Cross border cooperation to identify 
points of entry and dealer networks is imperative for both the Garda Siochana and the 
Police Service of Northern Ireland (PSNI). Data gathered could be used to generate a 
drug intelligence data bank which would be beneficial to national and international 
law enforcement agencies.
The general trend in drug seizures in Ireland has changed in recent years. In 2003 
ecstasy was the most seized drug in Ireland after cannabis, hence the reason for 
choosing ecstasy as the drug to study in this thesis. After 2004, cocaine overtook
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ecstasy as the most seized drug, after cannabis. Currently ecstasy is no longer one of 
the most common illegal drugs seized. As reported in the Annual Garda Report 2010, 
seizures of ecstasy have plummeted to 398 tablets, a decline of 95% since its height in 
2000 (Figure 1.1). Cocaine quantities seized still remains very high in comparison 
with other drugs, 94,804 grams of cocaine versus 26,462 grams of amphetamine and 
30,158 grams of heroin (Annual Garda Report 2010). Recently there has been a 
significant change in the types of drugs seized due to new legislation in March 2009, 
when benzylpiperazine (BZP) was made illegal. In 2010, 351,536 tablets, 3,271 grams 
and 371 capsules of this drug were seized. Also, there has been an increase in 
seizures of abused prescription drugs. For example, Alprazolam or ‘Xanax’ as it is 
more commonly known, is a benzodiazepine and is listed as a Schedule IV medicine 
under the Misuse of Drugs Act 1984. Over seventy thousand tablets of this drug were 
seized in 2010 alone. Equally, nearly 146000 tablets of diazepam, or Valium as it is 
known as, were seized. Other abused prescription drugs that have been seized include 
Clonazepam, Flunitrazepam (Rohypnol), Lorazepam, Prazepam, Temazepam, 
Triazolam. Future studies on drugs in Ireland should reflect this shift in drug use.
At European level, the current major concern is the new psychoactive substances or 
‘legal highs’ as they are known as. The EMCDDA received reports on forty one new 
drugs in 2010, a huge increase from twenty four substances in 2009 and thirteen in 
2008. The three main categories of emerging drugs include pipazerines, synthetic 
cathinones and synthetic cannabinoids. They are all slightly modified versions of 
existing illegal drugs. The piperazines include BZP, CPP (chlorophenylpiperazine), 
TFMPP (l-(3-trifluoromethylphenyl) piperazine) and DBZP (1, 4-dibenzylpiperaine). 
Synthetic cathinones derived from Khat (Catha edulis Forsk), are closely related to 
the phenethylamine family and the most common types are mephedrone and 
methylone. Synthetic cannabinoids are compounds that have the same effect as 
cannabis but are not structurally similar to A9-THC, the active ingredient in cannabis. 
This group of compounds include ‘Spice’ and twenty six other similar compounds. 
The major concern regarding these products is the ease at which they can be 
purchased and the escalating rate of their popularity. As they are new to the market, 
in-depth and long term studies have not yet been performed on their possible health 
effects.
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Given the rise in seizures of BZP pills and prescription drugs, illegal drug purchases 
may not be conducted by traditional street deals but are more likely internet 
purchases. This poses problems for the law enforcement agencies, as identifying 
dealer networks and apprehending the main dealers is much more complex. Ghost IP 
addresses can be created easily by a computer enthusiast thus hiding the location of 
the dealer. The dealer network may be more intricate and more global. Efforts must be 
made not only by the analytical chemist but also the computer forensic scientist to 
assist the law enforcement agencies in the crackdown in internet sales of illegal drugs.
In summary this research project, has been undertaken with the support and co­
operation of the Garda Forensic Science Laboratory and provided an excellent 
opportunity for the development and application of a liquid chromatographic method 
for the chemical profiling of ecstasy and cocaine drugs of abuse. From an 
investigative point of view linking drug seizures with chemical profiles provide a 
means of determining the synthetic or natural origins o f the sample and provide 
evidence of links between seized samples or between materials found at illegal 
laboratories.
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Appendix: Table A1. Physical and chem ical data (i.e. active & sugar com ponents) for the 183 ecstasy tablet sam ples used in this study
Sample Physical characteristics Chemical data (mg/g)
# Logo Colour Weight
(mg)
Thickness
(mm)
Diameter
(mm) MDMA MDEA Amp Caffeine Lactose Sorbitol
i Mitsubishi White 302.3 4.5 11.5 285.1 0.0 ' 0.0 0.0 291.8 0.0
! >■* Mitsubishi White 285.2 4.5 11.5 337.3 0.0 0.0 0.0 234.2 0.0
: u ....... Mitsubishi White 309.7 4.5 11.5 222.1 0.0 0.0 0.0 407.7 0.0 j
2.1 Armani White 313.8 4.5 10.5 259.4 0.0 0.0 0.0 430.1 0.0
2.2 Armani White 323.2 4.5 10.5 232.9 0.0 0.0 0.0 534.6 0.0
2.3 Armani White 327.4 4.5 10.5 182.3 0.0 0.0 0.0 444.5 0.0
3.1 Motorola White 183.5 3.5 10.0 433.4 ~ 0 .0 0.0 0.0 528.7 0.0 j
3.2 Motorola White 206.9 3.5 10.0 394.5 0.0 0.0 0.0 567.0 0.0 1
3.3 Motorola White 210.2 3.5 10.0 410.0 0.0 0.0 0.0 574.7 0.0 ¡
4.1 Bird White 246.2 ■ 4.0 12.0 259.9 0.0 0.0 0.0 0.0 668.1
4.2 Bird White 256.3 4.0 12.0 281.5 0.0 0.0 0.0 0.0 586.9
4.3 Bird White 255.2 4.0 12.0 337.7 0.0 0.0 0.0 0.0 654.0
C T i No logo White 243.3 4.0 10.5 421. i 0.0 0.0 0.0~ 357.9 0.0
1 5.2 No logo White 246.1 4.0 10.5 423.0 0.0 0.0 0.0 404.8 0.0
!
c*i 
1
vv 
[1 No logo White 244.0 4.0 10.5 351.6 0.0 0.0 0.0 408.3 0.0
6.1 Chi White 314.9 3.0 10.0 285.2 0.0 0.0 0.0 576.4 0.0
6.2 Chi White 324.9 3.0 10.0 301.1 0.0 0.0 0.0 588.3 0.0
6.3 Chi White 319.9 3.0 10.0 260.5 0.0 0.0 0.0 560.8 0.0
! 7J Bird White 256.4 4.0 1ÏÏ5 334.8 0.0 0.0 0.0 641.2 0.0 j
! 7.2 Bird White 250.6 4.0 11.5 272.1 0.0 0.0 0.0 629.9 o.o 1
! 7.3 Bird White 253.7 4.0 11.5 271.7 0.0 0.0 0.0 668.2 o.o !
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Table Al (contd.)
S a m p le # Logo Colour Weight(mg)
Thickness
(mm)
Diameter
(mm)
MDMA MDEA A m p Caffeine Lactose Sorbitol
i *A Bird White 260.6 3.0 10.0 286.6 0.0 0.0 0.0 732.8 • 0.0
; 8.2
L
Bird White 264.5 3.0 10.0 266.7 0.0 0.0 0.0 696.3 0.0
? . f L Bird White 253.4 3.0 !0.0 291.6 0.0 0.0 0.0 722.8 0.0
9.1 Mitsubishi White (BS) 302.4 3.5 9.5 380.2 0.0 0.0 0.0 575.4 0.0
9.2 Mitsubishi White (BS) 317.3 3.5 9.5 396.7 0.0 0.0 0.0 583.6 0.0
9.3 Mitsubishi White (BS) 311.2 3.5 9.5 289.8 0.0 0.0 0.0 601.4 0.0
Í 10.1 Crown White ~  322.6 5.5 10.0 312.7 0.0 a o 0.0 610.2 0.0
I 10.2
I
Crown White 298.9 5.5 10.0 326.4 0.0 0.0 0.0 625.3 0.0
[ 10.3 Crown White 313.3 5.5 10.0 328.4 0.0 0.0 0.0 622.9 0.0
I I .1 Dexter White 370.6 4.0 10.0 297.1 0.0 0.0 0.0 589.6 0.0
11.2 Dexter White 349.6 4.0 10.0 316.5 0.0 0.0 0.0 574.8 0,0
11.3 Dexter White 338.7 4.0 10,0 271.6 0.0 0.0 0.0 596.3 0.0
j 12.1 V2 White .288.4 4.5 10.5 324.3 0.0 0.0 0.0 610.1 0.0
1 12.2
i
V2 White 296.9 4.5 10.5 355.4 0.0 0.0 0.0 624.3 0.0
t 12.3 V2 White 285.9 4.5 10.5 295.2 0.0 0.0 0.0 622.7 0.0
13.1 Smirnoff White (BS) 194.4 4.0 9.0 365.3 2.1 0.0 0.0 686.7 0.0
13.2 Smirnoff . White (BS) 195.2 4.0 9.0 355,4 1.9 0.0 0.0 685.4 0.0
13.3 Smirnoff White (BS) 183.0 4.0 9.0 3S7.7 Î.1 0.0 0.0 673.2 0.0
r  i4-] Bird Pink 336.2
ii1 o
 
i ^i
9.0 70,8 0.0 14.2 0.5 0.0 0.0
1 14.2 Bird Pink 328.0 5.0 9.0 97.7 0.0 18.7 0.7 0.0 0.0
i 14.3 Bird Pink 336.0 5.0 9.0 76.1 0.0 15.1 0.5 0.0 0.0
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Table Al (contd.)
Sample U Logo Colour Weight
(mg)
Thickness
(mm)
Diameter
(mm) MDMA MDEA Amp Caffeine Lactose Sorbitol
Í 15.1 Smirnoff White (BS) 193.2- 3.5 10,0 302.3 0.0 0.0 0.0 594.7 0.0 ¡
1 15.2 Smirnoff White (BS) 193.8 3.5 10.0 339.4 0.0 0.0 0.0 461.3 0.0 ¡
L . Smirnoff White (BS) 183.4 3.5 10.0 357.3 0.0 0.0 0.0 483.1 o.o ;
16.1 Taz Devi) White (BS) ’ 243.5 3.5 11.5 257.0 0.0 0.0 0.0 0.0 0.0
16.2 Taz Devil White (BS) 247.6 3.5 *11.5 321.1 0.0 0.0 0.0 0.0 0.0
16.3 Taz Devil White (BS) 246.5 3.5 11.5 306.7 0.0 0.0 0.0 0.0 0.0
r nj Red Bull White ~194~Z 4.0 10.0 331.7 ~0.0 0.0 6.2 369.1 OS) }
, 7 , Red Bull White 200.5 4.0 10.0 419.1 0.0 0.0 7.6 366.5 0.0
L 173 Red Bull White 196.5 4.0 10.0 359.8 0.0 0.0 7.5 355.2 0.0 !
18.1 Smiley White (BS) 275.8 4.0 11.0 278.5 0.0 0.0 0.0 0.0 0.0
18.2 Smiley White (BS) 288.3 4.0 11.0 278.3 0.0 0.0 0.0 0.0 0.0
18.3 Smiley White (BS) 279.1 4.0 11.0 336.4 0.0 0.0 0.0 0.0 0.0
1 19.1 Bird White 305.4 4.0 ; 12.0 253.0 0.0 0.0 0.0 715.4 0.0 !
j 19.2 Bird White 304.5 4.0 12.0 217.3 0.0 0.0 0.0 655.1 0.0 !
[  19.3 Bird White 305.8 4.0 12.0 283.3 0.0 0.0 0.0 637.6 0.0 I
20.1 Euro White 301.5 3.5 11.0 192.2 0.0 0.0 0.0 762.8 0.0
20.2 Euro White 305.0 3.5 11.0 240.2 0.0 0.0 0.0 696.3 0.0
20.3 Euro White 298.7 3.5 11.0 330.6 0.0 0.0 0.0 722.8 0.0
¡ 21.1 Mitsubishi White 309.3 4.0 11.0~ 244.2 0.0 0.0 0.0 576.4 0.0 1
j 21.2 Mitsubishi White 297.8 4.0 II.O 216.0 0.0 0.0 0.0 5S8.3 0.0 f
j 21.3 Mitsubishi White 297.4 4.0 11.0 166.2 0.0 0.0 0.0 560.8 0.0 !
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Table Al (contd.)
Sample # Logo Colour Weight
(mg)
Thickness
(mm)
Diameter
(mm) MDMA MDEA Amp Caffeine Lactose Sorbitol
i 22.1 Crown White 242.9 4.5 10.0 37.4 58.7 0.0 3.0 652.1 o.o ;
22.2 Crown White ■ 245.2 4.5 10.0 26.6 52.1 0.0 2.8 457.5 0.0 1
22.3 Crown White 260.6 4.5 io:o 21.8 52.2 0.0 2.1 486.1 0.0 ‘
23.1 ' m&m’s White (BS) 186.7 3.5 10.0 297.2 0.0 0.0 10.7 189.0 0.0
23.2 m&m’s White (BS) 195.6 3.5 10.0 315.9 0.0 0.0 10.2 206.0 0.0
23.3 m&m’s White (BS) 188.7 3.5 10.0 259.5 0.0 0.0 11,4 205.0 0.0
j 24.1 m&m’s White (BS) 193.8 4;0 10.0 316.0 0.0 0.0 10.5 200.2 o.o :
1 24.2 m&m’s White (BS) 197.1 4.0 10.0 342.4 0.0 0.0 11.6 184.1
oo
[ 24.3- m&m’s White (BS) 196.7 4.0 10.0 285.1 0.0 0.0 10.9 185.0 0.0 ,
25.1 m&m’s White (BS) 192.6 3.5 10.0 291.8 0.0 0.0 9.5 624.0 0.0
25.2 m&m’s White (BS) 195.9 3.5 10.0 234.2 0.0 0.0 8.8 550.2 0.0
25.3 m&m’s White (BS) 191.2 3.5 10.0 407.7 0.0 0.0 8.5 573.2 0.0
|~~ 26.1 Euro White 285.5 4.0 I z o 280.5 0.0 0.0 0.0 0.0~ 737.6 !
j 26.2 Euro White 287.2 4.0 12.0 239.3 0.0 0.0 0.0 0.0 916.0 j
L  26,3 Euro White 289.3 4.0 12.0 208.3 0.0 0.0 0.0 0.0 807.4 1
27.1 Mitsubishi White 311.9 3.5 10.5 221.2 0.0 0.0 0.0 648.2 0.0
27.2 Mitsubishi White 309.6 3.5 10.5 173.8 0.0 0.0 0.0 666.0 0.0
27.3 Mitsubishi White 311.0 3.5 Î0.5 180.1 0.0 0.0 0.0 615.7 0.0
28.1 Mitsubishi White 301.1 3.5 11.0 ~ 229.1 ~~o.o 0.0 0.0 6ÏÏ.Q ~~~0-°“ i
28.2 Mitsubishi White . 292.0 3.5 11.0 240.2 0.0 0.0 0.0 588.3 0.0 j
28.3 Mitsubishi White 304.2 3.5 11.0 . 187.1 0.0 0.0 0.0 567.0 0.0 j
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Table Al (contd.)
Sample # Logo Colour Weight
(mg)
Thickness
(mm)
Diameter
(mm) MDMA MDEA Amp Caffeine Lactose Sorbitol
* 29.1 1 Rolls Royce White (BS) 206.6 5.0 8:0 357.9 0.0 0.0 ' 0.0 395.4 o.o 1
29.2 Rolls Royce White (BS) 197.4 5.0 8.0 404.8 0.0. 0.0 0.0 426.5 o.o 1
* 29.3 Rolls Royce White (BS) 203.7 5.0 8.0 408.3 0.0 0.0 0.0 462.9 o.o !
30.1 Superman Green 214.4 2.5 11.0 0.0 0.0 38.5 0.0 634.3 0.0
30.2 Superman Green 234.4 2.5 11.0 0.0 0.0 21.3 0.0 752.5 0.0
30.3 Superman Green 233.7 2.5 11.0 0.0 0.0 28.6 0.0 679.0 0.0. .
Mitsubishi White 303.7 4.0 12.0 308.4 0.0 0.0 0.0 669.4 0.0 1
I 31.2 Mitsubishi White 302.4 4.0 12.0 208.7 0.0 0.0 0.0 697.7 0.0 j
L j l l _
Mitsubishi White 311.5 4.0 12.0 167:2 0.0 0.0 0.0 647.1 0.0 J
32.1 Bird White 306.4 4.0 11.0 258.2 0.0 0.0 0.0 660.2 0.0
32.2 Bird White 312.6 4.0 11.0 241.4 0.0 0.0 0.0 682.0 0.0
32.3 Bird White 307.7 4.0 11.0 177.3 0.0 0.0 0.0 662.0 0.0
: 33.1 Mitsubishi White 300.2 3.5 11.0 234.0 0.0 0.0 0.0 690.5
i (
o 
1 
Ö 
; j
; • 33.2 Mitsubishi White 309.9 3.5 11.0 227.4 0.0 0.0 0.0 622.7 0.0 j
Mitsubishi White 3 J 0.9 3.5 11.0 226.7 .0.0 0.0 0.0 639.1 0;0 1
34.1 Mitsubishi White 321.5 4.5 11.5 208.1 0.0 0.0 0.0 668.1 0.0
34.2 Mitsubishi White 315.2 4.5 11.5 183.0 0.0 0.0 0.0 586.9 0.0
34.3 Mitsubishi White 298.3 4.5 11.5 166.5 0.0 0.0 0.0 654.0 0.0
I 35.1 Mitsubishi White 293.0 4.5 10.5 394.5 0.0 0.0 0.0 0.0 o.o 11
j  35.2 Mitsubishi White 298.4 4.5 10.5 283.0 0.0 0.0 0.0 0.0 0.0
1 35.3 Mitsubishi White 296.7 4.5 10.5 319.0 0.0 0.0 0.0 0.0 0.0
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Table Al (contd.)
Sample # Logo Colour Weight
(mg)
Thickness
(mm)
Diameter
(mm) MDMA MDEA Amp Caffeine Lactose Sorbitol
i 36.1 Durex White (BS) 245.9 4.0 10.5 249.4 11.6 0.0 0.0 633.5 o.o 1
j 36.2 Durex White (BS) 248.6 4.0 10.5 323.8 13.3 0.0 0.0 617.8 0.0 i
I 36.3 Darex White (BS) 248.9 4.0 10.5 204.3 12.9 0.0 0.0 584.9 . ;
37.1 Mitsubishi White 300.3 4.0 1J.5 39).2 0.0 0.0 0.0 ~ 659.6 0.0
37.2 Mitsubishi White 297.3 4.0 11.5 205.4 0.0 0.0 0.0 643.4 0.0
37.3 Mitsubishi White 300.3 4.0 11.5 229.1 0.0 0.0 0.0 634.7 0.0
j 38.] Mitsubishi White (BS) 295.1 4.0 11.0 253.6 0.0 0.0 * 0.0 616.0 0.0 1
1 38.2 Mitsubishi White (BS) 290.7 4.0 11.0 221.9 0.0 0.0 0.0 642.9 0.0 !
1 38.3 Mitsubishi White (BS) 299.0 4.0 11.0 203.5 0.0 0.0 0.0 640.1 0.0 j
39.1 Red Bull White (BS) 199.0 3.0 9.0 325.1 0.0 0.0 3.9 654.2 0.0
39.2 Red Bull White (BS) 199.5 3.0 9.0 448.7 0.0 0.0 3.6 610.0 0.0
39.3 Red Bull White (BS) 189.3 3.0 9.0 297.3 0.0 0.0 4.2 567.3 0.0
[ 40.1 m&nvs White (BS) ~"~200Y 3.5 10.0' 317.9 0.0 0.0 11.2 171.2 0.0
j 40.2 m&m's White (BS) 205.2 3.5 10.0 282.5 0.0 0.0 8.3 194.9 o.o !1
! 40.3 m&m’s White (BS) 190.9 3.5 10.0 197.0 0.0 0.0 8.8 183.3 0.0 1
41.1 m&m’s White (BS) 199.3 3.5 10.0 431.7 0.0 0.0 13.5 171.6 0.0
41.2 m&m’s White (BS) 197.3 3.5 10.0 327.7 0.0 0.0 11.9 196.6 0.0
41.3 m&m’s White (BS) 194.1 3.5 10.0 443.3 0.0 0.0 13.1 174.6 0.0
42.]' Durex White 248. r ‘ 4ÄT 11.5 ^336.3 13.4 Io 0.0 .138.0 0.0 "Î
42.2 Durex White 247.2 4.0 11.5 306.1 13.2 0.0 0.0 559.8 0.0 j
42.3 Durex White 246.8 4.0 11.5. ' 193.1 14.8 0.0 0.0 555.9 0.0 ¡
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Table Al (contd.)
Sample # Logo Colour Weight(mg)
Thickness
(mm)
Diameter
(mm) MDMA MDEA Amp Caffeine Lactose Sorbitol
; « , Durex White <BS) 246,0 3.5 10.5 422.3 16.9 0.0 0.0 519.5 0.0 -
! 43.2 Durex White (BS) 241.7 3.5 10.5 332.7 14.5 0.0 0.0 531.2 o.o ;
! 43.3 Durex White (BS) 241.7 3.5 10.5 227.7 16.2 0.0 0.0 555.2 0.0
44.1 Mitsubishi White 304.8 5.0 11.o' 247.4 0.0 0.0 0.0 578.7 0.0
44.2 Mitsubishi White 301.5 5.0 11.0 252.7 0.0 0.0 0.0 591.7 0.0
44.3 Mitsubishi White 291.6 5.0 11.0 184.9 0.0 0.0 0.0 551.7 0.0
Ì 45.1 Red Bull. White (BS) 195.9 3.0 10.0 2637 0.0 0.0 3.6 573.2 oTo ,
; 45, Red Bull White (BS) 187.3 3.0 10.0 326.6 0.0 0.0 3.3 547.7 0.0 '
L 453 Red Bull White (BS) 190.8 3.0 10.0 269.5 0.0 0.0 2.8 571.8 0.0
46.1 Smirnoff White (BS) 195.7 3.0 10.0 408.4 0.0 0.0 0.0 482.8 0.0
46.2 Smirnoff White (BS) 192.9 3.0 10.0 264.9 0.0 0.0 0.0 469.6 0.0
46.3 Smirnoff White (BS) 191.8 3.0 10.0 327.1 0.0 0.0 0.0 507.8 0.0
1 47.1 Mitsubishi White 303.4 4.0 11.5 198^5 Ò.0 0.0 0.0 652.6 0.0 j
47.2 Mitsubishi White 287.3 4.0 11.5 294.3 0.0 0.0 0.0 635.0 0.0 1
L  4.7'3 Mitsubishi White 295.5 4.0 11.5 176.2 0.0 0.0 0.0 633.5 0.0 ;
48.1 Coca-Cola White (BS) 202.9 3.0 10.0 294.1 4.8 0.0 5.0 413.5 0.0
48.2 Coca-Cola White (BS) 193.4 3.0 10.0 359.9 4.9 0.0 5.8 453.9 0.0
48.3 Coca-Cola White (BS) 208.7 3.0 10.0 238.1 4.4 0.0 5.9 448.0 0.0
|~~ 49.1 Coca-Cola White (BS) 186:8 3.5 9.5 ~ 15275 4.9 0.0 4.6 367.2 0.0 "I
1 49.2 Coca-Cola White (BS) 191.5 3.5 9.5 318.2 4.2 0.0 4.6 430.2 0.0 !
1 49.3 • Coca-Cola White (BS) 185.8 3.5 9.5 308.5 4.3 0.0 4.6 423.5 o.o !
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Table Al (contd.)
Sample # Logo Colour Weight(mg)
Thickness
(mm)
Diameter
(mm) MDMA MDEA Amp Caffeine Lactose Sorbitol
Î 50.1 Mitsubishi White 295.8 4.0 11.5 268.7 0.0 0.0 0.0 528.7 0.0 i
1 50.2 Mitsubishi White 296.8 4.0 11.5 265.3 0.0 0.0 0.0 • 567.0 0.0 1 1
; . Mitsubishi White 287.8 4.0 11.5 235.8 ■ 0.0 0.0 0.0 574.7 0.0 i
51.1 Smiley White m.4 4.5 8.5 455.9 0.0 0.0 0.0 418.3 0.0
51.2 Smiley White 196.8 4.5 8.5 410.2 0.0 0.0 0.0 436.4 0.0
51.3 Smiley White 200.7 4.5 8.5 529.9 0.0 0.0 0.0 415.5 0.0
1 52.1 Coca-Cola White <BS) 199^ 0 3.0 10.0 385.4 0.0 0.0 11.4 ~503.5 0.0 J
j 52.2 Coca-Cola White,(BS) 196.6 3.0 10.0 439.5 0.0 0.0 18.9 490.8 0.0 1
[ 52.3 Coca-Cola White (BS) 203.0 3.0 10.0 321.6 0.0 0.0 13.2 491.1 0.0 1
53.1 Crown White 253.6 5.0 10.0 29.1 36.2 0.0 3.5 421.1 0.0
53.2 Crown White 256.7 5.0 10.0 27.9 42.1 0.0 2.5 434.7 0.0
53.3 Crown White 253.8 5.0 10.0 22.3 38.1 0.0 3.0 437.3 0.0
Í 54.1 Heart White (BS) 279.2 6.0 10.0 306.3 0.0 0.0 0.0 "  469.2 0.0 1
1 54.2 Heart White (BS) 273.5 6.0 10.0 289.2 0.0 0.0 0.0 410.0 o.o !
1 54.3 Heart White (BS) 289.9 6.0 10.0 362.2 0.0 0.0 0.0 468.7 0.0__ 1
55.1 Heart Pink 269.2 5.5 10.0 209.9 0.0 0.0 0.0 324.2 268.2
55.2 Heart Pink 278.7 5.5 . 10.0 301.5 0.0 0.0 0.0 385.3 257.9
55.3 Heart Pink 282.8 5.5 10.0 245.3 0.0 0.0 0.0 327.4 305.1
56.1 Horse White (BS) 251.0 4.0 10.0 261.4 0.0 0.0 0.0 454.5 0.0 1
56.2 Horse White (BS) 249.8 4.0 10.0 278.4 0.0 0.0 0.0 430.3 0.0 1
56.3 Horse White (BS) 253.1 4.0 10.0 235.8 0.0 0.0 0.0 459.1 0.0 !
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Table A1 (contd.)
Sample # Logo Colour Weight(mg)
Thickness
(mm)
Diameter
(mm) MDMA MDEA Amp Ca frei ne Lactose Sorbitol
; 57.1 Horse White 248.3 4.5 10.5 383.7 0.0 0.0 0.0 430.1 0.0 Í
! 57.2 Horse White 242.6 4.5 10.5 170.9 0.0 0.0 0.0 534.6 0.0 '
57.3 Horse White 245.2 4.5 10.5 407.2 0.0 0.0 0.0 444.5 0.0
58.1 Euro White (BS) 290.9 3.5 12.0 216.6 0.0 0.0 0.0 0.0 0.0
58.2 Euro White (BS) 294.1 3.5 12.0 158.6 0.0 0.0 0.0 0.0 0.0
58.3 Euro White (BS) 286.1 3.5 12.0 244.7 0.0 0.0 0.0 0.0 0.0
j 59.1 Mitsubishi White 296.0 3.0 9:0 304.1 0.0 0.0 0.0 568.5 0.0 <i
’ 59.2 Mitsubishi White 304.0 3:0 9.0 246.1 0.0 0.0 0.0 577.6
Oo
¡ 59.3 Mitsubishi White 277.9 3.0 9.0 205.9 0.0 0.0 0.0 517.0 o.o !
60.1 Heart White (BS) 294.1 5.5 8.0 255.4 0.0 0.0 0.0 0.0 351.1
60.2 Heart While (BS) 257.8 5.5 8.0 265.9 0.0 0.0 0.0 0.0 372.1
60.3 Heart White (BS) 257.1 !i 8.0 252.1 0.0 0.0 0.0 0.0 515.7
¡ 611 Heart While (BS) 294.9 5.5 8.0 344.4 0.0 0.0 0.0 0.0 287.9 j
! 6 , , Heart White (BS) 273.9 5.5 8.0 291.0 0.0 0.0 0.0 0.0 316.2 j
j 61.3 Heart White (BS) 295.7 5.5 8.0 341.5 0.0 0.0 0.0 0.0 391.6 1
Mean - - 260.39 3.98 10.4 280.42 18.28 22.73 7.01 525.49 495.72
Min - - 183 2.5 8.0 21.8 1.1 14.2 0.5 171.2 257.9
Max - - 370.6 6 12.0 529.9 58.7 38.5 18.9 762.8 916.0
SD - - 47.40 0.74 0.98 89.54 17.87 9.29 4.29 141.44 217.59
% Occur. - - - - - 98.36 13.11 3.28 22.95 85.24 8.19
White (BS) = white with brown speckles
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Appendix: Table A2. Metal data for the 183 ecstasy samples used in this study.
Sample #
Metal concentration (Mg/g)
Al Zn Fe Mg Ca Cr Pb Na K
1.1 17.739 5.757 23.313 0.209 43.350 0.000 0.000 0.080 0.055
1.2 22.120 8 875 24.094 0.803 78.339 0.000 0.000 0.019 0.032
1.3 24.175 6.611 18.474 0.329 54.640 0.000 0.000 0.054 0.044
2.1 44 141 40.672 79.253 2.957 189.602 0.000 0.000 0.131 0.113
2.2 47.524 45.939 89.699 1.563 198.492 0.000 0.000 0.118 0.156
2.3 41.713 26.653 81.044 4.080 211.196 0.000 0.000 0.125 0 125
3.1 70.508 3.060 36.377 1.497 353.774 0.446 0.000 0.000 0.091
3.2 58.984 2.229 27.119 1.170 397.924 0.330 0.000 0.000 0.086
3.3 74.896 1.694 37.159 1.203 409.574 0.803 0.000 0.000 0.056
4.1 185.045 12.304 25.000 1.092 287.169 0.000 0.000 0.113 0.160
4.2 204.036 18.213 29.848 1.199 354.354 0.000 0.000 0.182 0.128
4.3 174.969 21.559 40.295 1.281 293.900 0.000 0.000 0.127 0.194
5.1 14.963 18.019 67.943 0.533 214.765 0.000 0.000 0.131 0.135
5.2 12.421 24.649 60.663 0.492 189.785 0.000 0.000 0.118 0.109
5.3 13.129 32.474 64.203 0.858 143.235 0.000 0.000 0.125 0.128
6.1 25.708 2.455 55.328 0669 252.174 0.000 1.241 0.127 0.206
6.2 43.350 2.803 62.763 0.463 287.169 0.000 1.083 0 092 0.176
6.3 25.140 2.739 61.163 0.395 330.827 0.000 0.430 0.046 0.190
7.1 47.814 1.186 6.901 1.322 79.253 0.000 0.000 0.099 0.197
7.2 43.587 1.110 10.763 1.241 89.699 0.000 0.000 0.129 0.183
7.3 28.659 1.170 4.576 1.204 63.409 0.000 0.000 0.118 0.229
8.1 78.339 16.960 30.208 1.694 174.969 0.621 0.000 0.140 0.220
8.2 54.260 18.694 28.022 1.556 245.739 0.571 0.000 0.155 0.206
8.3 54.640 15.159 48.593 1.766 185.045 1.886 0.000 0.242 0.176
9.1 29.236 9.736 4.435 0.755 89.699 0.000 0.000 0.040 0.148
9.2 30.349 8.289 7.196 0.803 70.508 0.000 0.000 0.078 0.162
9.3 20.833 8.333 6.894 0.501 56.398 0.000 0.000 0.098 0.142
10.1 2.572 4.580 5.068 0.162 121.615 0.000 0.000 0.073 0.127
10.2 4 065 4.435 4.576 0.250 109.307 0.000 0.000 0.096 0.142
10.3 2079 3.740 2.337 0.305 150.187 0.000 0.000 0.114 0.150
11.1 39.441 16.527 22.241 0.190 98.908 0.572 0.000 1.700 0.164
11.2 62.948 23.318 28.571 0.140 105.981 0.195 0.000 1.556 0.107
11.3 40.295 25.140 41.763 0.155 140.533 0.670 0.000 1.856 0.187
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T ab le  A2 (contcL) 
S am p le  # A1 Zn F e M g C a C r P b Na K
12.1 13.875 40.672 61.399 0.319 170.257 0.000 0.000 0.236 0.114
\ 12.2 16.041 45.939 58.273 0.233 220.414 . 0.000 0.000 0.180 0.160 •
12.3 17.601 26.653 71.674 0.252 234.198 0.000 0.000 0.223 0.194 :
13.1 44.141 9.974 121.615 1.224 122.715 0.276 9.571 0.169 0.156
13.2 79.253 6.057 402.062 2.139 153.191 0.756 6.955 0.232 0.156
13.3 47.524 8.939 49.764 1.262 141.161 0.211 3.641 0.189 0.142
j 14.1 71.009 78.756 18.662 1.948 24.739 0.000 0.433 3.052 0.141 ;
| 14.2 74.074 92.063 30.952 1.958 21.264 0.000 0.177 3.188 0.146
14.3 89.699 80.324 28.935 1.933 24.063 0.000 0.615 3.067 0.116
15.1 41.713 7.196 30.387 1.478 205.374 0.000 0.271 0.207 0.180
15.2 30.208 6.273 18.750 0.891 142.066 0.000 0.242 0.220 0.162
15.3 67.720 7.239 83.791 1,566 216.319 0.000 0.356 0.234 0.165
j 16.1i 28.022 7.706 19.918 1,277 165.775 0.000 0.000 0.137 0.110 ,
! 16.2J 81.044 7.940 24.863 1.250 157.439 0.000 0.000 0.206 0.124 ’
[ 16.3 55.288 8.113 19.231 1.262 155.556 0.000 0.000 0.240 0.096 1_ j
17.1 48.593 6.894 109.307 0.974 141.287 0.064 0.864 0.173 0.162
17.2 36.099 6.207 45.905 1.034 166.667 0.067 0.648 0.280 0.162
17.3 74.500 12.150 52.833 1.083 89.163 0.130 0.755 0.383 0.250
[  18.1 70.508 12.168 26.367 0.898 73.836 1.242 0.000 0.176 0.215 |
i 18.2i 32.309 5.932 71.186 1.081 182.143 1.471 0.000 0.148 0.127 j
j 18.3 56.398 9.348 33.175 1.090 116.603 3.506 0.000 0.190 0.142 j
19.1 58.984 10.176 30.078 0.430 42.226 0.000 0.000 0.098 0.215
19.2 22.120 6.901 4.804 0.438 63.439 0.000 0.000 0.035 0.150
19.3 74.896 6.100 16.701 0.456 74.830 0.000 0.000 0.093 0.124
| 20.1 245.739 15,341 57.528 1.932 125.926 0.000 0.000 0.057 0.142 !
j 20.2 237.854 5.051 62.652 1.447 286.573 0.000 0.000 0.051 0.132 1i
j 20.3 310.976 9.736 64.837 2.622 269.311 0.000 0.000 0.142 0.305 j
21.1 72.932 8.289 30.827 0.432 52.154 0.000 0.000 0.094 0.150
21.2 47.842 12.788 40.647 0.432 33.755 0.000 0.000 0.108 0.126
21.3 185.045 15.893 62.277 0.491 30.899 0.000 0.000 0.156 0.201
22.1 36.094 12.031 43.906 1.844 153.247 0.000 0.306 1.688 0.141 j
22,2 > 63.667 8.333 49,167 1.017 122.000 0.000 0.000 2.467 0.133 i
22.3 ' 51.796 9.296 . 36.377 2.201 . 236.715 0.000 0.000 2.335 0.135 |
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T ab le  A2 (contd.)
S am p le  # A1 Z n Fe M g C a C r P b N a K
23.1 51.093 6.639 79.098 1.844 277.778 0.683 0.000 0.082 0.109 '
23.2 52.821 . 0.000 69.615 1,731 0.000 0.000 0.000 0.103 0.128 !
23.3
L  . -  -  -  . * _ _____
42.284 0.000 92.284 1.790 0.000 0.000 0.000 0.170 0.123 !
24.1 77.181 6.628 16.527 0.034 5.063 0.356 0.000 0.067 0.168
24.2 94.175 5.649 12.500 0.035 6.263 0.245 0.000 0.035 0.106
24.3 123.517 10.763 27.119 1.186 10.236 0.621 0.000 0.127 0.233
' 25.1 104.036 7.354 23.318 1.110 150.915 0.460 0.446 0.157 0.179 :
! 25.2 83.283 4.292 23.069 1.170 272.500 0.369 0.426 0.064 o .i6 i :
| 25-3 94.796 11.803 18.401 1.180 100.000 0.571 1.140 0.074 0.232 :
26.1 205.556 4,944 76.806 1.597 323.034 0.000 0.000 0.028 0.181
26.2 248.188 5.797 104.348 1.993 343.750 0.000 0.000 0.018 0.145
26.3 266.129 6.624 59.101 1.671 252.174 0,036 0.000 0.035 0.115
i 27.1 47.739 1411 18.568 0.467 330.882 ‘ 0.000 0.000 0.052 0.124
j 27.2 63.409 1.466 37.159 0.455 310.078 0.000 0.000 0.068 0.114 1
! 27.3 68.921 0.558 22.120 0.458 821,596 0.000 0.000 0.092 0.170
28.1 2.712 5.094 25.708 0.542 106.481 0.000 0.000 0.000 0.189
28.2 7.685 ' 0.825 43.350 0.468 567.164 0.000 0.000 0.000 0.111
28.3 1.439 0.000 25.140 0.517 0.000 0.000 0.000 0.000 0.140
| 29.1 40.672 4.580 44.403 1.315 287.169 1.886 1.172 0.345 0.326 !
1 29.21 45.939 4.226 54.569 1.497 354.354 0.863 0.000 0.406 0.190 ;
L 29-3 26.653 3.130 49.690 1.405 448.845 0.114 0.622 0.331
0.134 :
30.1 55.328 5.068 47.814 0.533 105.121 0.119 0.183 0.178 0.314
30.2 31.630 4.435 43.587 0.435 98.039 0.108 0.330 0.174 0.391
30.3 36.125 1.186 28.659 0.434 365.714 0.156 0.209 0.081 0.190
31.1 15.289 3.740 12.328 0.475 127.072 0.000 0.025 0.083 0.193
31.2 29.073 5.056 45.787 0.478 94.444 0.000 0.000 0.197 0.281
31.3 21.904 4.576 35.780 0.528 115.288 0.000 0.000 0.183 0.149 1
32.1 16.960 6.222 49.670 0.551 88.496 0.000 0.000 0.055 0.121
32.2 18.694 2.337 25.000 0.490 209.524 0.000 0.803 0.045 0.096
32.3 15.159 2.595 28.889 0.492 189.602 0.000 0.127 0.032 0.190
33.1 23.039 3.060 33.403 0.448 146.453 0.000 0.020 0.056 0.091 ~j
33.2 15.378 2.229 28.536 0.428 191.882 0.000 0.000 0.058 0.090 [j
33.3 10.768 1.694 18.019 0.433 255.591 0.000 0.000 0.060 0.092 ;
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T ab le  A2 (contd.)
S am ple  # A1 Z n Fe M g C a C r P b N a K
34.1 14.912 3.000 24.649 0.439 146.199 0.000 0.000 0.044 0.132
34.2 14.820 2.249 32.474 0.432 191.977 0.000 0.000 0.039 0.097 ;
34.3 10.575 1.920 22.241 0.483 251.497 0.000 0.000 0.040 0.103 j
35.1 12.234 3.537 32.979 1.170 330.827 0.000 0.000 0.594 0.080
35.2 16.823 4.164 28.571 1.203 288.939 0.000 0.000 0.536 0.019
35.3 17.176 3.975 24.910 1.196 300.905 0.000 0.000 0.755 0.054
! 36.1 29.789 5.757 48.659 1.140 198.003 0.000 0.000 0.546 0.000 f
36.2 22.448 8.875 41.763 0.969 109.150 0.000 0.329 0.122 0.116 ;
| 36.3 30.095 6.611 67.417 1.173 177.419 0.000 0.000 0.166 0.320 ;
37.1 62.763 4.287 66.517 0.511 119.089 0.000 0.041 0.113 0.143
37.2 53.416 2.605 45.419 0.517 198.492 0.000 0.000 0.111 0.131
37.3 43.115 15.082 151.639 0.533 35.326 0.000 0.501 0.156 0.131
[ 38.1 12.304 2.572 38.613 0.543 211.196 0.000 0.000 0.098 0.1 18 ;
! 38.2 18.213 4.065 29.848 0.533 131.175 0.000 0.000 0.125 0.125
| 38.3 21.559 2.079 30.829 0.527 253.378 0.000 0.000 0.091 0.316 ■
39.1 32.463 3.750 150.187 0.858 228.856 0.000 0.000 0.121 0.140
39.2 46.455 3.945 165.455 0.900 228.111 0.000 0.573 0.136 0.155
39.3 59.662 5.145 99.034 1.486 288.732 0.000 0.000 0.229 0.242
40.1 25.278 5.889 65.972 2.139 363.208 0.000 0.000 0.125 0.319 !
40.2 15.855 1.556 80.517 0.885 568.690 0.000 0.000 0.055 0.065 !
40.3 30.037 4.304 140.110 1.511 351.064 0.000 0.819 0.046 0.128 !
41.1 29.656 6.457 63.462 0.030 4.702 0.000 4.816 0.192 0.121
41.2 25.268 3.795 64.375 0.036 9.412 0.000 2.069 0.161 0.732
41.3 29.911 16.815 81.845 0.060 3.540 0.000 2.999 0.327 0.134
4 ? : r 24.007 6.570 78.339 1.155 175.. 824 0.000 0.000 0.099 0.063 |
42.2 23.071 7.974 54.260 1.166 146.169 0.000 0.000 0.129 0.105 Ij
42.3 20.914 5.042 54.640 0.963 190;934 0.000 0.000 0.118 0.111 i
43.1 19.788 6.384 16.694 1.148 179.847 0.000 1.202 0.114 0.122
43.2 31.579 9.487 102.895 1.908 201.110 0.000 3.087 0.197 0.184
43.3 18.536 4.914 45.249 1.114 226.624 0.000 1.332 0.086 0.164
44.1 8.761 1.766 49.217 0.506 286.290 0.000 0.000 0.028 0.107 |
• 44.2 6.460 1.510 55.769 0.534 353.774 0.000 0.224 0.036 0.064 !
44.3 7.078 1.813 29.063 0.555 306.034 0.000 0.000 0.031 0.188 )
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T ab le  A2 (contd.)
S am ple  # Al Zn Fe M g C a C r P b N a K
45.1 13.846 1.853 98.718 0.737 397.924 0.000 0.000 0.032 0.077 !
45.2 10.505 2.093 131.107 1.050 501.946 0.000 0.000 0.024 0.187
45.3 9.595 2.482 98.908 1.092 439.716 0.000 0.000 0.044 . 0.220 :
46.1 14.963 2.835 105.981 1.199 422.951 0.000 0.807 0,056 0.260
46.2 12.421 1.714 140.533 1.281 747.706 0.000 0.000 0.063 0.181
46.3 13.129 3.255 58.273 1,322 406.077 0.000 0.000 0.081 0.189
| 47.1 8.798 3.176 71.674 0.494 155.405 0.000 0.000 0.236 0.376
47.2 7:765 1.259 49.811 0.464 368.421 0.000 0.000 0,180 0.862 !
47.31 6.781 3.724 65.411 0.916 245.977 0.000 0.000 0.223 0.214 ;
48.1 18.426 3.307 36.853 1.285 388.554 0.000 0.000 0.966 0.319
48.2 10.310 2,298 48.450 0.964 419.355 0.000 0.000 0.276 0.263
48.3 12.135 3.659 93.978 1.241 339.152 0.000 0.000 0.447 0.319
j 49.1 8.488 1.728 49.614 1.204 696.429 0.000 0.772 0.448 0.370 ;
! 49.2i 5.870 1.883 68.927 1.083 575.269 0.000 0.000 0.294 0.233 ;
!_ 493 27.606 0.344 56.270 0.977 2836.879 0.000 0.000 0.326 0.252
50.1 63.012 0.730 85.041 0.430 589.888 0.000 0.000 0.000 0.143
50.2 29.288 0.836 53,779 0.480 573.913 0.000 0.000 0.000 0.073
50.3 12.410 0.000 209.532 0.432 0.000 0.000 0.000 0.000 0.099
j 51.1 19.206 2.017 68.348 0.826 409.574 0.000 0.000 0.086 0.204 ;I
* 51.2 13.011 1.465 39.441 0.572 390.698 0.000 0.000 0.061 0.102 i
L  5 U ...... 25.326 6.270 62.948 0.806 128.571 0.000 0.000 0.090
0.138 j
52.1 40.823 2.215 40.295 1.350 609.524 0.000 0,000 0.232 0.570
52.2 30.825 2.597 98.908 1.468 565.421 0.000 0.000 0.303 0.279
52.3 41.627 2.225 105.981 1.220 548.387 0.000 0.000 0.311 0.251
f 53.1 37.796 2.959 140.533 1.324 447.500 0.000 0.000 1.324 0.111 ;
| 53.2 45.741 5.009 56.759 1.472 293.900 0.000 0.000 1.370 0.093 ;
[ 53.3 4.437 4.340 22.565 1.028 236.908 0.000 0.000 1.315 0.070 [
54.1 5.125 0.569 13.875 0.400 702.525 0.000 0.000 0.000 0.056
54.2 4.794 1.241 16.041 0.333 268.293 0,000 0.000 0.000 0.073
54.3 13.407 2.263 51.814 0.670 296.167 0.000 0.000 0.000 0.103
55.1 29.639. 1.045 94.459 0.799 764.488 0.000 0.000 0,876 0.155 !
55.2 12.885 0.959 19-1.176 0.973 1014.599 0.000 0.000 1.085 0.112 ;
55.3 16.507 . 3.050 67.943 0.766 250.980 0.000 0.000 2.022 0.203 |
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T a b le  A2 (contd.)
S am p le  # A1 Zn F e M g C a C r P b N a K
56.1 12.896 1.960 60.663 0.706 360.294 0 . 0 0 0 0 . 0 0 0 0.029 0.115
56.2 13.841 4.609 64.203 0.725 '157.233 0 . 0 0 0 0 . 0 0 0 0.043 0.109 ;
56.3 15.644 t 1.700 38.531 0.669 393.491 0 . 0 0 0 0 . 0 0 0 0.040 0.096 ,
57.1 23.313 3.036 19.578 0.536 176.587 0 . 0 0 0 0 . 0 0 0 0.078 0.114
57.2 15.564 1.556 21.201 0.551 354.331 0 . 0 0 0 0 . 0 0 0 0.098 0.092
57.3 24.110 1.856 39.110 0.598 322.314 0.000 0 . 0 0 0 0.107 0.123
! 58.1| 14.236 2.813 29.236 1.229 437.037 0 . 0 0 0 0 . 0 0 0 0.160 0.479 j
| 58.2 61.163 4.419 30.349 1.698 384.211 0 . 0 0 0 0 . 0 0 0 0.198 0.558
| 58.3 12.639 3.028 20.833 1.257 415.138 0.000 0 . 0 0 0 0.125 0.486 .j
59.1 24.094 1.775 9.894 0.491 276.596 0.000 0 . 0 0 0 0.128 0.113
59.2 39.806 4.005 18.689 0.534 133.333 0 . 0 0 0 0 . 0 0 0 0.194 0.182
59.3 21.866 2.455 8.507 0.463 188.450 0 . 0 0 0 0 . 0 0 0 0.142 0.127
i 60.1i 18.618 2.803 18.618 0.355 126.761 0.000 0 . 0 0 0 1.158 0.092 ;
! 60.2 18.474 2.739 28.952 0:588 214.765 0 . 0 0 0 0 . 0 0 0 1.994 0.046 ;
[  60.3 31.818 1.188 30.861 0.395 332.326 0 . 0 0 0 0 . 0 0 0 2.285 0.084
61.1 23.295 0.795 21.429 0,292 367.722 0 . 0 0 0 0 . 0 0 0 1.047 0.057
61.2 33.556 0.691 35.333 0.311 450.161 0.000 0 . 0 0 0 2.167 0.067
61.3 14.603 0.901 9.675 0.325 360,000 0 . 0 0 0 0 . 0 0 0 0.980 0.030
Mean 43.945 8.204 52.013 0.932 262.473 0.636 1.225 0.360 0.168 I
Min 1.439 0.344 2.337 0.030 3.540 0.036 0.020 0.018 0.019 ;
J ' Max 310.976 92.063 402.062 4.080 2836.879 3.506 9.571 3.188 0.862 j
| SD 50.5.31 • 12.609 44.253 0.591 . 258.889 0.714 1.892 0.617 0 . 1 1 0  ij
j % Occur. 100 97.8 100 100 98.4 17.5 23 93.4 99.5 |
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